Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 1 CLINICAL STUDY PROTO COL  
Protocol Number:  PLX108 -10 
  
Title : A Double -blind, Randomized, Placebo -controlled Phase 3 
Study of Orally Administered PLX3397 in Subjects  with 
Pigmented Villonodular Synovitis or Giant Cell Tumor of the 
Tendon Sheath  (ENLIVEN ) 
  
Indication:  Pigmented villonodular sy novitis (PVNS) / giant cell tumo r of 
the tendon sheath (GCT -TS) 
  
Phase:  3 
  
Sponsor:  
 Daiichi Sankyo , Inc.  
211 Mount Airy Road  
Basking Ridge, N J 07920, U SA 
  
EudraCT Number:  2014 -000148 -14 
  
Therapeutic Area:  Antineoplastic agent  
  
IND Number:  117,332  
  
Version:  
Superseded Versions:  10.0, 22 Jan 2020  
9.0, 15 Dec 2017  
8.0, 11 Sep 2017  
7.0, 10 Feb 2017  
6.0, 10 Oct 2016  
5.0, 19 Jul 2016  
4.0, 25 Mar  2016  
 3.0, 11 Feb 2015  
2.0, 05 Dec 2014  
Original Protocol:  1.0, 18 Sep 2014  
  
CONFIDENTIALITY STATEMENT  
Information contained in this document is proprietary to Daiichi Sankyo Inc. (DSI). The 
information is provided to you in confidence which is requested under an agreed upon and signed 
Confidentiality and Disclosure Agreement. Do not give this document or any copy of it or reveal 
any proprietary information contained in it to any third party (other than thos e in your 
organization who are assisting you in this work and are bound by the Confidentiality and 
Disclosure Agreement) without the prior written permission of an authorized representative of 
DSI. 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 3 TABLE OF CONTENTS  
INVESTIGATOR AGREEME NT................................ ................................ ................................ ...2 
GLOBAL AMENDMENT, PR OTOCOL V 10.0  ................................ ................................ ......... 12 
LIST OF ABBREVIATION S ................................ ................................ ................................ ........ 13 
PROTOCOL SYN OPSIS  ................................ ................................ ................................ .............. 16 
1. INTRODUCTION AND BAC KGROUND INFORMATION  ................................ .......26 
1.1. Scientific Background  ................................ ................................ ................................ .....26 
1.1.1.  Pigmented Villonodular Synovitis and Giant Cell Tumors of the Tendon Sheath  ......... 26 
1.1.2.  Pexidartinib (PLX3397)  ................................ ................................ ................................ ..27 
1.2. Nonclinical Studies  ................................ ................................ ................................ .......... 27 
1.3. Clinical Experience  ................................ ................................ ................................ ......... 27 
1.3.1.  Subjects with PVNS/GCT -TS Treated in Study PLX108 -01 ................................ .......... 29 
1.4. Study Rationale  ................................ ................................ ................................ ............... 30 
1.4.1.  Study Purpose  ................................ ................................ ................................ .................. 31 
1.5. Risks and Benefits for Study Subjects  ................................ ................................ ............. 32 
1.6. Updated Risk Information and Change in Study Conduct  ................................ .............. 33 
2. STUDY OBJECTIVES AND  HYPOTHESIS  ................................ ................................ 35 
2.1. Study Objectives  ................................ ................................ ................................ .............. 35 
2.2. Study Endpoints  ................................ ................................ ................................ ............... 35 
2.2.1.  Primary Efficacy Endpoint  ................................ ................................ .............................. 35 
2.2.2.  Secondary Efficacy Endpoints  ................................ ................................ ........................ 37 
2.2.3.  Additional Endpoints  ................................ ................................ ................................ .......39 
2.3. Study Hypothesis  ................................ ................................ ................................ ............. 40 
3. STUDY DESIGN  ................................ ................................ ................................ ............ 41 
3.1. Overall Plan  ................................ ................................ ................................ ..................... 41 
3.2. Number of S ubjects  ................................ ................................ ................................ ......... 45 
3.3. Duration of Study  ................................ ................................ ................................ ............ 45 
4. STUDY POPULATION  ................................ ................................ ................................ ..46 
4.1. Enrollment  ................................ ................................ ................................ ....................... 46 
4.1.1.  Inclusion Criteria  ................................ ................................ ................................ ............. 46 
4.1.2.  Exclusion Criteria  ................................ ................................ ................................ ............ 47 
4.2. Removal of Subject From Therapy  ................................ ................................ ................. 48 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 4 4.2.1.  Reasons for Withdrawal/Early Discontinuation  ................................ .............................. 48 
4.2.2.  Withdrawal Procedures  ................................ ................................ ................................ ...48 
4.2.3. Subject Replacement  ................................ ................................ ................................ .......49 
4.3. Subject Re -screening Procedures  ................................ ................................ .................... 49 
5. TREATMENTS ADMINISTE RED  ................................ ................................ ................ 50 
5.1. Investigational Products  ................................ ................................ ................................ ..50 
5.2. Study Treatment Administration  ................................ ................................ ..................... 50 
5.3. Dose Modification Guidelines  ................................ ................................ ......................... 51 
5.3.1.  Renal Impairment  ................................ ................................ ................................ ............ 54 
5.4. Concomitant Medications  ................................ ................................ ................................ 54 
5.4.1.  CYP3A and UGT Inhibitors  ................................ ................................ ............................ 54 
5.4.2.  Hormonal Contraceptives  ................................ ................................ ................................ 55 
5.4.3.  Acid -reducing Agents  ................................ ................................ ................................ ......55 
5.5. Precautions and Restrictions  ................................ ................................ ............................ 55 
5.6. Blinding and Unblinding  ................................ ................................ ................................ .55 
5.6.1. Unblinding  ................................ ................................ ................................ ....................... 56 
5.6.1.1.  Emergency Unblinding  ................................ ................................ ................................ ....56 
5.6.1.2.  Unblinding during Part 1 Week 13 to Week 25 for Disease Progression  ....................... 56 
5.6.1.3.  Unblinding at the End of Part 1  ................................ ................................ ....................... 57 
5.7. Description of Investigational Agents  ................................ ................................ ............. 57 
5.8. Packaging and Labeling  ................................ ................................ ................................ ..58 
5.9. Storage, Handling, and Accountability  ................................ ................................ ........... 58 
6. STUDY CONDUCT  ................................ ................................ ................................ .......60 
6.1. Study Personnel and Organizations  ................................ ................................ ................. 60 
6.2. Recruitment of Subjects  ................................ ................................ ................................ ..60 
6.3. Treatment Group Assignments  ................................ ................................ ........................ 60 
6.4. Study Procedures  ................................ ................................ ................................ ............. 60 
6.4.1.  Demographics and Medical History  ................................ ................................ ................ 61 
6.4.2.  Vital Signs and Subject Weight  ................................ ................................ ....................... 61 
6.4.3.  Physical Examination  ................................ ................................ ................................ ......61 
6.4.4.  Range of Motion Assessment  ................................ ................................ .......................... 61 
6.4.5.  Electrocardiogram  ................................ ................................ ................................ ........... 61 
6.4.6.  Echocardiogram  ................................ ................................ ................................ ............... 62 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 5 6.4.7.  Clinical Laboratory Evaluations  ................................ ................................ ...................... 62 
6.4.8.  Patient Reported Outcome Instruments  ................................ ................................ ........... 64 
6.4.8.1.  Most Disturbing Symptom Assessment  ................................ ................................ .......... 64 
6.4.8.2.  BPI Worst Pain NRS Item  ................................ ................................ ............................... 64 
6.4.8.3.  Worst Stiffness NRS item  ................................ ................................ ............................... 64 
6.4.8.4.  PROMIS Physical Function Scale  ................................ ................................ ................... 64 
6.4.8.5.  EQ-5D-5L ................................ ................................ ................................ ........................ 65 
6.4.8.6.  Patient Global Impression of Change and Global Rating of Concept Items  ................... 65 
6.4.9.  Tumor Imaging  ................................ ................................ ................................ ................ 65 
6.4.10.  Surgical Assessment Questionnaire  ................................ ................................ ................ 66 
6.4.11.  Surgical Data and Outcome Follow -up ................................ ................................ ........... 66 
6.4.12.  Analgesic Use and Analgesic Regimen  ................................ ................................ ........... 66 
6.4.13.  Healthcare Resource Use and Productivity  ................................ ................................ .....67 
6.4.14.  Pregnancy Test  ................................ ................................ ................................ ................ 67 
6.4.15.  Pharmacodynamic Sampling  ................................ ................................ ........................... 67 
6.4.16.  Pharmacokinetic (PK) Sampling  ................................ ................................ ..................... 67 
6.4.17.  Adverse Events  ................................ ................................ ................................ ................ 68 
6.4.18.  Study Treatment Compliance  ................................ ................................ .......................... 68 
6.5. Study Procedures  ................................ ................................ ................................ ............. 69 
7. STATISTICAL METHODS  ................................ ................................ ........................... 70 
7.1. Randomization and Stratification  ................................ ................................ .................... 70 
7.2. Analysis Sets  ................................ ................................ ................................ ................... 70 
7.3. Procedures for Handling Missing, Unused, and Spurious Data  ................................ ......70 
7.4. General Statistical Considerations  ................................ ................................ ................... 70 
7.5. Study Population Data  ................................ ................................ ................................ .....71 
7.6. Efficacy Analyses  ................................ ................................ ................................ ............ 71 
7.6.1.  Primary Efficacy Analysis  ................................ ................................ ............................... 71 
7.6.2.  Secondary Efficacy Analyses  ................................ ................................ .......................... 71 
7.6.3.  Additional Efficacy Analyses  ................................ ................................ .......................... 73 
7.6.4.  Subgroup Analyses  ................................ ................................ ................................ .......... 75 
7.7. Pharmacodynamics/Biomarkers  ................................ ................................ ...................... 75 
7.8. Pharmacogenomic Analysis  ................................ ................................ ............................ 75 
7.8.1.  Genomic or Genetic Banking and Analysis  ................................ ................................ ....75 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 6 7.8.1.1.  Disclosure of the Results of Genomic or Genetic Analysis  ................................ ............ 76 
7.8.1.2.  Storage and Disposal of Specimens for Genomic or Genetic Banking and 
Analysis  ................................ ................................ ................................ ........................... 76 
7.9. Pharmacokinetics and Exposure –Response Analyses  ................................ ..................... 76 
7.10.  Safety Analysis  ................................ ................................ ................................ ................ 76 
7.10.1.  Analysis of Treatment -emergent Adverse Events  ................................ ........................... 77 
7.10.2.  Clinical Laboratory Evaluation Analyses  ................................ ................................ ........ 77 
7.10.3.  Vital Sign Analyses  ................................ ................................ ................................ ......... 77 
7.10.4.  Electrocardiogram Analyses  ................................ ................................ ............................ 78 
7.10.5.  Echocardiogram Analyses  ................................ ................................ ............................... 78 
7.10.6.  Analysis of Physical Examination Findings  ................................ ................................ ....78 
7.10.7.  Concomitant Medication Analyses  ................................ ................................ .................. 78 
7.11.  Data Monitoring Committee  ................................ ................................ ............................ 78 
7.12. Sample Size Determination  ................................ ................................ ............................. 78 
8. ETHICAL CONSIDERATIO NS ................................ ................................ .................... 80 
9. SAFETY ASSESSMENT  ................................ ................................ ............................... 81 
9.1. Reporti ng Adverse Events and Serious Adverse Events  ................................ ................. 81 
9.2. Definitions  ................................ ................................ ................................ ....................... 82 
9.2.1.  Adverse Event  ................................ ................................ ................................ ................. 82 
9.2.2.  Serio us Adverse Event  ................................ ................................ ................................ ....82 
9.2.3.  Adverse Event Severity  ................................ ................................ ................................ ...82 
9.2.4.  Causality Assessment  ................................ ................................ ................................ ......83 
9.2.5.  Action Taken Regarding the Study Treatment  ................................ ................................ 83 
9.2.6.  Adverse Event Outcome  ................................ ................................ ................................ ..84 
9.2.7.  Other Action Taken for Event  ................................ ................................ ......................... 84 
9.3. Serious Adverse Event Reporting Procedure for Investigators  ................................ .......84 
9.3.1.  Reporting by Investigators  ................................ ................................ .............................. 84 
9.3.2.  Notifying Regulatory Authorities, Investigators, and Inst itutional Review 
Boards/Institutional Ethics Committees  ................................ ................................ .......... 85 
9.4. Procedures for Reporting Drug Exposure During Pregnancy and Birth Events  ............. 85 
10. STUDY ADMINISTRATIVE  INFORMATION  ................................ ............................ 86 
10.1.  Study Contacts  ................................ ................................ ................................ ................. 86 
10.1.1.  Sponsor  ................................ ................................ ................................ ............................ 86 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 7 10.1.2.  Medical Mo nitor  ................................ ................................ ................................ .............. 86 
10.1.2.1.  Sponsor Medical Monitor  ................................ ................................ ................................ 86 
10.1.2.2.  Contract Research Organization Medical Monitor  ................................ .......................... 86 
10.1.3.  SAE Reporting Contact  ................................ ................................ ................................ ...86 
11. ADMINISTRATIVE REQUI REMENTS  ................................ ................................ .......87 
11.1.  Good Clinical Practice  ................................ ................................ ................................ .....87 
11.2.  Data Quality Assurance  ................................ ................................ ................................ ...87 
11.3.  Electronic Case Report Form Completion  ................................ ................................ ......87 
11.4.  Data Management  ................................ ................................ ................................ ............ 87 
11.5.  Study Monitoring  ................................ ................................ ................................ ............. 88 
11.6.  Subject Information and Informed Consent  ................................ ................................ ....88 
11.7.  Subject Confidentiality  ................................ ................................ ................................ ....88 
11.8.  Investigator Compliance  ................................ ................................ ................................ ..88 
11.9. On-site Audits  ................................ ................................ ................................ .................. 89 
11.10.  Investigator and Site Responsibility for Drug Accountability  ................................ ........ 89 
11.11.  Product Complaints  ................................ ................................ ................................ ......... 89 
11.12.  Study Closure  ................................ ................................ ................................ .................. 89 
11.13.  Study  Documentation and Storage  ................................ ................................ .................. 90 
11.14.  Record Retention  ................................ ................................ ................................ ............. 90 
11.15.  Record Keeping  ................................ ................................ ................................ ............... 91 
12. FINANCING AND INSURA NCE  ................................ ................................ .................. 92 
12.1.  Finances  ................................ ................................ ................................ ........................... 92 
12.2.  Reimbursement, Indemnity, and Insurance  ................................ ................................ .....92 
13. USE OF INFORMATION  ................................ ................................ .............................. 93 
14. REFERENCES  ................................ ................................ ................................ ................ 94 
15. APPENDICES  ................................ ................................ ................................ ................. 97 
15.1.  List of Common CYP3A4 Inhibitors and Inducers  ................................ ......................... 97 
15.2.  Detailed Study Procedures by Visit — Part 1  ................................ ................................ .97 
15.2.1.  Screening (Day –42 to Day –1) ................................ ................................ ....................... 97 
15.2.2.  Part 1 – Cycle 1 (Randomization)  ................................ ................................ ................... 99 
15.2.3.  Part 1 –Cycle 1, Day 1 (P1 -C1D1; Week 1)  ................................ ................................ ....99 
15.2.4.  Part 1 –Cycle 1, Day 8 (P1 -C1D8; Week 2) ± 2 days  ................................ .................... 101 
15.2.5.  Part 1 –Cycle 1, Day 15 (P1 -C1D15; Week 3) ± 2 days  ................................ ................ 101 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 8 15.2.6.  Part 1 –Cycle 1, Day 22 (P1 -C1D22; Week  4) ± 2 days  ................................ ................ 101 
15.2.7.  Part 1 –Cycle 2, Day 1 (P1 -C2D1; Week 5) ± 2 days  ................................ .................... 102 
15.2.8.  Part 1 –Cycle 2, Day 8 (P1 -C2D8; Week 6) ± 2 days  ................................ .................... 102 
15.2.9.  Part 1 –Cycle 2, Day 15 (P1 -C2D15; Week 7) ± 2 days  ................................ ................ 102 
15.2.10.  Part 1 –Cycle 2, Day 22 (P1 -C2D22; Week 8) ± 2 days  ................................ ................ 102 
15.2.11.  Part 1 –Cycle 3, Day 1 (P1 -C3D1; Week 9) ± 7 days  ................................ .................... 102 
15.2.12.  Part 1 –Cycle 3, Day 15 (P1 -C3D15; Week 11) ± 7 days  ................................ .............. 103 
15.2.13.  Part 1 –Cycle 4, Day 1 (P1 -C4D1; Week 13) ± 7 days  ................................ .................. 103 
15.2.14.  Part 1 –Cycle 5, Day 1 (P1 -C5D1; Week 17) ± 7 days  ................................ .................. 104 
15.2.15.  Part 1 –Cycle 6, Day 1 (P1 -C5D1; Week 21) ± 7 days  ................................ .................. 104 
15.2.16.  Part 1 Completion visit/Early Termination Visit (Week 25) ± 7 days  .......................... 105 
15.2.17.  Part 1 28 Day Post -Treatment Visit (last dose + 28 days) ± 7 days  .............................. 106 
15.2.18.  Part 1 End -of-Study/12 Week Post-Treatment Visit (12 weeks ± 7 days after the 
last dose)  ................................ ................................ ................................ ........................ 107 
15.3.  Detailed Study Procedures by Visit — Part 2  ................................ ............................... 108 
15.3.1.  Part 2 –Cycle 1, Day 1 (P2 -C1D1; Week 25)  ................................ ................................ 108 
15.3.2.  Part 2 –Cycle 1, Day 8 (P2 -C1D8; Week 26) ± 2 days  ................................ .................. 109 
15.3.3.  Part 2 –Cycle 1, Day 15 (P2 -C1D15; Week 27) ± 2 days  ................................ .............. 109 
15.3.4.  Part 2 –Cycle 1, Day 22 (P2 -C1D22; Week 28) ± 2 days  ................................ .............. 110 
15.3.5.  Part 2 –Cycle 2, Day 1 (P2 -C2D1; Week 29) ± 2 days  ................................ .................. 110 
15.3.6.  Part 2 –Cycle 2, Day 8 (P2 -C2D8; Week 30) ± 2 days  ................................ .................. 110 
15.3.7.  Part 2 –Cycle 2, Day 15 (P2 -C2D15; Week 31) ± 2 days  ................................ .............. 111 
15.3.8.  Part 2 –Cycle 2, Day 22 (P2 -C2D22; Week 32) ± 2 days  ................................ .............. 111 
15.3.9.  Part 2 –Cycle 3, Day 1 (P2 -C3D1; Week 33) ± 7 days  ................................ .................. 111 
15.3.10.  Part 2 –Cycle 3, Day 15 (P2 -C3D15; Week 35) ± 7 days  ................................ .............. 111 
15.3.11.  Part 2 –Cycle 4, Day 1 (P2 -C4D1; Week 37) ± 7 days  ................................ .................. 111 
15.3.12.  Part 2 –Cycle 5, Day 1 (P2 -C5D1; Week 41) ± 7 days  ................................ .................. 112 
15.3.13.  Part 2 –Cycle 6, Day 1 (P2 -C6D1; Week 45) ± 7 days  ................................ .................. 112 
15.3.14.  Part 2 –Cycle 7, Day 1 (P2 -C7D1; Week 49) ± 7 days  ................................ .................. 113 
15.3.15.  Part 2 –Cycle 10+, Day 1 (P2 -C10+D1; Week 61+) ± 7 days  ................................ .......114 
15.3.16.  Post-Treatment Visit (Part 2)  ................................ ................................ ......................... 115 
15.3.17.  End-of-Study or Early Termination Visit  ................................ ................................ ......116 
15.4.  Detailed Study Procedures by Visit — Surgical Outcome  ................................ ............ 116 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 9 15.4.1.  Four weeks Prior to Surgery  ................................ ................................ .......................... 117 
15.4.2.  During or shortly after Surgery  ................................ ................................ ..................... 117 
15.4.3.  4 Months (± 2 weeks) after Surgery  ................................ ................................ .............. 117 
15.4.4.  8, 12, 18, and 24 Months (± 2 weeks) after Surgery  ................................ ..................... 118 
15.5.  Brief Pain Inventory (BPI) Worst Pain Numeric Rating Scale (NRS) Item  ................. 118 
15.6.  Worst Stiffness NRS item ................................ ................................ ............................. 118 
15.7.  PROMIS Physical Function Scale  ................................ ................................ ................. 119 
15.8.  EQ-5D-5L ................................ ................................ ................................ ...................... 122 
15.9.  Patient Global Impression of Change and Rating of Concept Items  ............................. 125 
15.10.  Surgical Assessment Questionnaire  ................................ ................................ .............. 126 
15.11.  Employment status and productivity questions  ................................ ............................. 126 
15.12.  Healthcare  Resource Use Questions  ................................ ................................ ............. 128 
15.13.  Schedule of Events  ................................ ................................ ................................ ........ 130 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 10 LIST OF TABLES  
Table  2.1: Definitions of Response for the Primary Efficacy Endpoint  ................................ ......36 
Table  5.1: Dose Modification Guidelines for Treatment -emergent Toxicities  ............................ 52 
Table  5.2: Additional Liver Evaluation  ................................ ................................ ....................... 53 
Table  5.3: Recommended Dosage Reductions for Pexidartinib with Concomitant Use of 
Moderate or Strong CYP3A Inhibitors or UGT Inhibitors  ................................ ......... 55 
Table  6.1: PK Schedules  ................................ ................................ ................................ .............. 68 
Table 15.1:  Sample Surgical Assessment Questionnaire  ................................ ............................. 126 
Table  15.2:  Schedule of Events – Part 1 (Blinded, Placebo -controlled Phase)  ........................... 131 
Table  15.3:  Schedule of Events – Part 2 (Open -label Phase)  ................................ ...................... 137 
Table  15.4:  Schedule of Events – For Subjects Who Undergo Surgical Resection  .................... 141 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 11 LIST OF FIGURES  
Figure  3.1: Study Schematic* ................................ ................................ ................................ ........ 42 
Figure  3.2: Post-treatment Assessments Vary With Reason for Study Withdrawal* .................... 44 
 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 12 GLOBAL AMENDMENT , PROTOCOL  V 10.0 
Amendment Rationale : 
The main purpose of this amendment is to update the safety information for pexidartinib and to 
revise the dose modification criteria  
Changes  to the Protocol : 
Please refer to the comparison document for protocol version 9.0 (dated 15 Dec 2017) vs. 
protocol version 10.0 (dated 22 Jan 2020 ) for actual changes in -text. The summary of changes 
below is a top-line summary of major changes in the PLX108 -10 clinical stu dy protocol 
(Version  10.0) by section.  
DESCRIPTION  OF EACH HIGH -LEVEL CHANGE  
1 Added option of transition to commercial pexidartinib for reason for withdrawal 
from study . 
The following sections of the protocol were updated:  
 Section 4.2.1 (Reasons for Withdrawal/Early Discontinuation ) 
2 Updated dose modification guidelines .  Added additional guidelines for subjects 
with renal impairment.  
The following sections of the protocol were updated:  
 Section 5.3 (Dose Modification Guidelines)  
 Section 5.3.1 (Renal  Impairment)  
3 Updated guidelines for concomitant dosing of CYP3A/UGT inhibitors, hormonal 
contraceptives, and proton -pump inhibitors.  
The following sections of the protocol were updated:  
 Section 5.4.1 (C YP3A and UGT Inhibitors/Inducers ) 
 Section 5.4.2 (Hormonal Contraceptives)  
 Section 5.4.3 (Acid -reducing Agents)  
4 Updated study contacts.  
The following section of the protocol w as updated:  
 Section 10.1 (Study Contacts)  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 13 LIST OF ABBREVIATION S 
Abbreviation or Term  Definition/Explanation  
AE Adverse event  
ALT  Alanine aminotransferase  
AML  Acute myeloid leukemia  
AST  Aspartate aminotransferase  
AUC ss Area under the time –concentration curve at steady state  
BPI Brief Pain Inventory  
Cav Average concentration  
CI Confidence Interval  
Cmax Peak concentration  
CR Complete response  
CSF-1 Colony stimulating factor 1  
CSF1R  Receptor for Colony stimulating factor 1  
CTCAE  Common Toxicity Criteria for Adverse Events  
Ctrough Minimum concentration  
CVA  Cerebrovascular accident  
CYP  Cytochrome P450  
DMC  Data Monitoring Committee  
DSI Daiichi Sankyo , Inc. 
ECG  Electrocardiogram  
ECHO  Echocardiogra m 
eCRF  Electronic case report form  
EDC  Electronic data capture  
EIU Exposure in utero  
EQ-5D-5L EuroQol five -dimensional descriptive system  
EU European Union  
Flt3 fms-like tyrosine kinase 3  
FSH Follicle -stimulating hormone  
GCP  Good Clinical Practice  
GCT -TS Giant cell tumor of the tendon sheath  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 14 Abbreviation or Term  Definition/Explanation  
GGT  Gamma -glutamyl transpeptidase  
HCl Hydrochloride  
HCRU  Healthcare resource u se 
HCV  Hepatitis C virus  
IB Investigator ’s Brochure  
ICH International Conference on Harmoni sation  
IEC Independent ethics committee  
INR International normalized ratio  
IRB Institutional review board 
ITT Intent -to-Treat 
LH Luteinizing hormone  
MedDRA Medical Dictionary for Drug Regulatory Activities  
Mg Milligram  
MMRM  Mixed models for repeated measurements  
MRI  Magnetic resonance imaging; magnetic resonance image  
MUGA  Multi -gated acquisition  
NCI National Cancer Institute  
NOAEL  No Observed Adverse Effect Level  
NRS  Numeric rating scale  
OTC  Over -the-counter  
PD Progressive disease  
PDy Pharmacodynamic(s)  
PGx Pharmacogenomic  
PK Pharmacokinetic(s)  
PopPK  Pooled population pharmacokinetic  
PR Partial response  
PRO  Patient -reported outcome  
PROMIS  Patient -reported Outcomes Measurement Information System  
PT Preferred term  
PVNS  Pigmented villonodular synovitis  
QD Once daily  
QTc Corrected QT interval  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 15 Abbreviation or Term  Definition/Explanation  
QTcF  Fridericia corrected QT interval   
RAMRIS  Rheumatoid Arthritis MRI Score  
RECIST  Response Ev aluation Criteria in Solid  Tumors  
RNA  Ribonucleic acid  
ROM  Range of motion  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SAVER  Serious adverse event report  
SD Stable disease  
SOC  System organ class  
SSD Sum of the short -axis dimension  
SUSAR  Suspected  unexpected serious adverse r eaction  
TEAE  Treatment -emergent adverse event  
TGCT  Tenosynovial giant cell tumor  
TVS  Tumor Volume Score  
ULN  Upper limit of normal  
US United States  
WORMS  Whole Organ MRI Score  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 16 PROTOCOL SYNOPSIS  
EudraCT No.  2014 -000148 -14 IND 
No. 117,332  Protocol 
No. PLX108 -10 
Investigational 
Product  Pexidartinib  (PLX3397)  Active Ingredient (s) 
INN Pexidartinib 
(PLX3397)  
Study Title  A Double -blind, Randomized, Placebo -controlled Phase 3 Study of 
Orally Administered PLX3397 in Subjects With Pigmented Villonodular 
Synovitis or Giant Cell Tumor of the Tendon Sheath  (ENLIVEN ) 
Study  Phase  3 
Indication  
Under 
Investigation  Pigmented villonodular synovitis (PVNS) / giant cell tumor of the tendon 
sheath (GCT -TS), also known as  tenosynovial gia nt cell tumors  (TGCT) , 
localized and diffuse types , according to the 2013 World Health 
Organization classification system . 
Study 
Objectives  The primary objective of this study is to compare the response rate of 
pexidartinib with that of placebo per Response Evaluation Criteria in 
Solid Tumors , versio n 1.1 ( RECIST 1.1 ) at Week  25 in subject s with 
symptomatic , locally advanced  PVNS or GCT -TS.  
The secondary efficacy objectives are to evaluate :  (i) patient -reported 
outcomes (PROs),  including the Brief Pain Inventory (BPI) Worst Pain 
Numeric Rating Scale (NRS) item, Patient -reported Outcomes 
Measurement Information System ( PROMIS ) Physical Function Scale, 
and Worst Stiffness NRS item , at Week 25 ; (ii) response based on 
Tumor Volume S core (TVS) at Week 25; (iii) range of motion  (ROM)  at 
Week 25 ; and (iv) duration of response . 
Other objectives are to evaluate :  (i) other measures of efficacy , (ii) 
long-term safety, (iii) pharmacokinetics ( PK), and 
(iv) pharmacodynamics ( PDy) of pexidartinib  in trea ted subject s. 
Study Design  This trial is a two -part multi -center Phase 3 study in subject s with 
symptomatic PVNS or GCT -TS for whom surgical resection would be  
associated with potentially worsening functional limitation or severe 
morbidity  (locally advanced disease) . In Part 1, the double -blind phase, 
eligible candidates  will be centrally randomized in a 1:1 ratio to receive 
either pexidartinib  or placebo for 24  weeks . Randomization will be 
stratified by US versus non-US sites  and by upper extremity vs . lower 
extremity involvement . 
Subject s will take five capsules a day (1000 mg/d pexidartinib  or 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 17 matching placebo ) divided into a morning dose of two capsules and an 
evening dose of three capsules for the first 2 weeks  in Part 1 . Thereafter , 
the dose will be reduced to four capsules a day (800  mg/d pexidartinib  or 
matching placebo ) divided equally between the morning and evening 
doses.  Doses will be taken in the fas ting state  at approximately the same 
times of the day and approximately 12  hours apart.  Each treatment cycle 
is 28 days  and subjects will be treated for up to 6 Cycles . Dose 
reductions, interruptions, and re-escalations after previous reductions for 
toxici ty are permitted according to pre -specified guidelines.  Those 
subjects, whether on pexidartinib  or matching placebo,  who complete 
Part 1 (ie, complete 24 weeks of dosing and the Week 25 assessments) 
will be eligible to advance to  Part 2, a long -term treatment  phase where 
all subject s will receive open -label pexidartinib  at a maximum starting 
dose of four capsules a day ( 800 mg/d  pexidartinib ). Effective 30 Sep 
2016 , per study Data Monitoring Committee  (DMC)  recommendation, 
subjects on placebo are no longer allowed into Part 2 to receive open -
label pexidartinib.  
MRIs will be performed at Week 13 (Cycle 4, Day 1 visit of Part 1 ) and 
Week 25. For those subjects who undergo surgical resection, an MRI 
will be performed 4 months after surgery. All MRI scans will be 
assessed by central readers blinded to treatment assignment and other 
clinical study data during both Parts 1 and 2 of the study, acco rding to 
procedures outlined in a separate MRI Imaging Charter. The central 
MRI assessment report of progression status will not be provided unless 
the Investigator  requests an expedited central review of a scan.  
If disease progression is indicated clinica lly or by local radiologic 
assessment according to RECIST 1.1 at  or after Week 13 but before 
Week 25 , the Investigator  may request a central review for evaluation of 
disease progression.  If a central reading confirms RECIST 1.1 -defined  
disease progression , treatment assignment will be unblinded, and 
subjects receiving placebo will be eligible for early entry into Part 2  of 
the study . Effective 30 Sep 2016, subjects receiving placebo will be 
discontinued instead of being eligible to enter Part 2.  Subjects re ceiving 
pexidartinib  will be discontinued from the study unless the Investigator  
and the Sponsor’s Medical Monitor judge that the subject would 
potentially benefit from continued treatment with pexidartinib . During 
Parts 1 & 2 of the protocol, the Investigator  may request an expedited 
central review of a scan locally assessed as disease progression 
according to RECIST 1.1.   
All subject s in Part  2 will continue to receive open -label pexidartinib  
until all subject s have either reached  at least the Wee k 49 visit (ie, an 
additional 24  weeks of open -label pexidartinib  treatment beyond the 
placebo -controlled phase)  or withdrawn from the trial . Those subjects 
who complete Part 2 will be eligible to continue for longer efficacy and 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 18 safety follow -up or to enter a separate protocol to continue receiving 
pexidartinib .  
For statistical analysis of endpoints at the end of Part 1 , a clinical data 
cut-off date will be defined for the point when all randomized subjects 
complete or are discontinued  from Part 1 with appropriate End of Part 1 
follow -up. All data up  to this date will be cleaned. Unblindi ng of 
database  will be performed to facilitate  the data analyses, including the 
data from the double -blind Part 1 a nd available data from Part 2. Such 
unblinding is only intended for the sponsor and the Contract Research 
Organization . Subjects who entered Part 2 may continue to receive open -
label pexidartinib treatment . Updated analysis of Part 2 data only, in the 
form of summary and descriptive statistics, will be pe rformed at the end 
of the trial.   Additional updates between the above -mentioned cut -off 
and end of the trial may also be performed . 
A range -of-motion assessment in  the affected joint or tumor location 
will be performed by an independent and blinded third party assessor at 
specified  time points . PRO instruments will also be completed at 
specified time points.  
Ongoing safety will be monitored by a n indepen dent DMC according to 
a separate charter.  
Subject s who end their study participation early with no radiologic 
disease progression will undergo :  (i) the 28 Day Post-treatment Visit 
assessment with an MRI 28 ± 7 days after their last dose of study 
treatment; and (ii) a final MRI 12 weeks ± 7 days after their last dose of 
study treatment or before any new  PVNS therapy,  including surgery,  
whichever occurs first (the “ Part 1 End-of-Study/ 12 Week Post -
Treatment  Visit”).  After completion of the end of Part 1 assessments 
(Part 1 Completion visit/Early Termination visit), subjects who wish to 
continue onto the o pen label part of this study (Part 2) will be unblinded 
and those on placebo will be discontinued; subjects on pexidartinib in 
Part 1 may continue into Part 2 to continue to receive pexidartinib.  
Subject s who complete Part 2 and choose to enter a separate protocol to 
continue receiving pexidartinib will not have the Post-treatment and 
End-of-Study Visit  assessments . Subject s who terminate the study with 
radiologic disease progression will undergo the Post -treatment Visit  
assessment  without  an MRI 28 ± 7 days after their last dose of study 
treatment or before any new PVNS therapy, including surgery, 
whichever occurs first.   
Subjects are allowed to undergo surgical resection of their tumor after 
the completion of Part 1 . For subjects who undergo surgica l resection 
within 12 weeks after their last dose of study treatment, they will not 
have the End -of-Study Visit assessments but will follow a separate visit 
schedule after the decision of surgery is made. The surgery is 
recommended to  be performed 1 -3 weeks  after the last dose of  study 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 19 treatment. Details of the surgery and its short and long term outcome 
will be collected . Data collection for the surgery and its outcome may 
continue in a separate protocol.   
Inclusion 
Criteria  1. Age ≥  18 years.  
2. A diagnosis of PVNS or GCT -TS (i) that has been histologically 
confirmed either by a pathologist  at the treating institution or a 
central pathologist , and (ii) where s urgical resection would be 
associated with potentially worsening functional limitation or  
severe morbidity  (locally advanced disease), with morbidity 
determined consensually  by qualified personnel ( eg, two 
surgeons or a multi -disciplinary tumor board) . 
3. Measurable disease as defined by RECIST 1.1  (except that a 
minimal size of 2 cm is required) , assessed from MRI scans by a 
central radiologist.  
4. Symptomatic disease  because of active PVNS or GCT -TS, 
defined  as one or more of the following:  
a. a worst pain of at least 4 at any time during the week 
preceding the Screening Visit (based on scale of 0  to 10, with 
10 representing  “pain as bad as you can imagine ”).  
b. a worst stiffness of at least 4 at any time during the week 
preceding the Screening Visit  (based on a scale of 0 to 10, 
with 10 representing “ stiffness as bad as you can imagine”).  
5. Stable prescri ption of analgesic regimen during the 2 weeks prior 
to randomization . 
6. During the 2 weeks prior to randomization, at least 4 of 7 
consecutive days  of BPI Worst Pain NRS items and Worst 
Stiffness NRS items completed correctly . 
7. Women of childbearing potential must have a negative serum 
pregnancy test within the14 -day period prior to randomization.  
(Where demanded by local regulations, this test may be required 
within 72  hours of randomization.)  
8. Males and females of childbearing p otential are permitted in the 
study so long as they consent to avoid getting their partner 
pregnant or becoming pregnant, respectively, by using a highly 
effective contraception method, as described below, throughout 
the study and for up to 90 days after c ompletion.  Highly 
effective methods of contraception include: intra -uterine device  
(nonhormonal or hormonal), bilateral tubal occlusion, vasectomy,  
sexual abstinence , or barrier methods (e.g., condom, diaphragm) 
used in combination  with hormonal methods a ssociated with 
inhibition of ovulation . Women of non -childbearing potential 
may be included if they are either surgically sterile or have been 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 20 postmenopausal for ≥  1 year.  Women who have documentation 
of at least 12 months of  spontaneous amenorrhea and hav e an 
follicle -stimulating hormone  level >  40 mIU/mL will be 
considered postmenopausal.  
9. Adequate hematologic, hepatic, and renal function, defined by:  
 Absolute neutrophil count ≥ 1.5× 109/L  
 Hemoglobin > 10 g/dL  
 Platelet count ≥ 100 × 109 /L  
 AST/ALT ≤ 1.5× ULN  
 Total bilirubin ≤ 1.5× ULN  
 Serum creatinine ≤  1.5× ULN  
10. Willingness and ability to complete the BPI Worst Pain NRS 
item, Worst Stiffness NRS item, PROMIS Physical Function 
Scale , and other self-assessment  instruments  throughout the 
study. 
11. Willingness and ability to use a n electronic  diary . 
12. Willingness and ability to provide written informed consent prior 
to any study -related procedures and to comply with all study 
requirements.  
Exclusion 
Criteria  1. Investigational drug use within 28 days of randomization . 
2. Previous use of pexidartinib  or any biologic treatment targeting 
colony stimulating factor 1  (CSF -1) or the CSF-1 receptor ; 
previous use of oral tyrosine kinase inhibitors, eg, imatinib or 
nilotinib, are allowed . 
3. Active cancer (either concurrent or within the last year of starting 
study treatment) that requires therapy ( eg, surgical, 
chemotherapy , or radiation therapy), with the exception of 
adequately treated basal or squamous cell carcinoma of the skin, 
melanoma in -situ, carcinoma in -situ of the cervix or breast, or 
prostate carcinoma with a prostate -specific antigen value <0.2 
ng/mL.  
4. Known m etastatic PVNS/GCT -TS. 
5. Active or chronic infection with hepatitis C virus or hepatitis B 
virus or known active or chronic infection with human 
immunodeficiency virus . 
6. Known a ctive tuberculosis.  
7. Significant concomitant arthropathy in the affected joint, serious 
illness, uncontrolled infection, or a medical or psychiatric history 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 21 that, in the Investigator ’s opinion, would likely interfere with a 
candidate’s study participation or the interpretation of his or her 
results.  
8. Women  who are breastfeeding.  
9. A screening Fridericia corrected QT interval (QTcF ) ≥ 450 ms 
(men) or ≥ 470 ms (women).  
10. MRI contraindications.  
11. History of hypersensi tivity to any exci pients in the investigational 
product . 
12. Inability to swallow capsules.  
Study  Duration  Each subject  will spend a maximum of 6 weeks in screening.  Part 1 will 
be a maximum of 24 weeks in duration . Patients for whom disease 
progression is confirmed at or after Week 13 but before W eek 25 (by 
independent central radiological evaluation) and are taking placebo are 
eligible for entry into Part 2  early  prior to 30 Sep 2016 . The duration of 
Part 2 will vary among subject s, as this portion of the trial will c ontinue 
until all subject s in this phase have either completed at least the Week 49 
Visit or withdrawn from the study . The study will end with the last 
subject  last visit.  Subject s who complete Part 2 will be eligible to 
continue for longer efficacy and safety follow -up or to enter a separate 
protocol to continue receiving pexidartinib  until disease progression, 
unacceptable toxicity, or the occurrence  of other termination criteria.   
Study Sites & 
Locations  Approximate ly 45 study sites  internationally across the US, Canada , EU, 
and Australia . 
Planned 
Sample Size  Approximately 12 6 subjects across sites globally  are planned.  
Test Product, 
Dose, and  
Route of 
Administration  The study treatment , either pexidartinib  or placebo, will be administered 
orally daily in capsule form.  Each capsule of pexidartinib  will contain 
200 mg of PLX3397 (J-3397 -AF in hydroxypropyl methylcellulose 
capsules)  or matching placebo.  In Part 1, subject s will take five capsules 
a day  (1000 mg/d pexidartinib or matching placebo ) divided into a 
morning dose of two capsules and an evening dose  of three capsules . 
After 2 weeks  (P1-C1D15 ), dosing wil l be reduced to two capsules in  the 
morning and two capsules in the evening (800 mg/d pexidartinib  or 
matching placebo ). All subject s will begin Part 2 by continuing to take 
the same number of  capsules per day of open -label 800 mg/d 
pexidartinib . Doses will be taken in the fasting state ( no food for 1 hour  
before and 2 hours after  dosing , with a low -fat snack  if needed)  at 
approximately the same times of the day and approximately 12  hours 
apart.  Each treatment cycle is 28 days.   
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 22 The study treatment for home administration during Part 1 will be 
dispensed to the subject  for the first time at the Cycle 1, Day 1 visit of 
Part 1, and the study treatment for home administration during Part  2 
will be dispensed to the subject  for the first time  at the Cycle 1, Day 1 
visit of Part 2 . 
Dose 
Modification 
Guidelines  Reduction or interruption of dosing can be implemented at any time to 
manage intolerable or clinically significant toxicity.  Subject s unable to 
tolerate two capsules per day (400 mg/d pexidartinib  or matching 
placebo ) will be discontinued.  Guidelines for dose modification are 
specified in Section  5.3. 
Study 
Assessments  Efficacy  — MRI, range of motion, BPI Worst Pain NRS item, Worst 
Stiffness NRS item, PROMIS Physical Function Scale, EuroQol five -
dimensional descriptive system ( EQ-5D-5L), Surgical Assessment 
Questionnaire, major healthcare resource use  (HCRU)  and productivity, 
analgesic medications.  
Safety  — Physical examination, vital signs, 12 -lead electrocardiogram 
(ECG ), echocardiography, adverse eve nt reports, serum chemistry, 
hematology, coagulation tests, urinalysis, hormone testing (as 
applicable), concomitant medications.  
PK — PK blood samples will be drawn.  
PDy — Plasma samples for pexidartinib  PDy markers and for 
exploratory markers of monocyte or macrophage activities. Available 
archival surgical tissue from tumors will be collected and stored for 
exploratory purposes . 
Efficacy 
Endpoints  Primary efficacy endpoint:  
The proportion of subjects who achieve a complete  response (CR)  or 
partial response  (PR)  at the Week 25 visit based on centrally read MRI 
scans and RECIST 1.1.  
 Secondary efficacy endpoints:  
 Mean change from baseline in range of motion of the affected 
joint, relative to a reference standard for the same joint, at the 
Week 25 visit  
 Proportion of responders based on centrally evaluated MRI 
scans and TVS at the Week 25 visit  
 Mean change from baseline score in the  PROMIS Physical 
Function Scale at the Week 25 visit  
 Mean change from baseline score in the Worst Stiffness NRS 
item at the Week 25 visit  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 23  Proportion of responders based on the BPI Worst Pain NRS 
item and analgesic use by BPI -30 definition [subject who (i) 
experienced a decrease of at least 30% in the mean BPI Worst 
Pain NRS item and (ii) did not experience a 30% or greater 
increase in narcotic analgesic use compared to baseline]  
 Duration of response  (CR or PR) based on MRI and RECIST 
1.1 
 Duration of respons e (CR or  PR) based on MRI and TVS  
 Additional efficacy endpoints to be analyzed at Week 25, with the 
exception of duration endpoints or otherwise indicated, include:  
 Proportion of responders on the BPI Worst Pain NRS item 
and analgesic use by B PI-2p definition [subject who (i ) 
experienced a decrease of at least 2 points in the mean BPI 
Worst Pain NRS item and ( ii) did not experience a 30% or 
greater increase in narcotic analgesic use  compared to 
baseline ] 
 Proportion of responders on the BPI Worst Pain  NRS item 
and analgesic use by BPI -50 definition [subject who ( i) 
experienced a decrease of at least 50% in the mean BPI Worst 
Pain NRS item and ( ii) did not experience a 30 % or greater 
increase in narcotic analgesic use  compared to baseline ] 
 Proportion o f responders on the Worst Stiffness NRS item  
 Proportion of responders on the PROMIS Physical Function 
Scale  
 Mean change from baseline in the BPI Worst Pain NRS item  
 Patient Global Impression of Change item for tumor -related 
stiffness and Patient Global Rat ing of Concept item for ability 
to carry out every day physical activities.  
 Duration of BPI -based symptom response, analyzed for BPI -
30, BPI -50 and BPI -2p. 
 Results of the Surgical Assessment Questionnaire in Part 1.  
 Response based on the change in the sum  of the short -axis 
dimension (SSD) of the tumor on MRI, referred to as 
"modified RECIST 1.1 -SSD"  
 Amount of joint/tissue damage (eg, bone erosion, bone 
edema, cartilage loss) assessed on MRI based on adaptations 
of the Rheumatoid Arthritis MRI Score  and Who le Organ 
MRI Score  
 Analgesic use expressed as morphine -equivalent doses in Part 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 24 1 
 EQ-5D-5L parameters in Part 1  
 Major HCRU  and productivity in Part 1  
 Duration of response based on MRI and modified RECIST 
1.1-SSD 
 Response based on the most disturbing symptom of pain, 
stiffness, or compromised ability to  carry out everyday 
activities  
 Proportion of subjects receiving surgical resection of their 
tumor by 25 weeks, 49 weeks, 73 weeks, and 97 weeks of 
pexidartinib treatment  
PK Analysis  Plasma –concentration time data for pexidartinib  will be summarized by 
visit and time using descriptive statistics. The data from these samples 
will be analyzed using a pooled population pharmacokinetic (PopPK) 
approach using nonlinear mixed effects modelin g. PK parameters will 
include apparent clearance and volume of distribution along with transfer 
rate constants such as absorption and elimination rates. Additionally, 
based on post -hoc Bayesian methods, estimates of exposure such as 
Cmax, Ctrough, Cav and AUC ss may also be reported  
PDy/Biomarker 
Analysis  No formal statistical analysis of PDy endpoints will be performed. PDy 
data from each assay will be listed and possible relationships between 
PK and PDy variables may be explored. Any biological activity w ill be 
described.  
Statistical 
Analyses  Efficacy analyses will be performed  on the i ntent -to-treat (ITT) Analysis 
Set. For the efficacy analyses, subjects will be included in the treatment 
group to which they were randomized.  
The primary endpoint is the proportion of subjects who achieve a CR or 
PR at the Week 25 Visit based on centrally read MRI scans and RECIST 
1.1. The proportions in the two treatment groups will be compared using 
Fisher’s exact test (two -sided) at the alpha  = 0.05 level of significance. 
In addition, the two -sided 95% confidence interval  (CI) for the 
difference between the responder proportions in the two treatment 
groups will be provided  using the Wilson method . 
The following treatment comparisons at the Wee k 25 visit are secondary 
efficacy analyses:  
1. Mean change from baseline in range of motion of the affected 
joint, relative to a reference standard for the same joint ; 
2. Proportion of responders based on centrally evaluated MRI scans 
and TVS ; 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 25 3. Mean change from b aseline in the PROMIS Physical Function 
Scale;  
4. Mean change from baseline in the Worst Stiffness NRS item ; 
5. Proportion of responders by BPI Worst Pain NRS item and 
analgesic use by BPI -30 definition . 
These above -listed endpoints will be analyzed using a hier archical 
(“gatekeeping”) testing procedure. Thus, if the primary analysis is 
statistically significant (p<0.05), then secondary endpoint #1 will be 
analyzed, also based on the use of a two -sided test at the alpha=0.05 
level of significance. If secondary en dpoint #1 is statistically significant 
(p<0.05), then the testing procedure will proceed to secondary endpoint 
#2, and so on. If the test for a particular endpoint is not statistically 
significant, the inference for all subsequent endpoints in the hierarch y 
will not be performed.  
Duration of response will also be a secondary efficacy endpoint and will 
be summarized by treatment group using the Kaplan -Meier product limit 
approach. The estimate and 95%  CI will be provided for the median and 
the 25th and 75th percentiles.  
All secondary endpoints of mean changes at Week 25 will be analyzed 
using mixed models for repeated measurements . The dependent variable 
will be the change from baseline.  Each of these models will include fixed 
effects for treatment group, tim e point, treatment group -by-time 
interaction, stratification factor of US sites versus non -US sites, and the 
baseline value of the corresponding endpoint as well as the baseline -by-
time interaction. An unstructured variance -covariance matrix will be 
used. Statistical comparisons between groups will be made at the 
specified time point. For secondary endpoint s #2 and # 5, the proportions 
of responders in the two treatment groups will be compared using 
Fisher’s exact test. 
Safety analyses will be performed on t he Safety Analysis Set, and safety 
variables, including treatment -emergent adverse events, laboratory tests, 
vital signs, and ECGs, will be summarized.  
Sample Size Evaluation  — The assumed responder rates for the primary 
endpoint are 10% (placebo) and 35 % (pexidartinib ). Based  on the use of 
a two -sided, two -sample comparison of proportions at the alpha=0.05 
level of significance by Fisher’s exact test, a sample size of 12 6 ITT 
subjects (6 3 per arm) provides 9 0% power to detect this magnitude of 
difference.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 26 1. INTRODUCTION AND BAC KGROUND INFORMATION  
A comprehensive review of pexidartinib  (PLX3397) is contained in the Investigator ’s Brochure 
(IB). Investigator s should review the IB prior to initiating this study. A brief review of 
pexidartinib  is provid ed here.  
1.1. Scientific Background  
1.1.1.  Pigmented Villonodular Synovitis and Giant Cell Tumors of the Tendon Sheath  
Pigmented villonodular synovitis (PVNS) and giant cell tumors of the tendon sheath (GCT -TS) 
are members of a single condition referred to as “tenosynovial giant cell tumour  (TGCT) , 
localized  and diffuse type”  and have a common pathogenesis  1. They are rare proliferati ve 
neoplasms involving the synovium and tendon sheaths that typically present in young and 
middle -aged adults of both sexes . PVNS and GCT -TS are usually monoarticular processes that 
involve the bone, soft tissue, synovium, or tendon sheath of small or larg e joints . Symptoms 
initially may be minimal due to the slowly progressive nature of the disease, but as the tumor 
mass grows and gradually expands within the fixed confines of the intra -articular space (and 
surrounding tissue) ; symptoms such as pain, stiff ness, swelling, and limitation in range of motion 
(ROM) can become severe and result in marked functional limitation . The diagnosis of PVNS is 
definitively made from pathologic evaluation; however, features highly suggestive of the disease 
may be found on radio logic  imaging, including computed tomography and magnetic resonance 
imag ing (MRI ). 
PVNS and GCT -TS tumors predominantly consist of mononuclear and multinucleated giant 
cells. In both diseases, expansion of the tumor mass appears to be driven by the presence of 
abundant Colony stimulating factor 1  (CSF-1) expressed by a subset of cells within the tumor 
and often associated with genetic translocations linking the collagen 6A3 gen e (on 2q35) with 
the CSF -1 gene (on 1p13) . The majority of cells in the tumor mass are non -neoplastic 
inflammatory cells that do not express CSF -1 but are attracted to the tumor site because of  their 
expression of the receptor , Colony stimulating factor 1  (CSF1R ). 
Both PVNS and GCT -TS are rare , with an estimated annual incidence of 1.8 cases per million 
and 9.2  cases per million, respectively , in the US.2  In a review of a  Scottish hospital case  series , 
Monaghan and coworkers  suggest ed an incidence of 0.2 cases of GCT -TS per 10, 000 in the EU .3  
Similarly , Ushijima et al.4  describ ed an incidence of 0.25  cases per 10,000 in Kyushu, Japan , 
while  a paired study suggest ed a PVNS  incidence of 0.06 per 10,000 .5  Patients are commonly 
diagnosed in their 20s to 50s , and the  disease affects men and women equally .2,6 
PVNS and GCT -TS are challenging diseases to manage . The current standard of care is surgical 
resection of the tumor as completely as possible in order to : (1) reduce pain, stiffness, and joint 
destruction caused by the disease process; (2) improve function; and (3) minimize the risk of 
recurrence . Patient outcome following surgery depends on multiple factors , including the 
location and extent of disease , thorough diagn ostic evaluation , and the technical skill of the 
surgeon . The overall recurrence rate for patients with focal localized disease is low, ranging from 
0% to 6%; however, in patients with diffuse forms of the disease, recurrence is considerably 
more common, e stimated to be in the range of 40% . Diffuse disease carries  a significant risk of 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 27 multiple recurrence, and affected patients often have more extensive involvement and a poorer 
likelihood of success with surgery . Surgical resection may involve removal of ma jor tendons, 
neurovascular structures, or limbs , leading to significant postsurgical morbidity.  
Currently, there are no systemic agents approved for the treatment of PVNS or GCT -TS. 
Products that are being evaluated in PVNS and GCT -TS include : imatinib (Gleevec)  7,8 a multi -
kinase inhibitor that targets Bcr -Abl tyrosine kinase yet also shows activity against CSF1R ; 
nilotinib (Tasigna), a second -generation drug based on imatinib  9, a macrophage colony 
stimulating factor antibody; and a humanized monoclonal antibody that targets CSF1R .10 
1.1.2.  Pexidartinib ( PLX3397 ) 
Pexidartinib  is a novel orally active small -molecule tyrosine kinase inhibitor that targets CSF1R, 
Kit (the receptor for stem cell factor), and  oncogenic fms-like tyrosine kinase 3 ( Flt3), the 
receptor for Flt3 ligand,  but remains highly selective versus other kinases . It is hypothesized that 
since PVNS and GCT -TS tumors cause pathology by secreting high levels of CSF -1, 
pexidartinib  should oppos e disease progression by directly targeting the CSF1R that drives the 
target cells . Inhibition of this pathogenetic pathway should block both the neoplastic cells that 
express CSF -1, which are often in the minority, and the non -neoplastic inflammatory cell s that 
comprise most of the tumor mass and do not express CSF -1 but  are attracted to the tumor 
because of  their expression of CSF1R . 
1.2. Nonclinical Studies  
When screened in vitro against a broad panel of 230 kinases, pexidartinib  shows potent and 
selective inhibition against its intended targets :  CSF1R, Kit, and activated Flt3 . Pexidartinib  also 
blocks osteoclast differentiation and cell growth of CSF -1-dependent cell lines . Althou gh 
nonclinical animal models of PVNS are not avai lable, pexidartinib  has shown the ability to block 
CSF1R activity in a variety of in vivo models . pexidartinib  shows dose -dependent inhibition of 
splenomegaly in an engineered CSF1R -dependent mouse model . In the collagen -induced arthritis 
model, pexidartin ib shows substantial efficacy by blocking the activity of macrophages and 
osteoclasts that infiltrate the diseased joints, reduces synovial inflammation and cartilage 
destruction, and reduces clinical scores for joint and digit swelling and redness even wi th 
treatment of advanced disease.  
Additional detailed information regarding the nonclinical pharmacology and toxicology of 
pexidartinib  can be found in the IB.11 
1.3. Clinical Experience  
Pexidartinib  has been evaluated in multiple  clinical studies , three  have either been completed  or 
have a report in progress : Study PLX108 -03, in patients with relapsed or refractory Hodgkin’s 
lymphoma; Study PLX108 -04, in recurre nt glioblastoma multiforme ; and Study PLX108 -06, in 
subject s advanced metastatic prostate cancer.  In addition, single -dose studies PLX108 -11 and 
PLX3397 -A-U114 were completed in healthy subjects. Seven  ongoing  studies are evaluating 
pexidartinib  in subject s with advanced incurable solid tumors . These trials focus on PVNS 
(PLX108 -01) 12 and PLX108 -10), relapsed or refractory acute myeloid leukemia (AML) 
(PLX108 -05), combination therapy in advanced incurable solid tumors (PLX108 -07, with 
paclitaxel; P LX108 -14, with pembrolizumab), in newly diagnosed glioblastoma multiforme 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 28 (GBM) (PLX108 -08, with temozolomide and radiation), and in BRAF -mutated metastatic 
melanoma (PLX108 -09, with vemurafenib).  All of these studies are open -label and 
uncontrolled .11 
See IB dated 07Dec2015 for total number of subjects exposed and the clinical experience s with 
pexidartinib.11  As of 31 -July-2015, 485  subjects  have been  exposed to pexidartinib . Cumulative 
safety data show the most commonly reported treatment -emergent adverse events ( TEAEs ) 
(> 10%) treatment -related TEAEs have included fatigue, nausea, decreased appetite, hair color 
changes, diarrhea, AST increased, vomiting, anemia, dysgeusia, ALT increased, and rash. 
Among com mon treatment -related TEAEs, fatigue, increased AST and ALT, anemia, and rash 
occurred at Grade 3 or higher severity and at a frequency greater than 1% .11  
Serious adverse event s (SAEs) that were assessed as subjects who experienced SAEs  as judged 
by the study Investigator  as possibly or probably related to study drug have been reported across 
all studies. Treatment -related SAEs reported more than once include neutropenia (including 
febrile neutropenia), increased ALT, increased AST, pneumonia, thrombocytopenia, 
dehydration , pyrexia, anemia, hyponatremia, increased INR, decreased neutrophil count, rash, 
and maculo -papular rash.   
A total of 21 deaths (excluding those attributed solely to disease progression) were recorded by 
31 July 2015, which include deaths occurring after study drug discontinuation in the follow -up 
period for assessment of overall survival. The majority of deaths attributed to an AE were 
considered unrelated to study treatment and some were likely related to a complication of their 
underlying malignancy.  Death was attributed to pexidartinib treatment by Investigator s in 2 
patients: Patient PLX001 -06-609 with widely metastatic Erdheim -Chester disease (polyostotic 
sclerosing histiocytosis) died from a cerebrovascular accident (CVA) 504 days after initiating 
treatment with pexidartinib at 1000 mg/day (PLX108 -01). The relationship of the CVA to 
pexidartinib was considered by the Sponsor’s Medical Monitor as being unlikely due to lack of 
pharmacologic plausibility (i.e., nonclinical data do not suggest any mechani sm for 
thromboembolic events); lack of similar events in the current safety database; and the presence 
of potential underlying predisposing clinical conditions, such as numerous old central nervous 
system infarcts on imaging of the brain, and bilateral int ernal carotid and middle cerebral artery 
abnormalities of the neck on computerized tomography with contrast. Patient PLX005 -07-009 
with AML died from cytokine release syndrome, which was reported as a Serious Adverse 
Reaction (SAR), 31 days after initiatin g treatment with pexidartinib at 3000 mg/day (PLX108 -
05). The fatal SAE of cytokine release syndrome was considered to be partly due to 
differentiation syndrome, a syndrome that can occur in patients manifesting a positive response 
to anti -leukemic therapy . Because this event is considered to occur only in AML patients 
responding to treatment, no additional safety assessments were recommended.  
No safety signals in vital signs, physical examinations, or electrocardiograms ( ECGs ) (including 
reports of potenti ally clinically significant QT prolongation) have been identified.  At 
pexidartinib  doses of ≥  600 mg/d, transient increases in AST and/or ALT have been observed 
across all clinical studies . In uncontrolled clinical studies of single agent pexidartinib and in 
combination with other anti -cancer agents, bone marrow suppression with leukopenia 
(neutropenia and/or lymphopenia), anemia and thrombocytopenia, either alone or with 
pancytopenia, has been observed. In addition, elevations of liver transaminases and bi lirubin 
have also been observed in studies with pexidartinib . 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 29 The current version of the IB is dated 26Oct2016.  
1.3.1.  Subjects with PVNS/GCT -TS Treated in Study PLX 108-01 
Study PLX108 -01, a n ongoing open -label uncontrolled dose -escalation study in subject s with 
advanced incurable solid tumors , has provided preliminary data for clinical improvement with 
pexidartinib  in a cohort of PVNS /GCT -TS subject s treated in th at study’s  extension phase . To be 
eligible for the PVNS /GCT -TS cohort, subjects  were required to have  a histologically confirmed 
diagnosis of inoperable progressive or relapsing PVNS/GCT -TS or have a potentially resectable 
tumor requiring mutilating surgery, and demonstrated progressive disease within the previous  12 
months . Subject s were given pexidartin ib at the recommended Phase 2 dose of 1000  mg/d 
adminis tered as a split do se (600 mg in the morning , 400 mg in the evening ), and they  were to 
continue  treatment until tumor progression or unacceptable toxicit y. Enrollment is ongoing.  
MRI was performed every two  cycles (8 weeks); evaluable scans were assess ed by a central 
musculoskeletal radiologist blinded to chronology using a novel Tumor Volume Score (TVS) 
developed specifically for PVNS/GCT -TS. This method was developed for PVNS/GCT -TS and 
used an extension of the 4 -point synovitis scale of the well -established and widely used Outcome 
Measures in Rheumatology Clinical Trials Rheumatoid Arthritis MRI Score (RAMRIS) erosion 
scale, originally developed for assessing rheumatoid arthritis of the hands and wrists13, and the 
Whole Organ MRI Score  (WORMS)14 originally developed for assessing osteoarthritis.  The 
percent change in the TVS i s calculated for each post -baseline MRI scan.  Responder criteria 
were defined as  follows : 
Complete Response  (CR) : Lesion completely gone by the end of the study . 
Partial Response  (PR) : ≥ 50% decrease in volume score relative to baseline . 
Progressive Disease  (PD) : ≥ 30% increase in volume relative to the lowest score 
during the study  whether at baseline or some other visit . 
Stable Disease  (SD) : Does not meet any of the pr evious  criteria based on score 
during the study . 
Subject  Characteristics and Tumor Responses  
Twenty -three subject s in this cohort  received at least one dose of study treatment . Median 
duration of treatment was 244 days, and the mean duration of treatment was 254 days (range, 15 
to 585  days).  Among those who withdrew from  the study, reasons for discontinuation were 
subject  decision (t hree subject s), adverse event (two subject s; pain in the non-PVNS extremity  
and fatigue , respectively ), noncompliance (one subject ), and disease progression (one subject ). A 
slight majority was female and most was  white.  The knee was the most common site of 
involvement . Prior to study enrollment, 18  of the subject s had undergone  surgery and four had 
been treated  with imatinib or nilotinib.  
As of 30-Jun-2014, an interim analysis data cutoff date,  14 of 23 subjects had a baseline and at 
least one post -baseline MRI that w as radiologically evaluable and assessed by central readers 
using a TVS  method (Plexxikon ; data on file) . The radiologically non -evaluable subject s 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 30 consisted of three subject s with no post -baseline MRI, four subject s with metallic artifact, and 
one subject  each with unevaluable tumor or lymph node CT only (metastatic disease).  
Most of the evaluable subject s had a rapid decline in TVS  that was maintained over time.  Eleven 
(79%) achieved a partial response , and three (21 %) experienced stable disease as a best response 
by TVS  criteria . None had a complete response or progressive disease.  Mean tumor size 
reduction was 61%. While metastatic PVNS/GCT -TS are quite uncommon, one subject  with 
metastatic disease was enrolled i n the study but was not evaluable by  TVS . This subject  had 
stable disease for 8 months before progressing at a metastatic focus.  From this dataset , this 
subject  is the only one who progressed while on therapy.  
All 23 subject s experienced at least one adverse event ( AE) considered by the Investigator  to be 
possibly or probably related to pexidartinib . The most frequently reported treatment -related AEs 
were hair color changes, fatigue, nausea, decreased appetite, diarrhoea, vomiting, anaemia, rash, 
periorbital edema , and dysgeusia . 11 11 
Treatment -related AEs of Grade  ≥ 3 severity was  reported in eight  subject s:  anemia ( one 
subject ), neutrope nia (one subject ), hyponatremia ( two subject s), elevated ALT and AST ( two 
subject ), fatigue ( one subject ) and diarrhea ( one subject ). Two subject s experienced three  AEs 
that led to hospitalization :  one subject  had Grade 3 cholecystitis and Grade  4 hyponatremia, and 
the other had Grade  3 acute renal failure.  In the subject  with cholecystitis and hyponatremia, t he 
cholecystitis was judged as unrelated to treatment  while the hyponatremia was judged to be 
treatment related.  The events  were treated and  resolved.  This subject  left the study because of  
noncompliance.  In the subject  who experienced  acute renal failure , the event  occurred in the 
context of an untreated urinary tract infection and dehydration; it was treated, resolved, and 
judged as unrelated to the study treatment.  The subject  resumed study treatment  without incident.  
No subject s in this cohort died during  the study.  
Approximately half of the subject s experienced  frequent  transient increases in AST and/or ALT.  
Most of these elevations  were of Grade 1 severity , remained stable or returned  to normal with 
continued dosing , and were not considered  to be AEs . Three subject s had Grade 3 ALT and/or 
AST elevations  that resolved to Grade 1 or less after drug holidays ; in two of these three 
subject s, dosing was resumed . One subject  had a Grade 2 AST elevation (with a Grade 1 ALT 
elevation) that resolved to Grade 1 or less with continued dosing . In all cases, total bilirubin was 
normal.  
Further details on  the clinical experience with pexidarti nib can be found in the IB. 11 
1.4. Study Rationale  
This study will be conducted in  two parts . Part 1 will be a double -blind randomized placebo -
controlled Phase 3 trial in subject s with symptomatic PVNS or GCT -TS for whom surg ical 
resection  would be associated with potentially worsening function al limitation or severe 
morbidity  (locally advanced dis ease) . Eligible candidates  will be randomized in a 1:1 ratio to 
receive either pexidartinib  or placebo twice daily for 24  weeks . The double -blind and 
randomized design will allow adequate comparison of pexidartinib  with a control group . Placebo 
was selecte d as the control group because there is no existing non -surgical treatment that is 
accepted as standard of care for PVNS /GCT -TS. Surgical treatment cannot be used as a control 
treatment because the patient population includes those for whom surgery is asso ciated with 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 31 potentially worsening function limitation or severe morbidity . Both the placebo and pexidartinib  
treatment groups will receive the usual supportive standard of care, eg, analgesic medications .  
Subjects will be started with 1000 mg/d pexidartinib  or matching placebo , ie five capsules , in 
Part 1 . It will be split into a morning dose of two capsules (400 mg  pexidartinib  or matching 
placebo ) and an evening dose of three capsules (600 mg  pexidartinib  or matching placebo ) and 
will be given in the fasting state ( no food for 1 hour  before and 2 hours after  dosing , with a low -
fat snack if needed) . Beginning on P1-C1D15 , the maximum daily dose will be reduced to four 
capsules ( 800 mg pexidartinib  or matching placebo ) if it has not already been reduc ed to that 
amount  or less. When subject s begin  Part 2, they will continue taking the same number of 
capsules  but of open -label pexidartinib , also split into a morning and an evening dose . Selection 
of the pexidartinib  starting dose of 1000  mg/d and the split-dose administration schedule is based 
on data from subjects with solid tumor s, including  the small cohort of subjects with PVNS who 
received pexidartinib  in Study PLX108 -01, a Phase  1 trial. In the dose -escalation portion of that 
trial, two subje cts receiving 1200  mg/d, administered as a split dose, experienced dose -limiting 
toxicities :  anemia, neutropenia, and syncope in one subject  and elevated AST in the other.  For 
this reason, 1000 mg /d given as a split dose was selected as the maximum tolerate d dose and the 
recommended Phase 2 dose. 
Data from the PVNS cohort in Study PLX108 -01, a  Phase 1 trial, suggest  that some subject s may 
require dose modification . While dose levels at and above 600 mg/d ha ve similar safety profiles,  
subject s who had  difficulty tolerating 1000 mg /d as a split dose were able to tolerate 600  or 800 
mg/d . Since approximately half of the PVNS subjects in Study PLX108 -01 required a dose 
reduction to at least 800 mg/d within the first 2 cycles (Plexxikon , data on file ), in this study 
subjects will be required to reduce their dose,  from 1000 mg/d or matching placebo to a 
maintenance dose of 800 mg/d of pexidartinib  or matching placebo, beginning on P1 -C1D15 . A 
dose reduction algorithm will allow subject s to further reduce the  dose of pexidartinib  or 
matching placebo in increments of one capsule, as needed  (Section  5.3). Those unable to tolerate 
pexidartinib  400 mg/d or matching placebo will be discontinued.    
The subject s to be studied in this trial are those with symptomatic nonmetastatic  PVNS or 
GCT -TS in whom  surgical resection is associated with potentially worsening functional 
limitation or severe morbidity . The use of pexidartinib , a selective kinase inhibitor that targets 
CSF1R (the receptor for colony stimulating factor 1, which is overexpressed in 
PVNS /GCT -TS)15, offers a promising new therapeutic option for patients with this diagnosis  
who would not be adequ ately treated with surgery, the existing standard of care . 
The 24-week duration of treatment  was selected on the basis of the preliminary data from Study 
PLX108 -01. Almost all of the decreases in TVS  have been observed before  the end of C6, ie, 
before the end of 24 weeks of pexidartinib  treatment . Accordingly, the duration  of Part 1 is 
ethically limited to 24 weeks to keep the placebo -control led portion as short as possible  and 
enabl e the placebo -treated  subject s to receive pexidartinib  as soon a s possible in Part 2 ; up to that 
point in the study , the subject s in the  placebo arm  will be receiv ing background standard  of care.  
1.4.1.  Study Purpose  
The purpose of th is study is to evaluate  the efficacy and long -term safety, pharmacokinetics, and 
pharmacodynamics of pexidartinib  treatment in subject s with symptomatic  PVNS/GCT -TS. The 
primary efficacy endpoint is the proportion of subject s who achieve a complete or partial 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 32 response  at the Wee k 25 visit  based on  centrally read MRI scans and Response Evaluation 
Criteria in Solid Tumors, v. 1.1  (RECIST 1.1 ).16 
1.5. Risks and Benefits  for Study Subjects  
In the Good Laboratory Practice  repeat -dose toxicology studies consisting of up to 13 weeks of 
pexidartinib  dosing, test article -related adverse effects were noted in testes  (testicular 
spermat ogonia reduction) , ovaries  (ovarian follicular degeneration) , bone and bone marrow, 
hematology and lymphoid changes; these changes are consistent with the pharmacological 
mechanism of action of pexidartinib . All test article -related findings were partially or fully 
reversible .11  Potential dose -related changes in bone marrow function can be monitored by 
peripheral cell count and differential counts . Because of the effects on reproductive organs, 
subject s will be monitored for  changes in luteinizing  hormone ( LH), follicle -stimulating 
hormone ( FSH), and other sex-speci fic hormone  levels.  
Effects on embryofetal development have been observed in both rat and rabbit toxicology studies  
up to 1 3 weeks . Dose level of 10 mg/kg/day was considered to be the NOAEL for embryofetal 
development when pexidartinib was a dministered orally by gavage to pregnant Sprague -Dawley 
rats. Dose of 20 mg/kg/day was considered to be the NOAEL for both reproduction in dams and 
embryo/fetal development. It was judged that pexidartinib was teratogenic in rabbits in the 
present study . Subject s in the study will be required to use adequate birth control during the 
study and for 90 days  after the last dose  of study treatment administered during study 
participation.  
Findings in the nonclinical canine safety  pharmacology study  suggest that pexidartinib  may have 
a negative inotropic effect . Subject s will be monitored for changes in ejection fraction with 
cardiac echocardiograms.  
In clinical evalu ation to date, the most common TEAEs of all grades have been fatigue, 
decreased appetite, nausea, vomiting, anemia, hair color depigmentation, and diarrhea . In a 
proportion of all subject s treated with pexidartinib , liver transaminases increased to 
approximately 1.5 × upper limit of normal ( ULN ) during the first cycle, followed by partial 
resolution du ring subsequent dosing . In some instances, the increase in liver enzymes may 
require dose hold or modification . Dosing modification guidance is included within the protocol 
for AE monitoring  (Section  5.3). Liver function (clinical chemistry), renal function (clinical 
chemistry), and heart electrophysiology (QTc evaluation) will be monitored during this study.  
Based on TEAE reports of increase d INR in subject s on warfarin who receive pexidartinib , 
subject s receiving warfarin should be carefully monitored when starting pexidartinib , and 
warfarin doses should be adjusted if an increase in INR is noted . 
More detailed and u pdated information regard ing clinical safety data can be found in the IB.11 
PVNS and GCT -TS are progressive diseases with no ideal or standardized treatments . No 
systemic treatments and no treatments specifically directed to the recently iden tified 
pathogenetic pathways have been approved for these diseases . Although the standard of care is 
surgery, guidelines and evidence -based data for the timing and extent of surgical intervention  are 
lacking .17 Surgical outcomes, even when curative, may result in marked patient morbidity as 
reflected in post -operative pain, limitation in function, and cosmetic disfig urement .18 In extreme 
or recurrent cases, the tumor may be aggressive and require limb amputation .19  The use of 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 33 pexidartinib , a selective kinase inhibitor that targets CSF1R (which is overexpressed in PVNS 
and GCT -TS)15, offers a promising new therapeutic option for patients with PVNS or GCT -TS. 
In summary, given the acceptable safety profile of the pexidartinib  at the selected dose and the 
promising Phase 1 data in subjects with PVNS/ GCT -TS, the potential  for a positive benefit/ risk 
profile is assumed for the Phase 3 study.  
1.6. Update d Risk Information and Change in Study Conduct  
During the conduct of this study, updated safety information became available including two 
SAEs  in this study consistent with cholestatic liver dysfunction. There were an estimated 80 
subject s who had been exposed to pexidartinib  at the time of this finding . The initial case, a 75 
year old woman with few risk factors, experienced hyperbilirubinemia for 2.5 months (ongoing), 
requiring study treatment discontinuation, hospitalization and two liver dialysis procedures. A 
liver biopsy showed cholestasis and duct openia. The second case, a 52 year old male with few 
risk factors, had grade 4 liver enzyme increase concurrent with hyperbilirubinemia, which 
resolved on study treatment discontinuation without further measures. Both cases were not re -
challenged with the study treatment.  
Five cases of this pattern of liver dysfunction have been observed in other pexidartinib trials, 
both in monotherapy and combination therapy. In total there are now 7 cholestatic/mixed type of 
liver dysfunction cases reported among approxi mately 550 subject s. In addition to the above 
ENLIVEN  study  cases, prolonged hyperbilirubinemia (> 8 months, ongoing) occurred in one 
case and two other cases took 2 -3 months to resolve. All cases occurred between 14 and 57 days 
of the start of pexidartini b treatment, suggesting a higher risk within the first 8 weeks of 
treatment. Three of the 7 cases had liver biopsy showing cholestasis and ductopenia. More 
detailed and u pdated information regarding clinical safety data can be found in the IB.11   
In response to the emergence of the two cases of potential cholestatic liver injury, the study Data 
Monitoring Committee (DMC) was requested to review the unblinded safety data related to these  
cases , other safety data from this study, and safety data for similar cases in other studies. The 
DMC recommended s afety measures that changed the conduct of this study to enhance the 
protection of subject s. The following measure s were implemented effective on 30  Sep 2016:  
1. Enrollment was stopped.  No new subject s may start study treatment. Subject s in 
screening and randomized subject s who have not started treatment must be discontinued.  
2. Subject s on placebo in Part 1 are no longer allowed to enter Part 2 to receive open -label 
pexidartinib. After completion of the end of Part 1 assessments (Part 1 Completion 
visit/Early Termination visit), subjects who wish to continue onto the open label p art of 
this study (Part 2) will be unblinded and those on placebo will be discontinued; subjects 
on pexidartinib in Part 1 may continue into Part 2 to continue to receive pexidartinib.  
3. Investigators and subject s must be informed of the new safety information and decide 
whether to continue in the study.  If, after consultation with the subject , it is deemed to be 
in their best interest to continue treatment, the subject  must be re -consented.  
4. The frequency of liver function testing is increased , and gamma -glutamyl transpeptidase 
(GGT ) is added to the laboratory panel . 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 34 Updated h epatic safety risk information  as of  December 2017 ; please consult the IB for more 
information . Hepatotoxicity is an important adverse drug reaction. Elevations of liver 
transam inases and bilirubin have been observed in studies with pexidartinib, together with cas es 
of drug -induced cholestasis.  Cases of cholestasis have been observed in the first 8 weeks and 
have generally resolved  with treatment discontinuation ; however,  some ca ses have be en severe, 
with a protracted course requiring liver dialysis and, in 1 case, transplantation. Hepatotoxicity 
may be fatal.  One fatal case with ongoing cholestatic liver injury at the time of deat h has been 
reported. Monitor patients closely as defined in the protocol. Protocol -defined dose reductions 
and discontinuations of pexidartinib, increased frequency of laboratory monitoring, and reporting 
of findings should be followed. In addition, rechallenge with pexidartinib should not be 
attempted w ithout prior discussion with the Sponsor’s Medical Monitor . 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 35 2. STUDY OBJECTIVES  AND HYPOTHESIS  
2.1. Study Objectives  
The primary objective  of this study  is to compare the response rate of pexidartinib  with that of 
placebo per RECIST 1.1 at Week 25 in subject s wit h symptomatic , locally advanced  PVNS or 
GCT -TS.  
The secondary efficacy objectives are to evaluate :  (i) Patient -reported Outcomes  (PROs),  
including the Brief Pain Inventory (BPI) Worst Pain Numeric Rating Scale (NRS) item, Patient -
reported Outcomes Measurement Information System ( PROMIS ) Physical Function Scale, and 
Worst Stiffness NRS item , at Week 25 ; (ii) response based on TVS at Week 25; (iii) range of 
motion  at Week 25 ; and (iv) duration of response.  
Other objectives are to evaluate  (i) other me asures of efficacy , (ii) long -term safety, 
(iii) pharmacokinetics ( PK), and (iv) pharmacodynamics ( PDy) of pexidartinib  in treated 
subject s. 
2.2. Study Endpoints  
2.2.1.  Primary Efficacy Endpoint  
The primary efficacy endpoint is the proportion of subject s who achieve a complete or partial 
response  at the Week 25 visit  based on  centrally read MRI scans and RECIST 1.1 . 
The RECIST 1.1 response categories are defined by the following criteria:  
 Complete Response  — Disappearance of all tumor s.  
 Partial Response  — At least a 30% decrease in the sum of diameters of target 
tumors, taking as reference the baseline sum diameters.  
 Progressive Disease  — At least a 20% increase in the sum of diameters of target 
tumors, using the smallest sum on study as the reference.  In addition to the relative 
increase of 20%, the sum must also demonstrate an absolute increase of at least 
5 mm. The appearance of one or more new tumors is also considered progression.  
 Stable Disease  — Neither sufficient shrinkage to qualify for PR nor su fficient 
increase to qualify for PD.  
No confirmation (ie, CR or PR at the subsequent MRI assessment) will be required for a CR or 
PR per RECIST 1.1 for a randomized study . Complete and partial response  will define response 
for the primary endpoint and additional efficacy analyses.  
Determination of an overall response for each time point is based on the combination of 
responses for target lesions, and the presence or absence of one or more new lesions.  For the 
purpose of this protocol and in alignment with RECIST 1.1, determination of the tumor response 
status for each subject in Part 1 with respect  to the primary efficacy endpoint is shown in  
Table  2.1. 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 36 To be considered a response, a tumor must meet the criteria for response and must have 
documented non -progression at Week 25.  A tumor that achieves PR at Week 13 followed by 
neither sufficient shrinkage  to qualify for CR nor sufficient increase to qualify for PD ( ie, non-
CR/non -PD/non -NE) at Week 25 will be considered a responder for the primary efficacy 
endpoint.  
Table  2.1: Definitions of Response for the Primary Efficacy Endpoint  
Time Point Response at 
Week 13  
(P1-C4D1 visit)  Time Point Response at Week 
25 
(Part 1 Completion visit)  End of Part 1  
Tumor Response Status  
(Primary efficacy endpoint)  
CR or PR  CR Response (CR)  
CR or PR  PD Non-response (PD)  
PR non-CR/non -PD/non -NEa Response (PR )b 
SD CR or PR  Response (CR or PR)  
SD SD Non-response (SD)  
SD PD Non-response (PD )c 
CR, PR, SD, or NE  NE Non-response (NE)  
PD Any Non-response (PD)  
NE CR or PR  Response (CR or PR)  
NE SD or PD  Non-response (SD or PD)  
CR = complete response; NE = not evaluated or inevaluable; PD = progressive disease; PR = partial response;  
SD = stable disease  
a Neither sufficient shrinkage to qualify for CR nor sufficient increase to qualify for PD, taking as reference the 
nadir  at Week 13 . 
b A tumor that has achieved the criteria of PR will be considered an ongoing PR until progressive disease is 
objectively doc umented.  
c To be considered SD, the tumor must achieve the criteria for SD at the Week 25 visit; shorter -duration SD will not 
be considered SD at the end of Part 1.  
For the entire study, c entrali zed review of the scans will be performed by readers blinded to 
treatment assignment and other clinical study data.  Scans will be obtained according to the MRI 
Imaging Charter . The imaging charter for this study describes the image acquisition standards 
and methodology to be used as well as the standards for  image interpretation.   
RECIST 1.1 has been used as a primary outcome measure in Phase 3 trials of several targeted 
therapies for the treatment of solid tumours ( eg, crizotinib for advanced non -small cell lung 
cancer, dabrafenib for BRAF V600 mutation -positive unresectable or metastatic melanoma)  and 
is supported by feedback  from regulatory agencies for this study . Eisenhauer et al, who proposed 
the revised RECIST guideline (version 1.1), noted the importance of future work in moving from 
anatomic unidirect ional assessment of tumour burden to either volumetric anatomical assessment 
or functional assessment with positron emission tomography  scan or MRI .16  However, they 
concluded that use of promising newer approaches in these areas would require appropriate 
clinical validation studies.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 37 2.2.2.  Secondary Efficacy Endpoints  
The following evaluations comprise  the secondary efficacy endpoints : 
1. Mean change from baseline in range of motion of the affected joint, relative to a 
reference standard for the same joint, at the Week 25 visit  
2. Proportion of responders based on centrally evaluated MRI sca ns and TVS at the Week 
25 visit  
3. Mean change from baseline score in the PRO MIS Physical Function Scale at the Week 
25 visit  
4. Mean change from baseline score in the Worst Stiffness NRS item  at the Week 25 visit  
5. Proportion of responders based on the BPI Worst Pain NRS item and analgesic use by 
BPI-30 definition (as defined in Section  7.6.2 ) 
6. Duration of respon se (CR or PR) based on  MRI  and RECIST 1.1  
7. Duration of respon se (CR or  PR) based on MRI and TVS  
The PRO instruments to be used as secondary outcome measures were selected on the basis of a 
process that involved : 
1. A targeted literature review  
2. Discussions with  four clinical experts with extensive experience managing PVNS/GCT -
TS 
3. A qualitative study carried out by the Sponsor to identify the key relevant concepts and 
confirm consistency with the literature  
4. Evaluation of a number of symptom instruments that were c onsidered of potential 
relevance and could be adapted for use in as sessing symptoms in PVNS/GCT -TS 
Reviews of the literature, input from clinical experts, and subject  cognitive debriefing supported 
the content and relevance of the BPI Worst Pain NRS Item . Subject s in the qualitative study 
often reported pain as a common and dominant symptom that varied on a daily basi s. For the BPI 
Worst Pain NRS i tem, subjects are asked to recall their worst pain at the site of their tumor in the 
past 24 hours.  The brief r ecall period of 24 hours could  provide information based on daily 
assessment , and the instrument is applicable to any  tumor location.  Assessments could be 
combined and summarized over a time period longer than 24 hours to yield more accurate 
estimates of subject s’ experiences of pain for weekly periods.   
Selection of stiffness and physical functioning as secondary endpoints was also based on a 
review of the literature, discussions with four clinical experts, and input from subjects with 
PVNS or GCT -TS. Stiffness was mentioned by 16 of the 22 participants (73%), including those 
with upper - and lower -extremity tumors, and specific impacts on functioning were mentioned by 
all participants either in the context of associations with specific symptoms or as a result of 
limitations to range of motion due to the tumors ( Plexxikon, data on file ).  
Specifically, the PROMIS Physical Functioning items and a Worst Stiffness NRS item were 
selected on the basis of (i) specific recommendations from the clinical experts a nd (ii) the 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 38 alignment of the concepts measured by these instruments with the symptom experiences reported 
by subject s with PVNS/ GCT -TS in the qualitative study.  
The PROMIS Physical Functioning items address symptoms of immobility.  The first scale is 
applicable to subject s with lower -extremity tumors, and the second scale applies to subject s with 
upper -extremity tumors.  Since tumors can be found in either the upper or lower extremities, the 
PROMIS Physical Functioning items provide the opportunity to inclu de measurement of both 
sites in a way that is not possible with other similar instruments ( eg, the Western Ontario and 
McMaster Universities Osteoarthritis Index  for PVNS and GCT -TS, which only measures 
functioning in the lower extremities).  
Stiffness wil l be evaluated using a Worst Stiffness NRS item.  Similar to the BPI Worst Pain 
item, the Wor st Stiffness NRS item uses a 24 -hour recall period.  Subjects are asked to recall their 
worst stiffness at  the site of their tumor in the past 24 hours.  Like the BPI  Worst Pain item, 
assessments can also be combined and summarized over a longer time period to yield more 
accurate estimates of subject s’ experiences of stiffness for weekly periods.  
TVS is a semi -quantitative MRI scoring system that describes tumor mass a nd is an extension of 
the 4 point synovitis scale of the well -established and widely used multi -feature score RAMRIS, 
originally developed for rheumatoid arthritis13, and WORMS, originally developed for 
osteoarthritis .14  The extended scale, the TVS, will be based on 10% increments of the estimated 
volume of the maximally distended synovial cavity or tendon sheath involved. Thus, a tu mor that 
is equal in volume to that of a maximally distended synovial cavity or tendon sheath will be 
scored 10, whereas a tumor that is 70% of that volume will be scored 7, a tumor that is twice the 
volume of the maximally distended synovial cavity or ten don sheath will be scored 20, and so 
on. A score of “0” means no evidence of tumor.  
Individual subject outcomes by TVS will be classified according to the followin g criteria 
inspired by RECIST:  
 Complete response: Lesion completely gone.  
 Partial response: ≥  50% decrease in volume score relative to baseline.  
 Progressive disease: ≥ 30% increase in volume relative to lowest score during the 
study whether at baseline or some other visit.  
 Stable disease: Does not meet any of the prior criteria based on score duri ng study.  
The cutoffs of 50% for PR and +30% for PD were developed in consultation with clinical 
experts. This magnitude of reduction was observed in a majority of evaluable subjects with 
PVNS from the Phase 1 study of pexidartinib  (Section  1.3.1 ). The tumor response status on this 
endpoint in Part 1 is determined in a way similar to that for the primary efficacy endpoint 
(Table  2.1). 
To minimize bias and reduce variability, all MRIs will be read cen trally in a blinded manner  for 
RECIST 1.1 - and TVS -based responses according to the separate MRI Imaging Charter . 
Treatment ef fects on physical functioning will be assessed by an objective range of motion 
assessment performed by a qualified independent third party such as an orthopedic surgeon or a 
physical therapist blinded to treatment assignment, and when possible, to investig ational drug 
name  and to study protocol. This assessment uses standard goniometers and has been 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 39 standardized according to American Medical Association disability criteria .20  Details of this 
analysis are described in Section  7.6.2 . 
2.2.3.  Additional Endpoints  
Additional endpoints to be analyzed at appropriate time points include : 
 The long -term safety of pexidartinib  in treated subjects, assessed from physical 
examination findings, vital sign data, 12 -lead ECGs, echocardiograms, AEs, serum 
chemistry, hematology, coagulation tests, urinalysis, and hormone testing (as 
applicable)  
 Proportion of responders on the BPI Worst Pain NRS item and analgesic use by 
BPI-2p definition (a s defined in Section  7.6.3 ) 
 Proportion of responders on the BPI Worst Pain NRS item and analgesic use  by 
BPI-50  definition (as defined in Section  7.6.3 ) 
 Proportion of responders on the Worst Stiffness NRS item  
 Proportion of responders on the PROMIS Physical Function Scale  
 Mean change from basel ine in the BPI Worst Pain NRS item  
 Patient Global Impression of C hange item for  tumor -related stiffness and Patient 
Global Rating of Concept item for ability to carry out every day  physical activities  
 Duration of BPI-based symptom response , analyzed for BP I-30, BPI -50 and BPI -2p 
 Results  of the Surgical Assessment Questionnaire  in Part 1  
 Response  based on the change in the  sum of the  short -axis dimension (SSD) of the 
tumor on MRI  
 Proportion of subjects receiving surgical resection  of their tumor by 25 weeks, 49 
weeks, 73 weeks, and 9 7 weeks  of pexidartinib  treatment  
In addition to standard RECIST 1.1, which is based on the longest unidimensional measurement, 
an exploratory endpoint will be the response based on centrally read MRI and the SSD of the 
tumor, hereafter referred to as “ modified RECIST 1.1 –SSD.” 
Short -axis measurements will be made perpendicular to a  reproducible adjacent landmark  such 
as the femoral bone or a tendon, where the tumor dimension appears greatest and yet confidently 
measurable . Measurement of this site will be repeated on the other visits.  The tumor response 
status on this endpoint in Part 1 will be determined in a way similar to that for the primary 
endpoint  Table  2.1. 
Amount of  joint/tissue damage ( eg, bone erosion, bone edema, cartilage loss)  assessed on MRI  
based on adaptations of the RAMRIS and WORMS : 
Bone e rosion will be scored based on the RAMRIS -erosion scale originally developed for 
assessing rheumatoid arthritis of the hands a nd wrists .13  The scale ranges from 0 to 10 in 10% 
increments of articular bone eroded  and is applied to each of the 14 regions  in the knee specified 
in WORMS14 or to each articular bone in the ankle/foot or elbow.  Articular bone is defined as 
bone within 1 cm of the art icular surface.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 40 Bone edema and cartilage loss will be scored based on WORMS in the same regions as bone 
erosion assessments.  
 Analgesic use expressed as morphine -equivalent doses in Part 1  
 EuroQol five -dimensional descriptive system (EQ-5D-5L) parameters  in Part 1  
 Major healthcare resource use (HCRU) and productivity  in Part 1  
 Duration of response based on MRI and modified RECIST 1.1 -SSD 
 Response based on the most disturbing symptom  of pain, stiffness, or compromised  
ability to carry out everyday activiti es 
The data from this study will be analyzed using a pooled population pharmacokinetic (PopPK) 
approach using nonlinear mixed effects modeling.  PK parameters will include apparent clearance 
and volume of distribution along with transfer rate constants such  as absorption and elimination 
rates.  Additionally, based on post -hoc Bayesian methods, estimates of exposure such as C max, 
Ctrough, Cav and AUC ss may also be reported.  
Plasma will be analyzed for pexidartinib  PDy markers and for exploratory markers of monocyte 
or macrophage activities, including CSF -1 and adiponectin.  When  available  and consented , 
archival surgical tissue from PVNS or GCT -TS tumor s will be  collected  for exploratory analysi s 
related to pexidartinib  and/or disease . 
2.3. Study Hypothesis  
Pexidartinib  is safe and more efficacious than  placebo when administered to subjects with 
symptomatic , locally advanced PVNS/GCT -TS. 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 41 3. STUDY DESIGN  
3.1. Over all Plan  
This trial is a two -part multi -center Phase 3 study in subject s with symptomatic PVNS or 
GCT -TS for whom surgical resection would be  associated with potentially worsening functional 
limitation or severe morbidity  (locally adva nced disease). In Part 1, the double -blind phase, 
eligible candidates will be centrally randomized in a 1:1 ratio to receive either pexidartinib  or 
placebo for 24  weeks.  Randomization will be stratified by US versus non-US sites and by upper 
extremity v ersus lower extremity involvement.   
Study treatment will be administered twice a day , every day . For the first 2 weeks in Part 1, 
subject s will take two capsules in the morning and three capsules in the evening, 1000  mg/d 
pexidartinib  or matching placebo . Thereafter, dosing will be reduced to two capsules in the 
morning and two capsules in the evening, 800  mg/d pexidartinib  or matching placebo . Subject s 
who had a dose reduction during the first 2 weeks will continue treatment at their reduced dose.  
Each tre atment cycle will be 28  days in duration  and subjects will be treated for up to 6 Cycles . 
Dose reductions, interruptions, and re-escalations after previous reductions for toxicity are 
permitted according to pre -specified guidelines.  Those subjects who complete Part 1 ( ie, 
complete 24 weeks of dosing and the Week  25 assessments) will be eligible to advance to Part  2, 
a long -term treatment phase where all subject s will take up to four capsules per day  (800 mg/d)  
of open -label pexidartinib . Effective 30 Se p 2016, subjects on placebo are no longer allowed into 
Part 2 to receive open -label pexidartinib . 
MRIs will be performed at Week 13 (Cycle 4, Day 1 visit of Part 1 [P1 -C4D1]) and Week 25. If 
disease progression is indicated clinically or by local radiologi c assessment according to 
RECIST 1.1 at or after Week 13 but before Week 25,  the Investigator  may request a central 
review  for evaluation of disease progression.   Any disease progression before Week 25 must  be 
verified by a central MRI reading. If a central reading confirms RECIST 1.1 -defined disease 
progression,  treatment assignment will be unblinded , and subjects receiving placebo  will be 
eligible for early entry into Part 2  of the study .  Effective 30 Sep 2016, subjects receiving 
placebo will be di scontinued instead of being eligible to enter Part 2. Subjects receiving 
pexidartinib  will be discontinued from the study unless the Investigator  and the Sponsor’s 
Medical Monitor judge that the subject would potentially benefit from continued treatment wi th 
pexidartinib . For those subjects who undergo surgical resection after Week 25, an MRI will be 
performed 4 months after surgery.  
Part 2 will continue until all subject s have either  reached  at least the Week 49 visit, ie, an 
additional 24 weeks of study treatment beyond the placebo -controlled phase , or withdrawn from 
the trial  (Figure  3.1). As in Part 1, dose reductions, interruptions, and re-escalation s after 
previous reductions for toxicity are permitted according to pre -specified guidelines.  Subject s 
who complete Part  2 will be eligible to continue pexidartinib treatment for study of longer 
efficacy and safety follow -up assessed per the schedule in Part 2 or to enter a separate protocol to 
continue receiving pexidartinib . 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 42 Figure  3.1: Study Schematic* 
 
* Effective 30 Sep 2016, subjects on placebo are no longer allowed into Part 2 to receive open -label pexidartinib.  
All MRI scans will be assessed by central readers blinded to treatment assignment and o ther 
clinical study data during both Parts 1 and 2 of the study, according to procedures outlined in a 
separate  Imaging  Independent Review Charter . The MRI report will not be provided in real -time 
unless requested by the Investigator . Results of the baseline MRI scan will be used to qualify a 
candidate . During Part 2, if indicated, Investigator s should request confirmation of radiologic 
disease progression by central read . Otherwise, central reads of MRI scans may be performed 
during or after the subject has completed the study.  The MRI scan for subjects who undergo 
surgical resection will be performed 4 months after surgery. Details of MRI requirements and 
data collection will be described in the MRI Procedure Manual . 
A range -of-motion  assessment in the affected joint or tumor location will be performed by an 
independent  and blinded third party assessor at specified time points . The BPI Worst Pain NRS 
item, physical function items from the PROMIS item bank (PROMIS Physical Function Scale) , 
and other PRO measures will be administered according to the Study Reference Manual . 
For statistical analysis of endpoints at the end of Part 1, a clinical data cut -off date will be 
defined for the point when all randomized subjects complete or are discon tinued from Part 1 with 
appropriate End of Part 1 follow -up. All data up to this date will be cleaned  and locked. 
Afterwards, u nblinding of database will be performed to facilitate the data analyses, including 
the data from the double -blind Part 1 and avai lable data from Part 2. Such unblinding is only 
intended for the sponsor and the Contract Research Organization. Subjects who entered Part 2 

Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 43 may continue to receive open -label pexidartinib treatment.  Updated analysis of Part 2 data only, 
in the form of sum mary and descriptive statistics, will be performed at the end of the 
trial.  Additional updates between the above -mentioned cut -off and end of the trial may also be 
performed.  
The timing and nature of p ost-treatme nt assessments are summarized  in Figure  3.2. Subject s who 
end their study participation with no documented disease progression will undergo :  (i) the 
28 Day Post-treatment Visit assessment with an MRI 28 ± 7 days after their last dose of study 
treatment; and (ii) a final MRI 12 weeks  ± 7 days after their last dose of study treatment or 
before any new PVNS/GCT -TS therapy,  including surgery,  whichever occurs first (the “ Part 1 
End-of-Study/ 12 Week  Post-Treatment ”). Subjects who wish to continue onto the open label part 
of this study (Part 2) will be unblinded after completion of the end of Part 1 assessments and 
those on placebo will be discontinued - they will not have the 28 Day Post-treatment and  End-of-
Study Visit assessments . The study will end with the last subject  last visit.  Subject s who 
complete Part 2 and enter a separate protocol to continue receiving pexidartinib  will not be 
scheduled for  the Post-treatment and End -of-Study Visit s. Subject s who terminate the study with 
documented progression will undergo a post -treatment assessment (the 28 Day “Post -treatment 
Visit”; see  Section  15.2.17  and Section  15.3.16 ) without  an MRI 28 ± 7 days after their last dose 
of study treatment or before any new PVNS/GCT -TS therapy, including surgery, whichever 
occurs first.  
Subjects are allowed to undergo surgical  resection of their tumor after the completion of Part 1. 
For subjects who undergo surgical resection within 12 weeks after their last dose of study 
treatment, they will not have the End -of-Study Visit assessments but will follow a separate visit 
schedule after the decision of surgery is made. The surgery is recommended to be performed  1-3 
weeks  after the last dose of study treatment. Details of the surgery and its short and long term 
outcome will be collected. Data collection for the surgery and its outcom e may continue in a 
separate protocol.  
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 44 Figure  3.2: Post-treatment Assessments Vary With  Reason for Study Withdrawal* 
 
* Effective 30 Sep 2016, subjects on placebo are no longer allowed into Part 2 to receive open -label pexidartinib. 
Subjects who wish to continue onto the open label part of this study (Part 2) will be unblinded after completion of 
the end of Part 1 assessmen ts and those on placebo will be discontinued - they will not have the 28 Day Post -
treatment and End -of-Study Visit assessments.  

Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 45 3.2. Number of Subject s 
Approximately 126 subject s across approximately 45 study sites in the US, Canada , EU, and  
Australia  are planned . 
3.3. Duration of Study  
Each subject  will spend approximately 3 to 6  weeks  in screening . Part 1 will be  24 weeks  in 
duration for all but those who qualify (see Section  3.1) for early entry into Part 2 because of 
disease progression.  Effective 30 Sep 2016, subjects on placebo are no longer allowed into Part 2 
to receive open -label pexidartinib.  The duration of P art 2 will vary among subject s, as this 
portion of the trial will continue until all subject s either complete 24  weeks of open -label 
treatment  or withdraw from the study . The study will end with the last subject  last visit. Subject s 
who complete Part 2 without experiencing progression or intolerability , or subjects who undergo 
surgical resection  of their tumor after study treatment will be eligible to continue for longer 
efficacy and safety follow -up or to enter a separate protocol to continue receiving pexidartinib  or 
for surgical data collection . 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 46 4. STUDY POPULATION  
4.1. Enrollment  
All subject s must provide written informed consent.  During the consent process, the person 
obtaining consent must inform the subject  of all elements of the study.  Each subject  must sign 
and date an institutional review board (IRB)/independent ethics committee (IEC) -approved 
informed consent form  before undergoing any study procedure (including screening procedures 
unless the screening procedure as outlined in the Study Reference Manu al is considered standard 
of care and was performed within 42 days of the P1-C1D1  visit). Participation in t he study 
begins with signing and dating the informed consent form.  A subject will be considered enrolled 
in the study when he or she has met all of the inclusion and exclusion criteria, been deemed 
eligible for study participation, and been randomized.  
4.1.1.  Inclusion Criteria  
Each subject  must meet all of the following criteria to qualify for enrollment : 
1. Age ≥  18 years.  
2. A diagnosis of PVNS or GCT -TS (i) that has been histologically confirmed either by a 
pathologist  at the treating institution or a central pathologist , and (ii) where s urgical 
resection would be associated with potentially worsening functional limitation or severe 
morbidity  (locally advanced disease), with morbidity determined consensually by 
qualified personnel ( eg, two surgeons or a multi -disciplinary tumor board) . 
3. Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2 cm is 
required), assessed from M RI scans by a central radiologist.    
4. Symptomatic disease because of active PVNS or GCT -TS, defined as one or more of the 
following:  
a. a worst pain of at least 4 at any time during the week preceding the Screening Visit 
(based on scale of 0 to 10, with 10 rep resenting “pain as bad as you can imagine”).  
b. a worst stiffness of at least 4 at any time during the week preceding the Screening 
Visit (based on a scale of 0 to 10, with 10 representing “stiffness as bad as you can 
imagine”).  
5. Stable prescription of analge sic regimen during the 2 weeks prior to randomization.  
6. During the 2 weeks prior to randomization, at least 4 of 7 consecutive days of BPI Worst 
Pain NRS items and Worst Stiffness NRS items completed correctly .   
7. Women of childbearing potential must have a negative serum pregnancy test within the 
14-day period prior to  randomization.  (Where demanded by local regulations, this test 
may be required within 72  hours of randomization.)  
8. Males and females of childbearing potential are permitted in the study so long  as they 
consent to avoid getting their partner pregnant or becoming pregnant, respectively, by 
using a highly effective contraception method, as described below, throughout the study 
and for up to 90 days after completion.  Highly effective methods of con traception 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 47 include: intra -uterine device  (nonhormonal or hormonal), bilateral tubal occlusion, 
vasectomy,  sexual abstinence , or barrier methods (e.g., condom, diaphragm) used in 
combination  with hormonal methods associated with inhibition of ovulation . Wom en of 
non-childbearing potential may be included if they are either surgically sterile or have 
been postmenopausal for ≥  1 year.  Women who have documentation of at least 
12 months of spontaneous ameno rrhea and have an FSH level >  40 mIU/mL will be 
consider ed postmenopausal.  
9. Adequate hematologic, hepatic, and renal function, defined by:  
 Absolute neutrophil count ≥ 1.5 × 109/L  
 Hemoglobin > 10 g/dL  
 Platelet count ≥ 100 × 109/L  
 AST/ALT ≤ 1.5 × ULN  
 Total bilirubin ≤ 1.5 × ULN  
 Serum creatinine ≤ 1.5 × ULN  
10. Willingness and ability to complete the BPI Worst Pain NRS item, Worst Stiffness NRS 
item, PROMIS Physical Function Scale, and other self -assessment instruments 
throughout the study.  
11. Willingness and ability to use an electronic diary.  
12. Willingness and abili ty to provide written informed consent prior to any study -related 
procedures and to comply with all study requirements.  
4.1.2.  Exclusion Criteria  
Candidates with any of the following conditions or activities are in eligible for study enrollment:  
1. Investigational drug use within 28 days  of randomization . 
2. Previous use of pexidartinib  or any biologic treatment targeting CSF -1 or the CSF1 R; 
previous use of oral tyrosine kinase inhibitors, eg, imatinib or nilotinib, are allowed . 
3. Active cancer (either concurrent or with in the last year of starting study treatment) that 
requires therapy (eg, surgical, chemotherapy, or radiation therapy), with the exception of 
adequately treated basal or squamous cell carcinoma of the skin, melanoma in -situ, 
carcinoma in -situ of the cervix  or breast, or prostate carcinoma with a prostate -specific 
antigen value <0.2 ng/mL . 
4. Known metastatic PVNS/GCT -TS. 
5. Active or chronic infection with hepatitis C virus or hepatitis B virus or known active or 
chronic infection with human immunodeficiency virus.  
6. Known a ctive tuberculosis.  
7. Significant concomitant arthropathy in the affected joint, serious illness, uncontrolled 
infection, or a medical or psychiatric history that, in the Investigator ’s opinion, would 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 48 likely interfere with the person ’s study pa rticipation or the interpretation of his or her 
results.  
8. Women who are breastfeeding.  
9. A screening Fridericia corrected QT interval (QT cF) ≥ 450 ms (men) or ≥  470 ms 
(women ). 
10. MRI contraindications . 
11. History of hypersensitivity to any excipients in the investigational product . 
12. Inability to swallow capsules.  
4.2. Removal of Subject From Therapy  
If a subject is withdrawn from the study, the Investigator  will complete and report the 
observations as thoroughly as possible up to the date of withdrawal including th e date of last 
treatment and the reason for withdrawal.  
If the subject is withdrawn due to an AE, the Investigator  will follow the subject until the AE has 
resolved or stabilized.  
Subjects can only be considered for surgical resection after the completion of Part 1.   
If a subject undergoes surgical resection of the tumor after Part 1 , the study treatment is 
recommended to be discontinued 1-3 weeks  before the surgery.  The subject will be followed for 
surgery and its outcome and not considered as discontinued from the study . Data collection for 
the surgery and its outcome may continue in a separate protocol . If a subject undergo es surgical 
resection prior to completion of Part 1, the information about surgery and its outcome will still 
be collected.   
4.2.1.  Reasons for Withdrawal/Early Discontinuation  
The reasons a subject may discontinue or be withdrawn from the study permanently include but 
are not limited to : 
 AE  Protocol vio lation  
 Disease progression   Subject noncompliance  
 Pregnancy  
 Subject request   Study termination by the Sponsor or IRB/IEC  
 Subject  transition to commercial pexidartinib   Investigator  decision  
During Part 2, if a subject experiences radiologic progression documented by central read, the 
subject may either be withdrawn from the study or, if the subject is continuing to have clinical 
benefit, the Investigator  may consult with the Sponsor’s Medical  Monitor or designee to allow 
the subject to remain in the  study.  
4.2.2.  Withdrawal Procedures  
When a subject discontinues or is permanently withdrawn from the study, the Investigator  will 
notify the Sponsor and ensure that the procedures listed in the 28 Day “Post -treatment Visit” 
column in the Schedule of Events (Table  15.2 and Table 15.3) are performed 28 ±7 days after the 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 49 subject’s last dose of study treatment and prior to initiating any new PVNS/GCT -TS therapy, 
including surgery.  
The consequence of a subject’s withdrawal of all consent will be that no  new information will be 
collected from that subject and added to the existing data or any database.  However, every effort 
will be made to follow all subjects for safety.  
The reason for study withdrawal will be recorded. If a subject discontinues study treatment to 
undergo surgery, information about the type of surgery and its outcome will be collected.  
If a subject discontinues study treatment before the end of  Part 1, the end of Part 1 assessments 
(Part 1 Completion visit/Early Termination  visit)  shoul d be performed  at the time of early 
discontinuation  (Table  15.2). These subjects will not be unblinded . 
4.2.3.  Subject Replacement  
Subjects withdrawn from the  study will not be replaced.  
4.3. Subject Re -screening Procedures  
Re-screening is permitted for any candidate who failed to meet eligibility criteria upon initial 
screening.  If rescreened, the candidate will not be given a new subject identification  number.  The 
initial screening information and the reason why the subject  is ineligible for the initial evaluation 
will be recorded on the Screening Log.  No data from the initial evaluation will be entered into 
the clinical database for a subject  who is rescreened.   However, MRI, ROM and surgical 
assessment may not need to be repeated , following con sultation with Sponsor Medical Monitor . 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 50 5. TREATMENT S ADMINISTERED  
5.1. Investigational Products  
The study treatment , pexidartinib  (PLX3397 ), is an HCl salt supplied in 200  mg-strength 
immediate -release capsule s for oral administration.  
The placebo capsules for this trial have an identical qualitative composition to the PLX3397 HCl 
capsules except no active pharmaceutical ingredient is included. The amount of mannitol is 
increased  in the placebo blend to compensate for amount of active ingredient that is not added.  
The placebo and pexidartinib capsules are identical in appearance to maintain the blind during 
Part 1. 
5.2. Study Treatment Administration  
Study treatment will only be given to randomized  subject s under the supervision of the Principal 
Investigator  or identified sub -Investigator (s). The study treatment for home administration 
during Part 1 will be dispensed to the subject  for the first time at the P1-C1D1  visit (within 3 
days of randomization) , and the study treatment for home administration during Part 2 will be 
dispensed to the subject  for the first time at the P2-C1D1 v isit. Capsules should be swallowed 
and not crushed, chewed , or dissolved in liquid.  In Part 1 , subject s will receive either 
pexidartinib  or matching placebo capsules . In Part 2, subject s will receive  only pexidartinib  
capsules . 
Study treatment  administration will begin at the P1-C1D1 visit  in the morning . At that visit, 
subject s will be instructed to take five capsules a day  for the first 2  weeks;  1000  mg/d 
pexidartinib  or matching p lacebo , this amount will be divided into a morning dose of two 
capsules and an evening dose  of three capsules . After 2 weeks  (at the P1-C1D15 v isit), the dose 
will be reduced to  two capsules in the morning and two capsules in the evening, 800 mg/d  
pexidartinib  or matching placebo . Subject s who had a dose reduction during the first 2 weeks 
will continue treatme nt at their reduced dose.  Doses  should be taken in the fasting state (ie, no 
food for 1 hour before and 2 hours after dose administration).  During  the fasting period, subjects 
will be permitted to eat a low -fat snack ( eg, cracker s, toast, tea)  if needed . Doses will be taken  at 
approximately the same times of the day and approximately 12  hours apart.  Each dosing cycle 
will be  28 days.  
For the P1-C1D15 and  P2-C1D15 visits and any visit when an ECG will be performed , subjects 
should be told to NOT take the ir morning dose of study treatment before  coming to their study 
visit, which should be scheduled for  the morning ; instead, they should be told to bring their 
bottle of study treatment to the clinic and take the ir morning dose upon instruction by the study 
site. The time of dosing will be recorded . Subject s will then take the ir evening dose at home.   If 
dose administered in the clinic is taken in the afternoon, then the subject should be instructed to  
skip their evening dose for that day.  
For the P2-C1D1 visit (Week 25), subjects should be told to NOT take the morning dose of study 
treatment before their visit and to bring all unused capsules to the clinic for accountability.  
Subjects who will continue into Part 2 will be given open -label pexidartinib  for the first time at  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 51 that v isit, taking the same number of  capsules per day as they were taking at the end of Part 1, ie, 
a maximum dose of 800 mg/d pexidartinib . 
Between clinic visits, subject s will administer their study treatment at home and record the 
dosing information in the study dosing diary.  Missed doses ( those generally outside of a ± 2-hour 
dosing window) should be skipped and NOT administered as a double dose at the next dosing 
time point . Subject s who vomit their dose should be instructed NOT to make up that dose . 
Further details on study treatment administra tion are contained in the separate Pharmacy Manual.  
For subjects who undergo surgical resection of their tumor, study treatment will be discontinued 
before surgery and will not be restarted after surgery.  
5.3. Dose  Modification Guidelines  
In both Parts 1 and 2,  reduc ing or interrup ting the dose for toxicity  may take place at any time 
according to the guidelines  in Table  5.1 and Table  5.2. Dose reduction/interruption guidelines for 
hematologic and non -hematologic treatment -related TE AEs are based on severity.  Dose 
interruptions can be implemented at the discretion of the treating physician to manage intolerable 
or cli nically significant toxicity.  If a dose interruption is required, study assessments should be 
performed as scheduled, irrespecti ve of the study treatment delay, with the exception of PK 
assessments which should be deferred until treatment is resumed.  Interruptions due to toxicity 
lasting >14 d require treatment discontinuation unless the medical mo nitor approves 
continuation . 
When  an odd number of capsules a day are to be taken , the larger number of capsules should be 
taken as the evening dose.  For example, 600  mg/d or matching placebo = 3 capsules ( 1 capsule 
in the morning, 2 capsule s in the evening).  When  an even number of capsules per day  is to be 
taken , the morning and evening doses should be the same  (eg, 800 mg /d or matching 
placebo  = 4 capsules (2 capsules in the morning, 2 capsules in the evening) or 400  mg/d or 
matching placebo  = 2 capsules  (1 capsule in the morning, 1  capsule in the evening ). 
Dose reductions should be applied in increments of 200 mg/d or matching placebo  (one capsule) , 
with a maximum total reduction of 600 mg/d  or matching placebo  (ie, a minimum dose of  
400 mg/d or matching placebo ). Subject s unable to tolerate 400 mg/d or matching placebo (two 
capsules) will be discontinued.  Once dose reduction takes place for toxicity, a dose re -escalation 
is generally not allowed unless approved after discussion with the Spo nsor's Medical Monitor or 
designee.  
Dose -modification guidelines for treatment –emergent  toxicities as well as guidelines for their   
management are presented Table  5.1 and Table  5.2. These parameters are only a guide and are 
not intended to supersede the cli nical judgment of the treating physician.  All adjustments should 
be communicated to the Sponsor’s Medical Monitor or  designee.   Rechallenge with a reduced 
dose of pexidartinib may result in a recurrence of increased serum transaminases, bilirubin, or 
ALP.   Monitor liver tests weekly for the first month after rechallenge.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 52 Table  5.1: Dose Modification Guidelines for Treatment -emergent  Toxicities  
Event  Severity  Pexidartini b Dosage Modifications  
Hepatoxicity  
Increased ALT 
and/or AST  >3 to 5 × ULN   Withhold and monitor liver tests weekly.  
 If AST and ALT ≤3 × ULN within 4 weeks, resume at 
reduced dose.  
 If AST or ALT not ≤3 × ULN in 4 weeks, permanently 
discontinue pexidartinib.  
>5 to 10 × ULN   Withhold and monitor liver tests twice weekly.  
 If AST and ALT ≤3 × ULN within 4 weeks, resume at 
reduced dose.  
 If AST or ALT not ≤3 × ULN in 4 weeks, permanently 
discontinue pexidartinib.  
>10 × ULN   Permanently discontinue pexidartinib.  
 Monitor liver tests twice weekly until AST or ALT ≤5 × 
ULN, then weekly until ≤3 × ULN.  
Increased ALPa 
and GGT  ALP >2 × ULN with GGT 
>2 × ULN   Permanently discontinue pexidartinib.  Monitor  liver tests 
twice weekly until ALP ≤5 times ULN, then weekly until 
≤2 × ULN.  
Increased 
bilirubin  TB >ULN to <2 × ULN  
or 
DB >ULN and <1.5 × ULN   Withhold and monitor liver tests twice weekly.  
 If an alternate cause for increased bilirubin is confirmed and 
bilirubin <ULN within 4 weeks, resume at reduced dose.  
 If bilirubin not <ULN in 4 weeks, permanently discontinue 
pexidartinib.  
TB ≥2 × ULN  
or 
DB >1.5 × ULN   Permanently discontinue pexidartinib.  
 Monitor liver tests twice weekly until bilirubin ≤ULN.  
Adverse Reactions or Other Laboratory Abnormalities  
Any Severe or intolerable   Withhold until improvement or resolution.  
 Resume at a reduced dose upon improvement or resolution.  
ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; DB = direct 
bilirubin; GGT = gamma -glutamyl transferase; TB = total bilirubin; ULN = upper limit of normal . 
a Confirm ALP elevations as liver isozyme fraction.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 53 Table  5.2: Additional Liver Evaluation  
Evaluation  Comments  
Increase frequency of testing liver chemistries 
to twice per week , including INR , and continue 
until liver chemistries have stabilized , and then 
reduce to weekly until liver chemistries return 
to normal or baseline  Investigational treatment  may be started after 
liver function tests recover to Grade 0  to 1 or 
baseline level , and in consultation with 
Medical Monitor  
Detailed history focusing on medications and 
substances used: alcohol, change in medication 
dosages, ne w medications added, attention to 
use of acetaminophen, OTC medication use 
and recreational drug use. Check for change in 
diet or use of dietary supplements , with 
particular attention to dose and duration of any 
herbal product  Suspect medications will be d iscontinued or 
substituted for if possible  
Detail ed medical history and physical exam 
seeking new abnormalities  Evaluate abnormalities found  
Full serological evaluation for hepatitis A,  B, C 
and E  (IgG and IgM) . Check for autoimmune 
hepatitis with serological laboratory studies  If viral hepatitis or autoimmune hepatitis 
suggested, have subject  evaluated by 
hepatologist  
Liver ultrasound performed to evaluate liver 
and biliary tree  Evaluate any abnormalities found  
Check history for exposure to chemi cal agents  Remove chemical exposure and have subject  
seen by hepatologist  
Obtain hepatology consult if liver function 
continues to rise beyond 14 days  Contact Medical Monitor  
We request that cases be discussed with the Medical Monitor whenever investigational 
product  is being held for  liver function test abnormality.  
Ig = Immunoglobulin; INR  = international normalized ratio; OTC  = over-the-counter.  
For suspected cases of cholestatic liver injury  (eg, aminotransferase increase concurrent with 
hyperbilirubinemia, or liver biopsy suggesting cholestasis and/or ductopenia ), patients will be 
followed to assess long -term outcome. Additional diagnostic and follow -up procedures might be 
implemented as appropriate to fully assess the event . 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 54 5.3.1.  Renal Impairme nt 
A reduced dose of 600 mg/day (200 mg in the morning and 400 mg in the evening)  is 
recommended in study subjects with mild to severe renal impairment  (creatinine clearance 
[CLcr] 15 to 89 mL/min estimated by Cockcroft -Gault using actual body weight).  
5.4. Concomitant Medications  
During the study, if the use of any concomitant treatment becomes necessary ( eg, for treatment 
of an AE), the treatment must be recorded on the source document and electronic Case Report 
Form  (eCRF) , including the reason for treatment, name of the drug, dosage, route, and date of 
administration . All medications including prescription, over -the-counter (OTC), herbal and other 
nutritional vitamins and/or supplements taken within 28 days of P1-C1D1 will  be recorded on 
the eCRF.  Analgesic use and analgesic regimen will be recorded as described in Section 6.4.11 . 
Subject s enroll ed in studies with pexidartinib  who are also receiving concomitant warfarin 
should have their anti -coagulation status carefully monitored, especially shortly after initiation of 
pexidartinib , for the potential need to make adjustments in warfarin dosing.  In particular, INR 
should be obtained just prior to initiation of pexidartinib , within 1 to 2 weeks after initiation, and 
periodically thereafter.  Dose adjustments of warfarin should be made as medically indicated . 
5.4.1.  CYP3A and UGT Inhibitors  
Although pexidartinib  does not appear to inhibit cytochrome P450 ( CYP ) drug-metabolizing 
enzymes to an important extent, caution is warranted when administering pexidartinib  to subject s 
taking drugs that are highly dependent on CYP  for metabolism and have a narrow therapeutic 
index . It is not known whether systemic exposure to these medications will increase while 
subject s are receiving pexidartinib . 
Of the five major CYP isoforms, 3A4 (BFC) may be involved in Phase 1 metabolism of 
pexidartinib , with possibly CYP1A2  playing a minor role  (see Section  15.1 for a list of common 
CYP3A4 inhibitors and inducers) . In general, strong inducers of CYP3A4 should be avoided 
unless clinically necessary.  These include anticonvulsants, certain mycin antimicrobials, and 
antiretrovirals.  Some common  examples include   inducers such as  rifampicin, carbamazepine, 
phenytoin , efavirenz, and nevirapine.21 
Avoid concomitant use of pexidartinib  with moderate or strong CYP3A inhibitors or UGT 
inhibitors.   If concomitant use with a moderate or strong CYP3A inhibitor or UGT inhibitor 
cannot be avoided, reduce the pexidartinib  dose according to the recommendations  in Table  5.3. 
If concomitant use of a moderate or strong CYP3A inhibitor or UGT inhibitor is discontinued, 
increase the pexidartinib  dose (after 3 plasma half -lives of the moderate or strong CYP3A 
inhibitor or UGT inhibitor) to the dose that was used before starting the inhibito r. 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 55 Table  5.3: Recommended Dosage Reductions for Pexidartinib  with  Concomitant Use of 
Moderate or Strong CYP3A Inhibitors or UGT Inhibitors  
Current  Total Daily Dos e Modified Total Daily Dose  Administration of Modified 
Total Daily Dose  
800 mg  400 mg  200 mg twice daily  
600 mg  400 mg  200 mg twice daily  
400 mg  200 mg  200 mg once daily  
5.4.2.  Hormonal Contraceptives  
Pexidartinib has been indicated to be a moderate CYP3A4 inducer , as concurrent administration 
of pexidartinib decreased the AUCinf of the CYP3A4 substrate midazolam by 57%.  As the 
hormonal contraceptive ethinyl estradiol is a CYP3A4 substrate, there is a potential that exposure 
of ethinyl estradiol may decreas e on concurrent administration with pexidartinib.   As 
pexidartinib  may cause embryo -fetal harm when administered to a pregnant woman , females of 
reproductive potential should be advised to use a n effective, non -hormonal method of 
contraception during treat ment with pexidartinib and for 1 month after the last dose.  Males with 
female partners of reproductive potential should be advised to use a n effective method of 
contraception during treatment with pexidartinib and for 1 month after the last dose.  Female 
partners of male patients should concurrently use effective contraceptive methods (hormonal or 
non-hormonal).  
5.4.3.  Acid -reducing Agents  
Avoid the concomitant use of proton pump inhibitors (PPIs) while taking pexidartinib.  As an 
alternative to a PPI, administer  pexidartinib 2 hours before or 2 hours after taking a 
locally -acting antacid, or if using a histamine 2 (H2) -receptor antagonist, administer pexidartinib 
at least 2 hours before or 10 hours after taking an H2 -receptor antagonist.  
5.5. Precautions and Restricti ons 
Because pexidartinib  is a substrate for CYP3A4/5 and some fruits are  CYP3A4/5 inhibitor s, 
foods or beverages containing CYP3A4 /5 inhibiting fruits ( eg, grapefruit , pomelo, star fruit, and 
pomegranate ) should be avoided throughout the study . 
5.6. Blinding and Unblinding  
Part 1 will be the placebo -controlled double -blind  phase of the study where treatment assignment 
will remain unknown to the study subject s, Investigator s, study site personnel, safety laboratory 
personnel, central imaging readers , and representatives of Daiichi Sankyo involved in the 
conduct and/or management of the trial.  Pexidartinib  and placebo capsules will be identical in 
appearance . All study treatment ( pexidartinib  or placebo) will b e labeled with the study number, 
a unique n umber , and any additional information  required in accordance with government 
regulations . Further details are contained in the  separate Pharmacy Manual.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 56 5.6.1.  Unblinding  
5.6.1.1.  Emergency Unblinding  
In the cases of emergency where, in the Investigator ’s opinion, immedia te unblinding of the 
treatment is necessary in order to evaluate further course of action, the Investigator  should access 
the interactive web/voice response system (IXRS) to initiate subject unblinding as follows:  
IXRS Option 04: Emergency Unblinding   
What  to enter for each subject:  
 Confirm to continue with unblinding  
 Subject ID  
What the IXRS will provide back to the site:  
 Subject’s randomized treatment arm  
 IXRS transaction confirmation  
The Investigator  may also contact the Sponsor’s Medical Monitor or desi gnee for information 
related to pexidartinib  adverse  effects in making the decision to unblind. (Contact inform ation –
refer to  Section 10.1.2 .)  It is important to note that, once unblinded , a subject cannot receive 
further study treatment and must discontinue from the study . 
The Investigator  should promptly document and report to the Sponsor any unblinding  for 
emergency reasons  (eg, accidental unblind ing, unblinding due to an SAE ) of the investigational 
product(s).   
The “ Emergency Unblind ing” option should not be used for subjects  who may need unblinding 
to move into Part 2 after the confirmed disease progression  in Part 1 . Please see the next section 
for more information.  
5.6.1.2.  Unblinding during Part 1 Week 13 to Week 25 for Disease P rogression  
In addition to the Emergency U nblind ing option , if a central reading confirms RECIST 1.1 -
defined disease progression at or after Week 13 but before Week 25 visit, treatment assignment 
may be unbl inded and potential continuation of a subject  to Part 2 of the study will be assessed . 
If an i nvestigator suspects disease progression during this period, an MRI should be submitted to 
the central reader  with a re quest for an expedited read for potential disease progression. The 
investigator should alert the Sponsor  and the Clinical Research Organization  (Novella Clinical) 
Medical Monitors that the expedited read request has been made. Once the expedited read results 
are received, the i nvestigator should discuss with the Sponsor and Novella Clinical Medical 
Monitors about the decision to unblind. If it is confirmed that the subject ’s study treatment  
should be unblinded, the Sponsor or designee will authorise the unblind in the IXRS system. 
Only once the Sponsor authorisation has been logged in IXRS can the  site then unblind the 
subject, which will also be done through IXRS:  
IXRS Option 04: Part 1 Wee k 13 Unblind  
What to enter for each subject:  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 57  Confirm to continue with unblinding  
 Subject ID  
What the IXRS will provide back to the site:  
 Subject’s randomized treatment arm  
 IXRS transaction confirmation  
DO NOT USE THE EMERGENCY UNBLIND FUNCTION FOR SUBJECTS WITH 
DISEASE PROGRESSION as they will not be able to receive further treatment and must 
discontinue from the study (as Emergency Unblind ing cannot be undone).  
Once in receipt of the unblind information, the site may then choose to continue the subject in to 
Part 2 of the study or discontinue the subject  from the study . Subjects receiving placebo will be 
eligible for early entry into Part 2 of the study. Effective 30 Sep 2016, subjects receiving placebo 
will be discontinued instead of being eligible to enter Part 2.  Subjects receiving pexidartinib will 
be discontinued from the study unless the Investigator and the Sponsor’s Medical Monitor judge 
that the subject would potentially benefit from contin ued treatment with pexidartinib . 
For statistical anal ysis of endpoints at the end of Part 1, a clinical data cut -off date will be 
defined for the point when all randomized subjects complete or are discontinued from Part 1 with 
appropriate End of Part 1 follow -up. All data up to this date will be cleaned and locked. 
Afterwards, unblinding of database will be performed to facilitate the data analyses, including 
the data from the double -blind Part 1 and available data from Part 2. Such unblinding is only 
intended for the sponsor and the Contract Research Organiz ation. Subjects who entered Part 2 
may continue to receive open -label pexidartinib treatment.  Updated analysis of Part 2 data only, 
in the form of summary and descriptive statistics, will be performed at the end of the 
trial.  Additional updates between th e above -mentioned cut -off and end of the trial may also be 
performed.  
5.6.1.3.  Unblinding  at the End of Part 1  
As of 30 Sep 2016, subjects  on placebo in Part 1 are no longer allowed to enter Part 2 to receive 
open -label pexidartinib. After completion of the end of Part 1 assessments (Part 1 Completion 
visit/Early Termination visit), subjects who wish to continue onto the open label part of this 
study (Part 2) will be unblinded and those on placebo will be discontinued; subjects on 
pexidartinib in Part 1 may continue  into Part 2 to continue to receive pexidartinib . (Detailed 
instructions will be provided separately.)  
5.7. Description of Investigational Agents  
Pexidartinib ( PLX3397 ) 
Pexidartinib  is an HCl salt with a white  to off -white crystalline solid appearance.  PLX3397 HCl 
capsules are provided as 200 mg (200 mg free base equivalent) hypromellose capsules  for oral 
administration containing the following excipients: Poloxamer 407, mannitol, crospovidone and 
magnesium stearate . Formulation of pexidartinib is J -3397 -AF in h ydroxypropyl methylcellulose 
capsules . 
Placebo  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 58 The matching placebo capsules for oral administration contain Poloxamer 407, mannitol, 
crospovidone and magnesium stearate only, with an increased amount of mannitol to adjust for 
the absence of the active pha rmaceutical ingredient.  
5.8. Packaging and Labeling  
PLX3397 -HCl 200 mg capsules and placebo capsules are manufactured, packaged, and labeled 
according to Good Manufacturing Practices  and Good Clinical Practices ( GCP ) at the following 
address:  
 Catalent Pharma Solutions, Inc.  
10245 Hickman Mills Drive  
Kansas City, MO  64137  
USA  
5.9. Storage, Handling, and Accountability  
Study treatment ( pexidartinib  and placebo ) in accordance with this protocol  should be stored at 
the sites in a secure controlled facility and only provided to subject s who signed a consent form 
and are participating in the study.  The study treatment must be stored at room temperature (do 
not store above 25ºC/77ºF).  Excursions are permitted from  15ºC to 30ºC (59 ºF to 86ºF) , however 
approval for continued use must be obtained  from Daiichi Sankyo  for excursions <15 ºC or 
≥25ºC (77ºF) . Subject s will be instructed to store the study treatment at room temperature out of 
the reach of children or other cohabitants.  
The Food and Drug Administration and other health authorities require accurate and up -to-date 
accounting of the disposition of all study treatment received by the site.  Records of study 
treatment disposition required by federal law include the date s and quantities  received from the 
Sponsor , the date s and quantities administered to a subject,  including the identity of the subject , 
the date s and quantities returned by a subject  (if applicable) , and the dates and quantities of final 
disposition (ie, dates/quantiti es that unused study treatment is returned to the Sponsor /designee 
or dates/quantities that unused study treatment is destroyed on-site/off -site as applicable  in 
accordance with GCP and site standard operating procedures ). For any study treatment that is 
destroyed, destruction details must be documented on accountability and destruction logs and 
include at a minimum the number of bottles and capsules destroyed, batch number (if 
applicable), and the date and method of destruction . Any study treatment acciden tly or 
deliberately destroyed must be recorded in a timely fashion, including an explanation for the 
destruction in writing . Any discrepancies between the amounts of study treatment dispensed and 
returned must also be explained in writing.  
The Investigator  is responsible for the overall accountability and accurate and up -to-date 
documentation/disposition of all unused and used study treatment  supplied by the Sponsor . 
Dosage form (ie, capsules) site level accountability documentation is to be included with each 
drug supply return shipment (or other returning facility, such as another depot). This is required 
as part of the receiving records for return shipments.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 59 Dosage form (ie, capsules) site level accountability documentation is required as part of the 
disposition records of IP. The dosage form site level accountability documentation should be 
appended to the Certificate of Destruction.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 60 6. STUDY CONDUCT  
6.1. Study Personnel and Organizations  
The contact information for the Sponsor and Novella Clinical Medical M onitor for this study can 
be found in the Study Reference Manual . The contact information for the central imaging reader , 
central and any additional clinical laboratories, the coordinating Investigator  for each member 
state/country, and Novella Clinical  can be  found in the Study Reference Manual.  A full list of 
Investigator s is available in the Sponsor ’s Investigator  database.  
6.2. Recruitment of Subject s 
Subject s may be recruited from the Investigator ’s local practice or referrals from other 
physicians.  Any advertisements used for recruitment purposes will be submitted to and reviewed 
by the IRB /IEC. It is not envisioned that prisoners or other populations who might be subject to 
coercion or exploitation will be enrolled into this study.  
6.3. Treatment Group Assig nments  
Once all screening procedures have been completed and study eligibility has been confirmed, 
subject s will be enrolled in the study and centrally randomized in a 1:1 ratio to receive either 
pexidartinib  or placebo twice daily for 24 weeks  during  Part 1 of the study . Randomization will 
be stratified by US versus non-US sites and by upper extremity versus  lower extremity 
involvement . The randomization schedule will be developed by an independent third party 
vendor to ensure that  the subject, site person nel, and Sponsor  remain blinded to treatment 
assignment . Clinical site staff will obtain investigational medicinal product  dispensing 
information  by accessing the I XRS . See Study Reference Manual for further details.  
After randomization, the first dose of study treatment (P1 -C1D1) should occur within 3 days of 
the randomization date.  
During Part 2 of the study, all subject s will receive open -label pexidartinib . 
6.4. Study Procedures  
Study procedures are summarized in Table  15.2 and Table 15.3. Descriptions of the specific 
study procedures are provided in the following subsection s, and s tudy procedures are listed by 
visit in  Section  15.2. Additional details are provided in the Study Reference Manual, MRI 
Procedure Manual , or Laboratory Manual  as applicable.  
Each subject  must sign and date an informed consent form before undergoing any study 
procedure (including screening procedures , unless the screening procedure as outlined in the 
Study Reference Manual and is considered standard of care ). New safety measures were 
implemented effective on 30 Sept 2016 (see Section  1.6). Investigators and subjects  must be 
informed of the new safety information and decide whether to continue in the study. If , after 
consultation with the subject , it is deemed to be in their best interest to contin ue treatment, the 
subject  must be re -consented.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 61 Screening procedures are to be performed within the 42 days  before the first dose of study 
treatment , unless otherwise noted . 
If a dose interruption is required, study assessments should be performed as sched uled, 
irrespective of the study treatment delay, with the exception of PK assessments which should be 
deferred until the first clinical visit af ter dosing resumed . 
The last subject last visit defines the end of the study . 
All subjects who complete at least 24 weeks of open -label pexidartinib treatment in Part 2 
without disease progression will be eligible to continue for longer efficacy and safety follow -up 
or to participate in a separate protocol to continue receiving pexi dartinib.  
6.4.1.  Demographics and Medical History  
Subject  demographic data such as age, sex, ethnicity (where  legally allowed), and race will be 
obtained during the Screening visit . A complete medical history will also be obtained during the 
Screening  visit. The medical history will comprise  all prior and current medical history , 
including PVNS/GCT -TS treatment history and smoking history . 
6.4.2.  Vital Signs and Subject  Weight  
Vital signs, including systolic/diastolic blood pressure, pulse rate and temperature  will b e 
measured in accordance with institutional standards  and generally should be  performed before 
invasive procedures, eg, blood draws . Vital signs and weight will be measured at the indicated 
study visits in the Schedule of Events.  
Height will be measured at  the Screening visit only.  
6.4.3.  Physical Examination  
A physical examination will includ e the following systems  or areas : general appearance; oral 
cavity and neck ; cardio thoracic ; dermatologic; abdominal; musculoskeletal; and neurological . 
The exam ination  will be performed by a qualified individual such as the Investigator  at the study 
visits indicated in the Schedule of Events  (Table  15.2 and Table 15.3). 
6.4.4.  Range of Motion  Assessment  
Range of motion of the joint will be assessed by a qualified, independent, and blinded third 
party , such as an orthopedic surgeon or a physical therapist , using goniometers according to a  
standardized  method based on  American Medical Association disability criteria .20  
Measurements will be recorded in degrees.  Details of the measurement procedure for each joint 
will be provided in the Study Reference Manual.  
6.4.5.  Electrocardiogram  
A standard 12-lead ECG will be obtained at the study visits indicated in the Schedule of Events  
(Table  15.2 and Table 15.3). Subject s should rest in the supine position for at least 5 minutes 
before the ECG recording is started . The ECG recordings must be performed using a standard 
high-quality  and high-fidelity electrocardiograph y machine equipped with computer -based 
interval measurements.  For safety monitoring purposes, t he ECGs should be reviewed , signed , 
and dated promptly by a qualified physician (or physician’s assistant, nurse practitioner) and any 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 62 clinically important findin g recorded on the appropriate eCRF.  The Investigator  is responsible 
for interpre ting all ECGs . The results may include heart rate,  RR interval , PR interval, QRS 
interval, QT interval, and QTcF interval . 
At the visits when ECGs are to be performed, subjects  should be told to NOT take the morning 
dose of study treatment; instead, they should be told to bring their bottle of study treatment to the 
clinic and to take the morning dose upon instruction by the site staff.  
6.4.6.  Echocardiogram  
A resting echocardiogram ( ECHO ) or multi -gated acquisition (MUGA) scan will be performed at 
the study visits indicated in the Schedule of Events for Part 1 (Table  15.2) and Part 2 
(Table 15.3) of the study to evaluate subject s’ cardiac function throughout study participation . 
(For the purposes of this protocol, “ECHO scan” and “MUGA scan” will be used 
interchangeably. ) The choice of whether to perform  ECHO or MUGA scan ning will be based on 
the preference of the Principal Investigator , but platforms should not be switched  during the 
course of a subject ’s study participation.  Echo cardiogram or MUGA scanning should only be 
repeated if more than 3 months have elapsed since the last procedure. Subjects who show a 
reduced ejection fraction relative to baseline at the last visit should be followed until a stable 
ejection fraction is mea sured by two consecutive tests.  For safety monitoring purposes, the  scan 
must be evaluated promptly by a qualified physician (or qualified physician’s assistant or nurse 
practitioner) . Clinically  important findings, including the ejection fraction,  will b e recorded on 
the appropriate eCRF . The Investigator  is responsible for providing the interpretation of all scan 
findings.    
6.4.7.  Clinical Laboratory Evaluations  
Clinical laboratory evaluations will be performed centrally  at the study visits indicated in the 
Schedule of Events  (Table  15.2 and Table 15.3). Collection, processing, labeling, handling , and 
shipment of samples will be outlined in the separate Laboratory Manual.  Local lab oratory 
evaluations  are permitted to facilitate assessment of AEs or support dosing decisions; every 
effort should be taken to submit a sample to the central laboratory at the same time  for 
unscheduled samples . 
Clinical laboratory evaluations will be performed as outlined be low: 
Blood samples for analysis of the following clinical chemistry, hematologic, coagulation, and 
hormone parameters will be obtained:  
Clinical Chemistry  
 Sodium   Total protein   
 Potassium   Albumin   
 Chloride   Triglycerides*  
 CO 2  Total cholesterol*  
 Calcium   HDL -cholesterol*  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 63  Phosphorus   LDL -cholesterol*  
 Glucose*   Uric acid   
 Blood urea nitrogen   Lactate dehydrogenase  
 Creatinine   
 * Fasting is recommended but not required . 
Liver  Function Tests  
Alkaline phosphatase  Total bilirubin  
 AST  
 ALT   Direct bilirubin  
 GGT  
Hematology  
Red blood cell count  Hemoglobin  
 White blood cell count with 
differential   Hematocrit  
 Platelet count   
Hepatitis Panel  
Hepatitis B virus surface antigen test and HCV antibody test  
Coagulation  
Prothrombin time, activated partial thromboplastin time, and INR . 
Hormon e Tests 
Females  Males  
 FSH  FSH 
 LH  LH 
 Progesterone   Testosterone  
 Estradiol   
Urinalysis  (dipstick  and microscopic analysis ) 
Urine samples will be obtained  for analysis of the following parameters : 
 pH  Ketones/acetone   
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 64  pH  Ketones/acetone   
 Protein/albumin   Hemoglobin/blood   
 Glucose/sugar   Red blood cells , white blood cell s, 
epithelial cells, bacteria, casts, 
crystals    Nitrites  
6.4.8.  Patient Reported Outcome Instruments  
Subject s will complete via a n electronic  diary the BPI Wors t Pain NRS item, the Worst Stiffness  
NRS item, the PROMIS Physical Function Scale , the EQ -5D-5L, and the Patient Global Rating 
of Concept item for ability to carry out everyday activities  at the indicated study visits in the 
Schedule of Events  (Table  15.2 and Table 15.3). In addition, subject s will be given both the BPI 
Worst Pa in NRS item and the Worst Stiffness NRS item  to complete on an outpatient basis , for 
at least 4 of  7 consecutive days (Day -7 to Day -1) prior to the indicated study visits in the 
Schedule of Events . At the Week 25 visit, subject s will also complete the Patient Global 
Impression of Change item for tumor -related stiffness.  
On study visit days including Screening, subject s will complete  instruments prior to any invasive 
procedures and prior to the morning dose.  
6.4.8.1.  Most Disturbing  Symptom Assessment  
Before init iating study treatment, the subject  will be  asked to identify which symptom of pain, 
stiffness, or compromised ability to carry out everyday activities  they find to be most disturbing . 
6.4.8.2.  BPI Wors t Pain NRS Item  
The BPI Worst Pain NRS item is a one-item self -administered questionnaire assessing the 
“worst” pain in the last 24 hours (Section  15.5). The NRS  for this item ranges from 0  (“no pain” ) 
to 10 (“pain as bad as you can imagine”).  
6.4.8.3.  Worst Stiffness NRS item  
The Worst Stiffness NRS item is a one-item self -administered questionnaire  assess ing the 
“worst” stiffness in the last 24 hours ( Section  15.6). The NRS for this item  ranges from 0 (“no 
stiffness” ) to 10 (“stiffness  as bad as you can imagine ”). 
6.4.8.4.  PROMIS Physical Function Scale  
Physical function items relevant to the assessment of lower and upper limb function are to be 
selected from the PROMIS physical function item bank  (Section  15.7). Items assessing lower 
limb function will be administered to subject s with the lower extremity tumor s, and items 
assessing upper limb function will be administered to subject s with u pper extremity tumor s. The 
results from both sets of items will be combined and analyzed  together.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 65 6.4.8.5.  EQ-5D-5L 
The EQ -5D-5L is a preference -based general health status or health -related quality of life 
instrument consisting of two parts  (Section  15.8). The first part comprises five domains 
(mobility, self-care, usual activities, pain/discomfort, and anxiety /depression) each of which can 
have  five levels ranging from no problems through profound difficul ties. Accordingly , 3125 
potential health profiles can be generated to which public preferences or utilities are applied.  
These data can subsequently be used in an economic evaluation or cost -utility analysis.  The 
second part of the EQ -5D-5L is a Visual Analogue Scale on which the subject rates their current 
health, with 0 representing the “worst health you can imagine” and 100 representing the “best 
health you can imagine.”  
6.4.8.6.  Patient Global Impres sion of Change and Global Rating of Concept Items  
A Patient  Global Impression of Change item (Section  15.9) assessing tumor -related stiffness will 
be administered at the Part 1 Completion ( Week 25 ) and 28 Day Post-treatment visits. A Patient 
Global Rating of Concept item (Section  15.9) for ability to carry out every day  physical activities 
will be administered at defined study visits.  Results from these items will be used in exploratory 
analys es to define the magnitude of meaningful change on the Worst Stiffness NRS and 
PROMIS Physical Function Scale, respectively.  
6.4.9.  Tumor Imaging  
Non-contrast MRI of the affected joint  will be performed at the study visits indicated in the 
Schedule of Events  (Table  15.2 and Table 15.3). All MRI scans will be centrally  read.  Local 
evaluation of radiological response, stable or progressive disease according to RECIST 1.1 will 
be recorded in the eCRF. The central MRI assessment report of progression status will not be 
provided unless requested.  The Investigator  will follow procedures (including instructions on 
proper imaging technique, and labeling) outlined in a separate MRI Procedure  Manual . The 
results of the baseline , centrally read  MRI scan will be used to qualify a subject , and all 
subsequent M RI scans will be read centrally in a manner blinded to treatment assignment and 
other clinical trial data  at the conclusion of Part 1, the placebo -controlled portion of the study.  
If disease progression is indicated clinically or by local radiologic assess ment according to 
RECIST 1.1 at or after Week 13 but before Week 25, the Investigator  may request a n expedited  
central review for evaluation of disease progression.  If a central reading confirms  RECIST 1.1 -
defined  disease progression , treatment assignment will be unblinded, and subjects receiving 
placebo will be eligible for early entry into Part 2 of the study as described in the Study 
Reference Manual.  Effective 30 Sep 2016, subjects receiving placebo will be discontinued 
instead of b eing eligible to enter Part 2.  Subjects receiving pexidartinib  will be discontinued 
from the study unless the Investigator  and the Sponsor’s Medical Monitor judge that the subject 
would potentially benefit from continued treatment with pexidartinib . 
During  Part 2, if indicated, Investigator s should request confirmation of radiologic disease 
progression by central read.  Otherwise, central reading of MRI scans may be performed during 
or after the subject has completed the study.  Details for Part 2 MRI scan re ads are outlined in the 
MRI Procedure Manual . 
Subject s who terminate the study because of  radiologic disease progression  will not have a 
follow -up MRI at their Post -treatment visit.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 66 6.4.10.  Surgical Assessment Questionnaire  
The Surgical Assessment Questionnaire (Section  15.10 ) will be completed by a qualified 
individual ( eg, orthopaedic oncologist) to assess the surgical status of the subject at the 
Screening  visit and at time points shown in the Schedule of Events.  
6.4.11.  Surgical Data and Outcome  Follow -up 
At or aft er Week 25 evaluation, subjects  may be considered for surgery to remove the tumor. The 
surgery is recommended to be performed 1-3 weeks  after the last d ose of the study treatment. 
After completion of the end of Part 1 assessments  (Part 1 Completion visit/Early Termination  
visit) , subjects who wish to continue onto the open label part of this study (Part 2) will be 
unblinded and those on placebo will be discontinued and will  not need to have surgical data 
follow -up. 
Detailed information about the surgery will be collected, including but not limited to:  
 Reasons of the surgery  
 Planned surgical procedure and actual surgical procedure  performed  
 Surgical margi n 
 Copies of surgical report and pathology report , if available  
 Surgery complications such as infection, delayed healing  
Surgically resected tumor samples will be collected for evaluation of study treatment effects on 
tumor cells.  
Before the surgery is perf ormed, the subject should have an additional visit for ROM and PRO 
(pain and stiffness scores, PROMIS questionnaire) evaluation, if these are not done within 6 
weeks prior to the surgery. Subjects do not need to have the End-of-Study visit if a decision ha s 
been made to have surgical resection of the tumor under study treatment.   
At 4 months (+/ - 2 weeks) after the surgery, the subject should have a visit for MRI scan of the 
tumor affected joint, ROM and PRO (pain and stiffness scores, PROMIS questionnaire)  
evaluations. After this visit, the subject should be followed for disease recurrence (defined as the 
need for any new therapeutic intervention of TGCT) at 8, 12, 18 and 24 months after surgery. 
Such follow -up can be performed via phone contact with the su bject.  
Subjects who undergo surgery may be rolled into a separate prot ocol for surgery  and its  outcome 
data collection . 
6.4.12.  Analgesic Use and Analgesic Regimen  
Subjects will have a n electronic  diary in which to record any analgesics, including nonsteroidal 
anti-inflammatory drugs and prescription analgesics, taken during the period  before 
investigational product  initiation and during the time period when the BPI Worst Pain and Worst 
stiffness Items are scheduled for completion. Subjects must have a stable prescribed analgesic 
regimen during the 2 weeks prior to the first dose of study treatment. During the study, whenever 
possible, the type and dose of long -acting narcotic analgesic and non -narco tic analgesic should 
be kept stable while the dose of short -acting (or rescue) narcotic analgesic might be titrated as 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 67 needed. Analgesic use will be quantified by multiplying the daily dose unit by the number of 
units taken, averaged by the number of days with available data .22  For subjects who have 
changed narcotic type or if dosages have been changed in subjects c oncomitantly receiving 
different narcotic types, analgesic use will be calculated following equianalgesic conversion to 
morphine -equivalent doses .23 
Analgesic regimen , both prescription and OTC , will be collected in the eCRF in the same 
manner as other concomitant medications.  
6.4.13.  Healthcare Resource Use and Productivity  
During Part 1, major HCRU  and subject productivity (Section  15.12 ) will be recorded at 
baseline, selected clinic visits, and at the Completion and 28 Day Post-treatment visits  
(Table  15.2). Questions will be administered to the subject as part of the clinical interview.  
Information will be captured about episodes of hospitalization, including date of admission, date 
of discharge, primary diagnosis at discharge, and days of different levels in inpatient intensity of  
care (Section  15.12 ). Information on subject employment status will be recorded and, if the 
subject is working, days lost from work because of PVNS/GCT -TS will be assessed  
(Section  15.11 ). 
6.4.14.  Pregnancy Test  
For female subject s of child -bearing potential only, a serum pregnancy test (β -human chorionic 
gonadotropin) will be performed at the study visits (centrally for all but local  laboratory  is 
allowed  at the end of study visit) indicated in the Schedule of Events  (Table  15.2 and 
Table 15.3). 
6.4.15.  Pharmacodynamic Sampling  
Archival s urgical tissue from PVNS/GCT -TS tumors (if available) will be obtained  at the 
Screening visit (or when available  and consented ) and will be collected and stored for 
exploratory biomarkers related to pexidartinib and/or disease . Plasma for circulating PDy 
biomarkers will be collected once per day on  the same days when PK blood sample (s) are drawn 
(eg, predose) and will be analyzed for markers of pexidartinib exposure and for exploratory 
biomarkers , including CSF -1 and adiponectin.  
Consult the Laboratory M anual for detailed instructions on c ollection, processing, handling , 
storage , and sample shipment.  
6.4.16.  Pharmacokinetic (PK) Sampling  
PK sampling will be performed at the study visits indicated in the Schedule of Events  for Part  1 
(Table  15.2) and Part  2 (Table 15.3). Each site must choose one of the schedules for each subject 
and must adhere to the selected schedule  (Table  6.1) for the duration of the study : 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 68 Table  6.1: PK Schedules  
Visit  Schedule 1  Schedule 2  
Week 1 P1C1D1  Pre-dose Pre-dose 
Week 3 P1C1D15  Pre-dose  
Post-dose: 0.5, 1, 2, 3, 4, and 6 hours  Pre-dose 
Post-dose: Between 1 -3 hours 
Week 5 P1C2D1   Random post -dose 
Week 9 P1C3D1  Random post -dose Random post -dose 
Week 17 P1C5D1  Random post -dose Random post -dose 
Week 25 P2C1D1  Pre-dose Pre-dose 
Week 27 P2C1D15  Pre-dose 
Post-dose: 0.5, 1, 2, 3, 4, and 6 hours    Pre-dose 
Post-dose: Between 1 -3 hours 
Week 29 P2C2D1   Random  post-dose 
Subject s should be told to NOT take the morning dose of study treatment at the P1-C1D15, 
P2-C1D1 (Week 25), and P2-C1D15 visits.  Instead, they should be told to bring their bottle of 
study treatment to the clinic and follow dosing  instruction b y the site  staff.  
The exact time of dose administration should be recorded along with  the corresponding PK blood 
samplings.  The exact time of the three preceding doses should also be recorded.  
Detailed instructions on collection, processing, handling, storage, and sample shipment are 
contained in the separate  Laboratory Manual.  
6.4.17.  Adverse Events  
Adverse events  will be monitored throughout the study . Adverse events and SAEs  will be 
monitored and recorded in the source documents and eCRFs from the time the subject  signs 
informed consent  through the subject ’s Post-Treatment Visit 28 days (± 7 days) after the last 
dose of study treatment . Adverse events (including clinically significant changes in laboratory 
results, ECHO  results, and hormon e testing results) should be monitored until they are resolved 
or are determined to be due to a subject ’s stable or chronic condition or intercurrent illness(es).  If 
an AE remains unresolved at the conclusion of the study, the Investigator  should follow the AE 
until s/he dee ms it to be resolved, stable, or not expected to worsen per medical judgment ( eg, 
resolved with sequelae) . Definitions, documentation, and reporting of AEs are described in detail 
in Section  9. 
6.4.18.  Study Treatment Compliance  
At the study visits indicated in the Schedule of Events, blinded  pexidartinib  or placebo will be 
dispensed to subject s in Part 1,  and open -label pexidartinib  will be dispensed to subjects in 
Part 2. The appropriate study personnel will document and maint ain records of study treatment 
dispensing to each subject  and any returns at each study visit.  
Subject s will complete a  dosing diary  to record the number of capsules/date/time taken during 
each dosing cycle.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 69 At each clinic visit, subject s will be assessed  for compliance with study treatment administration , 
ie, actual capsules taken / expected capsules taken; so must return all bottles (us ed/unused) at 
each dispensing visit . 
Further details can be found in the Study Reference Manual.  
6.5. Study Procedures  
The Investigator  should conduct the study in compliance with the protocol agreed to by Sponsor 
and, if required, by the regulatory authority(ies), and that was given approval/favorable opinion 
by the IRB/IEC.  
A deviation to any protocol procedure, or a waiver to any state d criteria will not be allowed in 
this study except where necessary to eliminate immediate hazard(s) to the subject.  Sponsor must 
be notified of all intended or unintended deviations to the protocol ( eg, inclusion/exclusion 
criteria, dosing, missed study v isits) on an expedited basis.  
The Investigator , or person designated by the Investigator , should document and explain any 
deviation from the approved protocol.  
If a subject was ineligible or received the incorrect dose or investigational treatment and had at 
least one administration of the study treatment, data should be collected for safety purposes , and 
the Sponsor’s Medical Monitor or designee should be informed immediately . 
The Investigator  should notify the IRB/IEC of deviations from the protocol in accordance with 
local procedures.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 70 7. STATISTICAL METHODS  
7.1. Randomization and Stratification  
The r andomization ratio for Part 1 of the study will be 1:1 for active (pexidartinib ) versus  
placebo.  Rando mization will be stratified by US versus non-US sites and by upper extremity 
versus  lower extremity involvement.  
7.2. Analysis  Sets 
Randomized Analysis Set  
The Randomized Analysis Set  consists of all subject s in this study that were ran domized.  
ITT Analysis Set  
The Intent -to-treat (ITT) Analysis Set  is defined as all randomized subjects, which is the same as 
the Randomized Analysis Set . The primary efficacy analysis as well as all other efficacy 
analyses will be performed in the ITT Analysis Set . Subject s will b e included in the treatment 
group to which they were randomized, regardless of the treatment actually received.  
Safety Analysis Set  
The Safety Analysis Set consists of  all subject s in the Randomized Analysis Set who received at 
least one dose of study treatment . All safety analyses will be completed in the Safety Analysis 
Set. Subject s will be included in the treatment group based on the actual treatment they received.  
Per-protocol Analysis Set  
The Per-protocol Analysis Set will be defined as subjects i n the ITT Analysis Set who did not 
have major eligibility/protocol violations and who are compliant with regard to study treatment  
administration , defined as taking  at least 70% of their  scheduled dose of study treatment, 
regardless of scheduled dose reduction . 
7.3. Procedures for Handling Missing, Unused, and Spurious Data  
For the primary efficacy analysis as well as for all analyses of responder proportion endpoints  
performed on the ITT and Per-protocol Analysis Sets , subject s who do not provide data for the 
responder endpoint will be considered nonresponders, ie, assigned to the less favorable outcome 
for the endpoint.  Subject s who discontinue the study before Week 25 and do not have a Week 25 
MRI will be considered nonresponders.  Analysis of t he endpoint s involving range of motion  and 
PROs, which  are measured at multiple time points , by comparing the central tendency of 
continuous variables between treatment groups (not the responder type of analysis for a binary 
variable), will be performed  using mixed models for repeated measurements  (MMRM)  
incorporating all  available measurements from each subject .24,25,26,27,28 
7.4. General Statistical Considerations  
Continuous variables will be summarized by the number of observations, mean, standard 
deviation, median, 25th and 75th percentile, and minimum and maximum values.  Categorical 
variables will be summarized using frequency counts and percentages.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 71 In general, the baseline value for an efficacy variable, including that for a PRO variable, is the 
last non -missing value before randomization.  The baseline va lue for a safety variable is the last 
non-missing value before the first dose of study treatment . The exceptions are several special 
variables in Part 2, such as the tumor response and duration of response variables evaluated for 
pexidartinib  treatment for  subject s randomized to placebo in Part 1 ; in such cases,  the baseline 
for Part 2 is defined as the last non -missing value before the first dose in Part 2 . Further d etails 
are contained  in the following  sections and  in the Statistical Analysis Plan ( SAP). 
For the primary efficacy endpoint and secondary efficacy endpoints with the exception of 
duration of response, treatment comparison at Week 25 will be performed based on the data 
collected during the visits between baseline and Week 25 . Point estimate and accompanying 95% 
confidence interval (CI) will be computed.  For duration of response, Kaplan -Meier product limit 
methodology will be utilized to provide estimates, including those for the median and 25th and 
75th percentiles.  
All statistical tests will be 2-sided.  Unless otherwise specified, all tests will be carried out at the 
alpha  = 0.05 level of significance.  
7.5. Study Population Data  
Subject  disposition will be summarized for each randomized treatment group and in total for the 
ITT Analysis Set . The total number of subject s for each defined analysis population will also be 
tabulated.  The demographic and baseline characteristics will be summarized descriptively for the 
ITT, Per-protocol , and Safety Analysis Sets . Study treatment  exposure and study duration will be 
summarized using descriptive statistics by treatment group for the Safety Analysis Set . 
7.6. Efficacy Analyses  
7.6.1.  Primary Efficacy  Analysis  
The primary efficacy endpoint is the proportion of subject s who achieve a CR or PR at the 
Week  25 Visit (Table  2.1) based on  centrally read MRI  scans and RECIST 1.1 . The primary 
analysis will be co mpleted using  the ITT Analysis Set . The proportions in the two treatment 
groups  will be compared using Fisher’s exact test (two-sided) at the alpha  = 0.05 level of 
significance.  In addition, the two -sided 95% CI for the difference between the responder 
proportions in the two treatment groups  will be provided , using the Wilson method .29,30 
As a supportive analysis, mid -p adjustment of Fisher’s exact test will  also be performed .31,32 
Additionally, as a s ensitivity analysis, the Cochran -Mantel -Haenszel test will also be carried o ut 
with the strata of US and non -US sites.  
7.6.2.  Secondary Efficacy  Analyses  
Secondary efficacy analyses will include t he following  treatment comparisons at the Week  25 
visit using  the ITT Analysis Set : 
1. Mean change from baseline in range of motion of the affected joint, relative to a 
reference standard for the same joint (as defined below).20 
2. Proportion of responders based on centrally evaluated MRI scans and TVS.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 72 3. Mean change from baseline score in the PROMIS Physical Function Scale . 
4. Mean change from basel ine score in the Worst Stiffness NRS item.  
5. Proportion of responders based on BPI Worst Pain NRS item and analgesic use (BPI -30, 
as defined below).  
The above -listed  endpoints will be analyzed using a hierarchical (“ gatekeeping”) testing 
procedure .33  Thus, if the primary analysis of responder rate by RECIST 1.1 is statistically 
significant favoring pexidartinib  (p <0.05), then secondary endpoint #1 will be analyzed, also 
based on the use of a two -sided test at the alpha  = 0.05 level of significan ce. If secondary 
endpoint #1 is statistically significant (p  <0.05), then the testing procedure will proceed to 
secondary end point #2, and so on . If the test for a particular endpoint is not statistically 
significant, the inference for all subsequent endpoints in the hierarchy will not be performed . 
For responder analysis based on the BPI Worst Pain NRS item and analgesic use, a  BPI-30 
responder will be defined as a subject who ( i) experienced a decrease of at least 30% in the mean 
BPI Worst Pain NRS item and ( ii) did not experience a 30% or greater increase in narcotic 
analgesic use, comparing data collected during a 7 -day perio d prior to the current visit for 
responder assessment with baseline values collected prior to the first dose of study treatment. A 
decrease of at least 30% in BPI Worst Pain NRS item has been shown to be clinically 
meaningful in  several therapeutic areas.34,35  Subjects who do not provide data for the endpoint 
will be considered to be non -responders. Definition for increase in analgesic use is outlined in 
Section  6.4.11 . See SAP for further details.  
The proportion of TVS responders  (ie, those who achieve a CR or PR based on TVS criteria)  at 
the Week 25 (Part 1 Completi on) visit will be analyzed using the same methodology as that used 
for the primary efficacy endpoint  (Section  7.6.1 ). 
Other secondary endpoints will be analyzed using MMRM . The dependent variable wil l be the 
change from baseline.  Each of these models will include fixed effects for treatment group, time 
point, treatment  group -by-time interaction, stratification factor of US sites versus  non-US sites, 
and the baseline value of the corresponding endpoint as well as the baseline -by-time interaction . 
An unstructured variance -covariance matrix will be used. Statistical comparisons between 
treatment groups will be made at the specified time point.  
For the endpoint  of range -of-motion, raw measurements of the affected joint will be performed 
using a goniometer and expressed in degrees (Section  6.4.4). The value for a given joint will be 
normalized to a reference standard, ie, full range -of-motion for the same joint, to provide a 
relative value. The reference  standard will be derived from American Medical Association 
disability criteria 20 and are included in the SAP. T he change from baseline in relative 
range -of-motion at the Week 13 and Week 25 visit s will then be calculated. MMRM will be 
employed to analyze the change from baseline, and a statistical comparison between treatment 
groups will be made for the Week 25 vis it. Joint type will also be properly accounted for in the 
model.  
Duration of response will also be analyzed as a secondary endpoint and will be summarized for 
responders based on (i) RECIST 1.1 and (ii)  TVS.  Duration of response is defined from the date 
of the first recorded response to the  first date of documented disease  progressi on. For subject s 
who do not have radiologic progressi on, the date of the last MRI scan will be  censored . The 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 73 Kaplan-Meier product limit method will be used to compute the estimate and 95% CI of the 
median and 25th and 75th percentiles.  The number of responders, the number with subsequent 
disease  progression , and the number with cens ored values will be displayed as well.  Within the 
framework of Kaplan -Meier method ology, the estimates for proportions of responders with 
response duration s longer than 3, 6, 12, 18, and 24 months w ill also be provided.  
Duration of response will be summarized for responders in each of the  following three groups : 
(A) Subject s randomized to receive  pexidartinib  in Part 1  using data from Part 1 and 
Part 2 ;  
(B) Subject s randomized to receive  placebo  in Part 1;  
(C) Subject s in Part 2 who were randomized to receive  placebo  in Part 1.   
For Group A, tumor assessment data from both Part 1 and Part 2 will be combined, and the 
baseline assessment will be  the one recorded at the S creening  visit. For Group B, the duration of 
response will be censored at Week 25 visit  if no disease progression was documented , with the 
screening assessment serving as baseline . For Group C, the tumor assessment data in Part 2 will 
be used, with the baseline assessment being the last one before the first dose of pexidartinib  in 
Part 2.  
For each of the above three groups, t he percentage and 95% CI will be provided for the best 
overall response in the order of CR, PR, SD, PD , and “Inevaluable .” 
The analyses for the primary efficacy endpoint and BPI Worst Pain NRS item associated 
endpoints will also be performed on the Per-protocol Analysis Set as a sensitivity analysis.  
7.6.3.  Additional Efficacy Analyses  
Additional efficacy endpoints to be analyzed at Week 25, with the exception of duration 
endpoints or  otherwise indicated , include:  
 Proportion of responders on the BPI Worst Pain NRS item and analgesic use by 
BPI-2p definition (see below)  
 Proportion of responders on the BPI Worst Pain NRS item  and analgesic use by 
BPI-50 (see below ) 
 Proportion of responders on the Worst Stiffness NRS item  
 Proportio n of responders on the PROMIS Physical Function Scale  
 Mean change from baseline  in the BPI Worst Pain NRS item  
 Patient Global Impression of C hange item for tumor -related stiffness and Patient 
Global Rating of Concept item for ability to carry out every day  physical activities.   
 Duration of BPI-based symptom response , analyzed for BPI -30, BPI -50 and BPI -2p. 
 Results of the Surgical Assessment Questionnaire in Part 1.  
 Response  based on the change in the SSD of  the tumor on MRI, referred to as 
“modified RECIST 1.1 –SSD”  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 74  Amount of joint/tissue damage ( eg, bone erosion, bone edema, cartilage loss) 
assessed on MRI  based on adaptations of  the RAMRIS and WORMS  
 Analgesic use expressed as morphine -equivalent doses in Pa rt 122 
 EQ-5D-5L parameters in Part 1  
 Major HCRU and productivity in Part  1 
 Duration of response based on MRI and modified RECIST 1.1 -SSD 
 Response based on the most disturbing symptom of pain, stiffness, or compromised  
ability to carry out everyday activities . 
 Proportion of subjects receiving surgical resection of their tumor by 25 weeks, 49 
weeks, 73 weeks, and 97 weeks of pexidartinib treatment  
For responder analysis based on the BPI Worst Pain NRS item and analgesic use, a BPI -2p 
responder will be defined as a subject who (i) experienced a decrease of at least 2 points in the 
mean BPI Worst Pain NRS item and (ii) did not experience a 30% or greater increase in narcotic 
analgesic use, comparing data collected during a 7-day period prior to the current visit for 
responder assessment with baseline values collected prior to the first dose of study treatment.  A 
BPI-50 will have the same definition except the subject must experience a decrease of at least 
50% in the  mean BPI  Worst Pain NRS item.  Subjects who do not provide data for the endpoint 
will be considered to be non -responders. Definition for increase in analgesic use is outlined in 
Section  6.4.11 . See SAP for further details.  
The endpoi nts involving the PRO assessments, amount of joint/tissue damage, response based on 
MRI and modified RECIST 1.1 -SSD, and duration of response will be analyzed using the same 
methods as those used for the primary and secondary endpoints.  
Duration of BPI symptom response for a responder is the interval from the first time BPI 
symptom response is documented to the first subsequent time point when t he BPI symptom 
response is not met . The definition applies to BPI symptom response of  BPI-30, BPI -50 and BPI -
2p. Duration of BPI symptom response will be summarized in a way similar to that for duration 
of tumor response by RECIST   1.1. 
For subjects who un dergo surgical resection, the surgery -related data will be listed, including 
those collected in the separate protocol, if applicable.  Proportion of subjects receiving surgical 
resection of their tumor by 25 weeks of pexidartinib treatment  will be calcula ted regardless of 
whether blinded or open -label pexidartinib  treatment, or both, was taken.  The numerator is the 
number of subjects having the surgical resection of the tumor within 36 weeks of the first 
treatment of pexidartinib, taking into account the 12 weeks allowable window. The denominator 
is the number of subjects who complete at least 24 weeks of pexidartinib  treatment.  Likewise, 
the proportion of subjects receiving surgical resection of their tumor by 49 weeks, 7 3 weeks, and 
97 weeks of pexidartinib treatment will be calculated similarly.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 75 7.6.4.  Subgroup Analyses  
The primary endpoint  and BPI Worst Pain NRS item  will be also analyzed in the following 
subgroups of the ITT population:  
 Subject s with disease located in large joints  (shoulde r, elbow, hip, or knee) ; 
 Subject s with disease located in small joints  (joints other than the shoulder, elbow, 
hip, or knee) ; 
 Subjects with disease located in the knee;  
 Subject s with GCT -TS type of TGCT;  
 Subject s with PVNS type of TGCT ; 
 Subject s with lower  extremity tumor s; 
 Subject s with upper extremity tumor s; 
 Subjects at US sites;  
 Subject s at site s outside of the US; 
 Subjects at sites in  the EU region only.  
In each subgroup defined above, the analysis will be carried out using the same type of 
methodology  as described for the overall analysis of the corresponding endpoint.  These results 
will be considered exploratory because of the multiplicity issue and also smaller sample sizes 
that cannot be pre -specified.  For subgroups without an adequate number of sub jects, the analysis 
will not be performed.  
7.7. Pharmacodynamics/Biomarkers  
Blood samples collected at specified time points will be analyzed for markers of pexidartinib 
exposure and for exploratory biomarkers, including CSF -1 and adiponectin.  
Available and con sented archival tissue specimens from PVNS/GCT -TS tumors will be collected 
and stored for exploratory biomarkers related to pexidartinib and/or disease . Plasma will be 
analyzed for markers of pexidartinib exposure and for exploratory biomarkers, including CSF-1 
and adiponectin. No formal statistical analysis of PDy endpoints will be performed.  
Pharmacodynamic data from each assay will be listed and possible relationships between PK and 
PDy variables may be explored. Any biological activity will be described . 
Biomarker data will be summarized using descriptive statistics by treatment and visit.  Exposure -
biomarker data will be analyzed graphically and may be modeled if data permit.  
7.8. Pharmacogenomic  Analysis  
7.8.1.  Genomic or Genetic Banking and Analysis  
A single blood  sample (10 mL) for pharmacogenomics analysis will be collected from each 
subject who consent to this test.  Pharmacogenomic sample may also be collected from 
discontinued subjects who provide consent.   Participation in this part of the study is optional fo r 
all subjects.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 76 The following procedures will be used for the long -term preservation (banking) of DNA 
specimens extracted from subjects' blood samples.  Pharmacogenomic samples may be analyzed 
for genes involved in absorption, distribution, metabolism, eli mination, safety, and efficacy of 
pexidartinib.  Additionally, samples may be analyzed for genes involved in pexidartinib related 
signaling pathways, or to examine diseases or physiologic processes related to pexidartinib.  
DNA samples will not be immortal ized or sold to anyone.  This information may be useful in 
increasing the knowledge of differences among individuals in the way they respond to the study 
drug, as well as helping in the development of new drugs or improvement of existing drugs.  
Specimen shipping and handling details will be included in the laboratory manual.  
7.8.1.1.  Disclosure of the Results of Genomic or Genetic Analysis  
Because the nature and value of future pharmacogenomic research cannot be known at this time, 
any results obtained from resear ch involving pharmacogenomic samples will not be disclosed to 
the subject or Investigators now or in the future.  
7.8.1.2.  Storage and Disposal of Specimens for Genomic or Genetic Banking and 
Analysis  
Samples will be retained until exhausted or until the Sponsor req uests disposition.  
If the subject withdraws consent, the banked blood samples will be properly and promptly 
dispos ed of.  However, the data will not be discarded if genetic analysis has been completed 
before the subject withdraws consent.  
7.9. Pharmacokinetics  and Exposure –Response Analyses  
Plasma –concentration time data for pexidartinib  will be summarized by visit and time using 
descriptive statistics.  Plasma –concentration data from these samples will be analyzed using a 
PopPK approach using nonlinear mixed effects modeling.  Data from Phase  1 studies will be used 
to inform and stabilize the structural PK model  and will be pooled with Phase  3 data to assess 
and characterize the inter - and intra -subject variability in PK and to identify significant 
covariates.  PK parameters will include apparent clearance and volume of distribution along with 
transfer rate constants such as absorption and elimination rates.  Additionally, based on post  hoc 
Bayesian methods, estimates of exposure such as C max, Ctrough, Cav and AUC ss may also be 
reported.  
Exposure –Response  
Bayesian individual exposures of pexidartinib  from the PopPK analysis will be used to explore 
relationships between exposure metrics and biomarkers and safety and efficacy endpoints.  These 
analyses will be summari zed in a separate report.  
7.10. Safety Analysis  
The analyses of safety will be performed on the Safety Analysis Set . The summary and display 
of TEAEs  will be performed for the following  data sets : 
(i) Part 1 data for the  subject s who received  blinded pexidartinib  in Part 1 ; 
(ii) Part 1 data for the  subject s who received  blinded placebo  in Part 1 ;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 77 (iii) All data from open -label pexidartinib  treatment , ie, Part 2 data  from all subject s; 
(iv) Aggregate pexidartinib  data, ie, data from Parts 1 and 2 for the subject s who received 
pexidartinib  in Parts  1 and 2 plus Part 2 data for the subject s who received blinded 
placebo in Part 1.  
Terminology from version 19.1 of the Medical Dictionary for Drug Regulatory Activities 
(MedDRA ) will be used to assign System Organ Class (SOC) and preferred term (PT) 
classification to AEs and diseases, based on the original terms entered on the eCRF.  
The incidence of TEAEs will be summarized by SOC, PT, relationship to the study treatment, 
and severity for each treatment group.  A by -subject  listing will be provided for those subject s 
who experience an SAE, including death, or experience an AE associated with early withdrawal 
from the study or study treatment.  
7.10.1.  Analysis of Treatment -emergent Adverse Event s 
TEAEs are AEs that occur, having been  absent before the first dose of study  treatment , or have 
worsen ed in severity after the initiating the  study treatment . TEAEs will be coded using 
MedDRA and assigned grades based on version 4.0 of the National Cancer Institute’s Common 
Terminology Criteri a for Adverse Events ( NCI CTCAE ). The number and percentage of subjects 
reporting TEAEs will be tabulated by the worst CTCAE grade, SOC , and PT, with a breakdown 
by data set ( Section  7.10). Similarly, the number and percentage of subjects reporting treatment -
emergent SAEs will be tabulated, as well as TEAEs leading to discontinuation of study 
treatment s. 
A by -subject AE (including treatment -emergent) data listing including but not limited to 
verbatim term, preferred term, system organ class, CTCAE grade, and relationship to study 
treatment  will be provided.  Deaths, other SAEs, and other significant AEs, in cluding those 
leading to discontinuation of study treatment s, will be listed.  
7.10.2.  Clinical Laboratory Evaluation Analyses  
Descriptive statistics will be provided for the clinical laboratory results by scheduled time of 
evaluation and by treatment group  and study part for the Safety Analysis Set , as well as for the 
change from baseline.  The baseline value is defined as the last non -missing value before the 
initial administration of study treatment.  In addition, mean change from  baseline will be 
summarized  for th e maximum and minimum post -treatment values and the values at the End of 
Treatment visit.  
Abnormal clinical laboratory results will be graded according to NCI CTCAE version 4.0, if 
applicable, and the grade will be presented in a by -subject data listing.  A shift table, presenting 
by treatment group the 2-way frequency tabulation for baseline and the worst post -treatment 
value according to the NCI CTCAE grade, will be provided for clinical laboratory tests.  
Abnormal clinical laboratory test results deemed o f clinical significance or of Grade 3 or 4 will 
be listed.  
7.10.3.  Vital Sign Analyses  
Descriptive statistics will be provided for the vital signs measurements by scheduled time of 
evaluation and by treatment group and study part for the Safety Analysis Set , as well as for the 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 78 change from baseline.  The baseline value is defined as the last non -missing value before the 
initial administration of study treatment.  In addition, mean change from baseline will be 
presented by treatment group for the maximum and minimum post-treatment values and the 
values at the End of Treatment visit.  
7.10.4.  Electrocardiogra m Analyses  
Descriptive statistics will be provided for the ECG measurements by scheduled time of 
evaluation and by treatment group for the Safety Analysis Set , as well as f or the change from 
baseline.  The baseline value  is defined as the last non -missing value before the initial 
administration of study treatment.  In addition, the number and percentage of subjects with ECG 
interval values meeting the criteria will be tabulate d (eg, QTc ≤ 450 ms, >  450 to ≤  480 ms, 
> 480 ms to ≤  500 ms, and >  500 ms) and QT cF maximum changes from baseline (> 30 and 
> 60 ms) over all post -treatment evaluations will be summarized . ECG d ata will also be 
presented in the data listings.  
7.10.5.  Echocardiogra m Analyses  
Ejection fraction data will be summarized descriptively, for the Safety Analysis Set , including 
values at baseline and each time point along with mean change from baseline.  
7.10.6.  Analysis of Physical Examination Finding s 
Physical examination data will be listed . 
7.10.7.  Concomitant Medication  Analyses  
Concomitant medications will be coded using the World Health Organization drug dictionary 
(most recent version).  Number and percentage of subject s taking concomitant medications will 
be summarized for the Safety Analysis Set by treatment group . 
7.11. Data Monitoring Committee  
An independent DMC will be responsible for safeguarding the interests of study subjects, 
assessing the safety of the interventions during the trial, and monitoring the overall conduct of 
the trial.  The DMC will also make recommendations about continuing , modifying, or stopping  
the trial.  To enhance the integrity of the study , the DMC may also formulate recommendations 
relating to subject selection, recruitment, and manag ement, improving adherence to protocol -
specified regimens and subject retention, and data management and quality control procedures.  
A separate DMC Charter will define the DMC membership, its roles and responsibilities, and the 
process for providing feedba ck to the Sponsor.  
7.12. Sample Size Determination  
For the purpose of sample size evaluation,  the assumed rates of responder s (subjects achieving a 
CR or PR) for the primary endpoint are 10% (placebo) and 35% (pexidartinib ), respectively.  
Based on the use of a 2-sided, two -sample comparison of proportions at the alpha=0.05 level of 
significance by Fisher’s exact test, a sample size of 12 6 ITT randomized subjects (6 3 per arm) 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 79 provides 90 % power to detect this magnitude of difference.  The sample size was calculated  using 
nQuery Advisor 7.0 with the module of two -group Fisher’s exact test of equal proportions.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 80 8. ETHICAL CONSIDERATIO NS 
This study will be conducted in accordance with ethical principles founded in the Declaration of 
Helsinki and in compliance with the pro tocol, GCP, and applicable regulatory requirements 
(including International Conference on Harmonisation [ICH] guidelines).  The IRB/IEC will 
review all appropriate study documentation in order to safeguard the rights, safety a nd well -
being of the subject s. The study will only be conducted at sites where IRB/I EC approval has 
been obtained.  The protocol, IB, informed consent form, advertisements (if applicable), written 
information given to the subject s (including diary cards and PRO instruments), safety updat es, 
annual progress reports, and any revisions to these documents will be provided to the IRB/IEC 
by the Investigator  or the Sponsor , as allowable by local regulations.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 81 9. SAFETY ASSESSMENT  
9.1. Reporting Adverse Events and Serious Adverse Events  
All A Es occurring  after the subject signs the informed consent form and through the Post -
Treatment Visit (28 ±  7 days after the last dose of study treatment ), whether observed by the 
Investigator  or reported by the subject, will be recorded on the AE eCRF page.  Medical 
conditions (including laboratory values/vital signs that are out of range) that were diagnosed or 
known to exist prior to informed consent will be recorded as part of medical history.  All SAEs  
are to be reported according to the procedures in Section  9.3 (SAE Reporting -Procedure for 
Investigator s). 
Always report diagnosis as the AE or SAE term (s). When a diagnosis is unavailable, report the 
primary sign or symptom as the AE or SAE term with a dditional details included in the narrative 
until the diagnosis becomes available.  
If the signs and symptoms are distinct and do not suggest a common diagnosis, report them as 
individual entries of AE or SAE.  For events that are serious due to hospitalizat ion, the reason for 
hospitalization must be reported as the SAE  (diagnosis or symptom requiring hospitalization).  A 
procedure is not an AE or SAE, but the reason for the procedure may be an AE or SAE.  Pre-
planned (prior to signing the informed consent form) procedure or treatment requiring 
hospitalization for pre -existing conditions that do not worsen in severity should not be rep orted 
as SAEs ( see Section  9.2 for definitions).  For deaths, the underlying or immediate cause of death 
should always be reported as an SAE.  Disease progression is a study endpoint and , consequently, 
should not be reported as an AE/SAE.  However, when a subject dies from disea se progression 
with no other immediate causes, “disease progression” should be reported as an SAE.  In 
addition, any serious untoward event that may occur subsequent to the reporting period that the 
Investigator  assesses as related to study treatment  should also be reported and managed as an 
SAE.  
At each visit, the Investigator  will determine whether any AEs  have occurred by evaluating the 
subject.  Adverse events may be directly observed, reported spontaneously by the subject or by 
questioning the sub ject at each study visit.  Subjects should be questioned in a general way, 
without asking about the occurrence of any specific symptoms.  The Investigator  must assess all 
AEs to determine seriousness, severity, and causality, in accordance with the definitio ns in 
Section  9.2. The Investigator ’s assessment must be clearly documented in the site’s source 
documentation with the Investigator ’s signature.  All laboratory values must be appraised by the 
Investigator  as to clinical significance.  All abnormal laboratory values considered clinically 
significant by the Investigator  must be recorded as an adverse event on the eCRF, and if serious, 
report as an SAE followi ng the procedures in Section  9.3. 
The Investigator  should follow subjects with AEs until the event has resolved or the condition 
has stabilized.  In case of unresolved AEs, including significant abnormal laboratory values at the 
end of study assessment, these events will be followed up until resolution or until they become 
clinically not  relevant.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 82 9.2. Definitions  
9.2.1.  Adverse Event  
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.36 
It is the responsibility of Investigator s, based on their knowledge and experience, to determine 
those circumstances o r abnormal lab oratory  findings that should be considered AEs. 
9.2.2.  Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose  that: 
 Results in death ; 
 Is life -threatening ; 
 Requires in patient  hospitalization or prolongation of existing hospitalization ; 
 Results in persistent or significant disability/incapacity ; 
 Is a congenital anomaly  or birth defect ; 
 Is an important medical event . 
Note : The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject wa s at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe .36  
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in deat h or hospitalization but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed in the definition above.  Examples 
include allergic bronchospasm, convulsions, and blood dyscrasias or development of drug 
dependency  or drug abuse.  
Note:  
 A procedure is not an AE or SAE, but the reason for the procedure may be an AE or 
SAE.  
 Pre-planned (prior to signing the informed consent form) procedures or treatment 
requiring hospitalizations for pre -existing conditions which do no t worsen in severity 
are not SAEs.  
9.2.3.  Adverse Event Severity  
All AEs will be graded (1 to 5; see below) according to the latest NCI CTCAE : 
 Grade 1 — Mild . 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 83  Grade 2 — Moderate . 
 Grade 3 — Severe . 
 Grade 4 — Life-threatening consequences; urgent intervention indicated . 
 Grade 5 — Death related to the AE . 
Severity v s. Seriousness  
Severity is used to describe the intensity of a specific event while the event itself, however, may 
be of relatively minor medical significance (such as severe headache).  This is not th e same as 
“seriousness,” which is based on subject /event outcome at the time of the event.  For example, the 
NCI CTCAE Grade 4 (life -threatening consequences; urgent intervention indicated) is assessed 
based on unique clinical descriptions of severity for e ach AE, and these criteria may be different 
from those used for the assessment of AE seriousness.  An AE assessed as Grade 4 based on the 
NCI CTCAE grades may or may not be assessed as serious based on the seriousness criteria.  
9.2.4.  Causality Assessment  
The Investigator  should assess causal relationship between an adverse event and the study 
treatment on the basis or his/her clinical judgment and the following definitions.  The causality 
assessment should be made based on the available information and can be updat ed as new 
information becomes available.  
 Related : 
o The AE follows a reasonable temporal sequence from study treatment  
administration, and cannot be reasonably explained by the subject’s clinical 
state or other factors ( eg, disease under study, concurrent diseases, and 
concomitant medications).  
o The AE follows a reasonable temporal sequence from study treatment  
administration, and is a known reaction to the drug under study or its chemical 
group, or is predicted by known phar macology.  
 Not Related : 
o The AE does not follow a reasonable sequence from study product 
administration, or can be reasonably explained by the subject’s clinical state 
or other factors ( eg, disease under study, concurrent diseases, and concomitant 
medication s). 
9.2.5.  Action Taken Regarding the Study Treatment  
 1 = Dose Not Changed :  No change in study treatment  dosage was made.  
 2 = Drug Withdrawn :  The study product was permanently stopped.  
 3 = Dose Reduced :  The dosage of study product was reduced.  
 4 = Drug Interru pted:  The study product was temporarily stopped.  
 5 = Dose Increased :  The dosage of study product was increased.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 84 9.2.6.  Adverse Event Outcome  
 1 = Recovered/Resolved  
o The subject fully recovered from the adverse event with no residual effect 
observed.  
 2 = Recovere d/Resolved with Sequelae  
o The residual effects of the adverse event are still present and observable.  
o Include sequelae/residual effects.  
 3 = Not Recovered/Not Resolved  
o The adverse event itself is still present and observable.  
 4 = Fatal  
9.2.7.  Other Action Taken for Event  
 1 = None.  
o No treatment was required.  
 2 = Medication required.  
o Prescription and/or OTC medication was required to treat the adverse event.  
 3 = Hospitalization or prolongation of hospitalization required.  
o Hospitalization was required or prolonged b ecause of the adverse event, 
whether or not medication was required.  
 4 = Other . 
9.3. Serious Adverse Event Reporting Procedure for Investigator s 
9.3.1.  Reporting by Investigator s 
All AEs  and SAEs  will be reported in the eCRF . 
The following types of events should also be reported on the Daiichi Sankyo Serious Adverse 
Event Report (SAVER) Form within 24 hours of awareness:  
 SAEs ( Section  9.2.2 ) 
 Hepatic events meeting combination abnormalities [ALT or AST ≥ 3 × ULN with 
simultaneous total bilirubin ≥ 2 × ULN] (potential Hy’s Law case), both serious and 
non-serious  
All AEs (serious a nd non -serious) must be reported with Investigator ’s assessment of the event’s 
seriousness, severity, and causality to the blinded study treatment . A detailed narrative 
summarizing the course of the event, including its evaluation, treatment, and outcome s hould be 
provided.  Specific or estimated dates of event onset, treatment, and resolution should be included 
when available. Medical history, concomitant medications, and laboratory data that are relevant 
to the event should also be summarized in the narrat ive. For fatal events, the narrative should 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 85 state whether an autopsy was or will be performed, and include the results if available.  Source 
documents will be retained in site’s files and should not be submitted to the Sponsor  for SAE 
reporting purposes.  
Urgent safety queries must be followed up and addressed promptly.  Follow -up information and 
response to non -urgent safety queries should be combined for reporting via eCRF to provide the 
most complete data possible within each follow -up. 
Please call the loca l SAE Hotline or your study monitor for any questions on SAE reporting (see 
Section 10.1.2.2 ). 
9.3.2.  Notifying Regulatory Authorities, Investigator s, and Institutional Review 
Boards/Institutional Ethics Committees  
The Sponsor and/or designee will inform Investigator s, IRBs/IECs, and regulatory authorities of 
any suspected unexpected serious adverse reactions (SUSARs) occurring in other study centers 
or othe r Daiichi Sankyo studies of the investigational product, as appropriate per local reporting 
requirements.  
In the US, upon receipt of the Sponsor ’s notification of SUSARs that occurred with the 
investigational product, unless delegated to the Sponsor, it is  the Investigator ’s responsibility to 
inform the IRB per the Sponsor’s instruction.  
In the European Economic Area member states, it is the Sponsor’s responsibility to report 
SUSARs to all IECs.  
9.4. Procedures for Reporting Drug Exposure During Pregnancy and 
Birth Events  
The Sponsor must be notified of any female subject or any male subject whose female partner 
who becomes pregnant while receiving or within 90 days of discontinuing the study treatment . 
Reporting after follow -up visit or early termination is done  voluntarily by the Investigator.  
Although pregnancy is not technically an AE, all pregnancies must be followed to conclusion to 
determine their outcome.  This information is important for both drug safety and public health 
concerns.  It is the responsibilit y of the Investigator  or designee to report any pregnancy in a 
female subject or a male subject’s female partner using the Exposure In Utero (EIU) Reporting 
Form. Please contact your study monitor to receive the EIU Reporting Form upon learning of a 
pregna ncy. The Investigator  should make every effort to follow the subject until completion of 
the pregnancy.  If the outcome of the pregnancy meets the criteria for immediate classification as 
an SAE ( ie, post-partum complications, spontaneous abortion, stillbirth, neonatal death, or 
congenital anomaly, including that in an aborted fetus), the Investigator  should follow the 
procedures for reporting SAEs  as outlined in Section 9.3. For reports of pregnancy in the female 
partner of a male subject, the EIU Reporting Form (or SAE form if associated with an adverse 
outcome) should be completed with the subj ect’s randomization number, initials, and date of 
birth, and details regarding the female partner should be entered in the narrative section.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 86 10. STUDY ADMINISTRATIVE  INFORMATION  
10.1. Study Contacts  
10.1.1.  Sponsor  
Daiichi Sankyo, Inc. 
211 Mount Airy Road Basking Ridge, NJ 07920, USA 
 
10.1.2.  Medical Monitor  
10.1.2.1.  Sponsor  Medical Monitor  
 
Senior Director, Global Oncology R&D  
 
10.1.2.2.  Contract Research Organization  Medical Monitor  
 
IQVIA  
All Regions Except Europe Medical Monitor  
 
Pivotal  
EU Medical M onitor  
10.1.3.  SAE Reporting Contact  
The Investigator  will ensure that the SAE reporting form is completed and e -mailed/eFaxed to 
the following address within 24 hours of learning of the occurrence of any SAE:  
Novella Clinical Safety Management Group  PPD
PPD
PPD
PPD
PPD
PPD
PPD
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 87 11. ADMINISTRATIVE REQUI REMENTS  
11.1. Good Clinical Practice  
The study will be conducted in accordance with the ICH Guideline for GCP and the appropriate 
regulatory requirement(s).  The Investigator  will be thoroughly familiar with the appropriate use 
of the study treatment as described in the protocol and the IB. 
11.2. Data Quality Assurance  
The Investigator  is required t o prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertinent to the study for each study subject . 
Study data will be entered into an eCRF by site personnel using a secure, validated web -based 
electronic data capture (EDC) application.  The Sponsor will have access to all data upon entry in 
the EDC application.  
Study monitors will discuss instances of missing or uninterpretable data with the Investigator  
and/or designee  for resolution.  Any changes to  study data will be made to the eCRF and 
documented via an electronic audit trail associated with the affected eCRF.  
11.3. Electronic Case Report Form Completion  
The Sponsor or Sponsor’s designee will provide the study sites with secure access to and training 
on the EDC application, sufficient to permit site personnel to enter or correct  information in the 
eCRFs for the subject s for which they are responsible.  
eCRFs will be completed for each study subject . It is the Investigator ’s responsibility to ensure 
the accuracy, completeness, clarity, and timeliness of the data reported in the subject ’s eCRF.  
The Investigator , or designated representative, should complete the eCRF as specified in the 
eCRF Completion Guidelines . 
The audit t rail entry will show the user’s identification information, and the date and time of the 
correction . The Investigator  must provide through the EDC application formal approval of all the 
information in the eCRFs and changes to the eCRFs to endorse the final  submitted data for the 
subject s for which he  or she  is responsible.  
The Sponsor  or a designee will retain the eCRF data and corresponding audit trails.  A copy of 
the final archival eCRF in the form of a compact disk or other electronic media will be place d in 
the Investigator ’s study file.  
11.4. Data Management  
Each subject will be identified in the database by a unique subject identifier as defined by the 
Sponsor.  
To ensure the quality of clinical data across all subjects and sites, a Clinical Data Management 
review will be performed on subject data according to specifications given to the Sponsor or 
Sponsor designee.  Data will be vetted both electronically and manually for eCRFs, and the data 
will be electronically vetted by programmed data rules within the ap plication.  Queries generated 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 88 by rules and raised by reviewers will be generated within the EDC application.  During this 
review, subject data will be checked for consistency, omissions, and any apparent discrepancies.  
Data received from external sources suc h as central lab oratorie s will be reconciled to the clinical 
database.  
Serious adverse events in the clinical database will be reconciled with the safety database.  All 
AEs will be coded using MedDRA.  
11.5. Study Monitoring  
Monitoring and auditing procedures developed or approved by the Sponsor will be followed, in 
order to comply with GCP guidelines.  
All information recorded on the eCRFs for this study must be consistent with the subject ’s 
source documentation.  During the co urse of the study, the study monitor will make study site 
visits to review protocol compliance, verify eCRFs against source documentation, assess drug 
accountability, and ensure that the study is being conducted according to pertinent regulatory 
requiremen ts. The review of medical records will be performed in a manner to ensure that 
subject  confidentiality is maintained.  
11.6. Subject Information and Informed Consent  
After the study has been fully explained, written informed consent will be obtained from either 
the subject  or his/her guardian or legal representative prior to study participation.  The method of 
obtaining and documenting the informed consent and the contents of the consent must comply 
with ICH -GCP and all applicable regulatory requirement(s).  
11.7. Subject  Confidentiality  
In order to maintain subject  privacy, all eCRFs, study treatment accountability records, study 
reports and communications will identify the subject  by initials where permitted  and/or by the 
assigned subject  number.  The subject ’s confidenti ality will be maintained and will not be made 
publicly available to the extent permitted by the applicable laws and regulations.  
11.8. Investigator  Compliance  
The Investigator  will conduct the trial in compliance with the protocol provided by the Sponsor , 
and gi ven approval/favorable opinion by the IRB/IEC and the appropriate regulatory authority 
(ies). Modifications to the protocol are not be made without agreement of both the Investigator  
and the Sponsor . Changes to the protocol will require written IRB/IEC app roval/favorable 
opinion prior to implementation, except when the modification is needed to eliminate an 
immediate hazard(s) to subject s. The Sponsor  or a designee will submit all protocol 
modifications to the appropriate regulatory authority ( ies) in accordance with the governing 
regulations.  
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
subject s, the Investigator  will contact the Sponsor  or a designee if circumstances permit, to 
discuss the planned cours e of action.  Any departures from the protocol must be documented.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 89 11.9. On-site Audits  
Regulatory authorities, the IEC/IRB, and/or the Sponsor or its designee(s) may request access to 
all source documents, eCRFs, and other study documentation for on -site audit o r inspection.  
Direct access to these documents must be guaranteed by the Investigator , who must provide 
support at all times for these activities.  
11.10.  Investigator  and Site Responsibility for Drug Accountability  
Accountability for the study treatment at the tr ial site is the responsibility of the Investigator . 
Drug accountability records including the study treatment’s delivery date to the site, inventory at 
the site, use by each subject , and amount returned to the Sponsor  or a designee (or disposal of the 
study treatment , if approved by the Sponsor ) will be maintained by the clinical site.  The Sponsor 
or its designee will review drug accountability at the site on an ongoing basis.  
All material containing study treatment will be treated and disposed of as hazardous waste in 
accordance with governing regulations.  
Also see Section  5.9 for specific details.  
11.11.  Product Complaints  
A product complaint is any d issatisfaction with a product that may be attributed to the identity, 
quality, durability, reliability, or safety of the product.  Individuals who identify a potential 
product complaint situation should immediately report the event.  Whenever possible, the 
associated product should be maintained in accordance with the label instructions pending 
further guidance from a quality representative  from the Sponsor . 
For product complaints , refer to the Study Pharmacy Manual for instructions and details.  
11.12.  Study Closure  
Within 90 days of the end of the study the Sponsor will notify the competent authorities and the 
IRBs/ IECs in all member states where the study is being carried out that the study has ended.  
Within 1 year of the end of the study, a summary of the clinical trial results will be submitted to 
the competent authorities and IRBs/ IECs in all  member states involved in the study.  
Study participation by individual sites or the entire study may be prema turely terminated, if in 
the opinion of the Investigator  or the Sponsor , there is sufficient reasonable cause.  Written 
notification documenting the reason for study termination will be provided to the Investigator  or 
the Sponsor by the terminating party.  
Circumstances that may warrant termination include, but are not limited to:  
 Determination of unexpected, significant, or unacceptable risk to subject s 
 Failure to enter subject s at an acceptable rate  
 Insufficient adherence to protocol requirements  
 Insufficient, incomplete, and/or unevaluable data  
 Plans to modify, suspend or discontinue the development of the study treatment  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 90 Should the study be closed prematurely, the site will no longer be able to access the EDC 
application, will not have a right to  use the EDC application, and will cease using the password 
or access materials once their participation in the study has concluded.  In the event that any 
access devices for the EDC application have been provided, these will be returned to the Sponsor  
or designee once the site’s participation in the study has concluded.  
Within 15 business days of premature closure, the Sponsor  must notify the competent authorities 
and IRBs/ IECs of any member state where the study is being conducted, providing the reasons 
for study closure.  
11.13.  Study Documentation and Storage  
The Investigator  will maintain a Signature List of appropriately qualified persons to whom 
he/she has delegated study duties.  All persons authorized to make entries and/or corrections on 
eCRFs will be included on the Signature List.  
Source documents are original documents, data, and records from which the subject’s eCRF data 
are obtained.  These include but are not limited to hospital records, clinical and office charts, 
laboratory and pharmacy records, diaries, microfiches, X -rays, and correspondence.  eCRF 
entries may be considered source data if the eCRF is the site of the original recording ( ie, there is 
no other written or electronic record of data).  
The Investigator  and study staff are responsible fo r maintaining a comprehensive and centralized 
filing system (Trial Master File) of all study -related (essential) documentation, suitable for 
inspection at any time by representatives from the Sponsor and/or applicable regulatory 
authorities.  Essential docu ments include:  
 Subject files containing completed copy of eCRFs, informed consents, and supporting 
copies of source documentation (if kept).  
 Study files containing the protocol with all amendments, Investigator ’s Brochure, 
copies of relevant essential docu ments required prior to commencing a clinical study, 
and all correspondence to and from the IEC/IRB and the Sponsor.  
 Records related to the investigational p roduct(s) including acknowledgment of receipt 
at site, accountability records and final reconciliat ion and applicable correspondence.  
In addition, all original source documents supporting entries in the eCRFs must be maintained 
and be readily available.  
11.14.  Record Retention  
All essential documentation will be retained by the Investigator  until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region or at least 2 years have lapsed since the 
formal discontinuation of clinical development of the investigational product.  These documents 
should be retained for a longer period, however, if required by the applicable regulatory 
requirements or by an agreement with the Sponsor.  It is the responsibility of the Sponsor to 
inform the Investigator /institution as to when these documents no longer need to be retained.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 91 No study document should be destroyed without prior written agreement between Sponsor and 
the Investigator . Should the Investigator  wish to assign the study records to another  party or 
move them to another location, he/she must notify Sponsor in writing of the new responsible 
person and/or the new location.  
11.15.  Record Keeping  
Records of subjects, source documents, monitoring visit logs, data correction forms, eCRFs, 
inventory of st udy product, regulatory documents ( eg, protocol and amendments, IRB/ IEC 
correspondence and approvals, approved and signed informed consent forms, Investigator ’s 
Agreement, clinical supplies receipts, distribution and return records), and other sponsor 
correspondence pertaining to the study must be kept in appropriate study files at the site.  Source 
documents include all recordings and observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction  of the clinical study.  These 
records will be retained in a secure file for the period required by the institution or site policy.  
Prior to transfer or destruction of these records, the Sponsor must be notified in writing and be 
given the opportunity to fu rther store such records.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 92 12. FINANCING AND INSURA NCE  
12.1. Finances  
Prior to starting the study, the Principal  Investigator  and/or institution will sign a clinical study 
agreement with the Sponsor.  This agreement will include the financial information agreed upon 
by the parties.  
12.2. Reimbursement, Indemnity, and Insurance  
Reimbursement, indemnity and insurance shall be addressed in a separate agreement on terms 
agreed upon by the parties.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 93 13. USE OF INFORMATION  
All information regarding pexidartinib  supplied by the Sponsor  to the Investigator  is privileged 
and confidential information.  The Investigator  agrees to use this information to accomplish the 
study and will not use it for other purposes without consent from the Sponsor . It is understood 
that there is an obligation t o provide the Sponsor  with complete data obtained during the study.  
The information obtained from the clinical study  will be used toward the development of 
pexidartinib  and may be disclosed to regulatory authority(ies), other Investigator s, corporate 
partn ers, public databases ( eg, ClinicalT rials.gov, EU Clinical Trial Register), or consultants as 
required.  
Upon completion of the clinical study  and evaluation of results by the Sponsor , the hospital or 
institution and/or Investigator  may publish or disclose the clinical trial results pursuant to the 
terms contained in the applicable Clinical Trial Agreement.  
It is anticipated that the results of this study will be presented at scientific meetings and/or 
published in a peer -reviewed sc ientific or medical journal.  A Publications Group  comprised of 
Sponsor  employees and study Investigator s will be formed to oversee the publication of the study 
results that will reflect the experience of all participating study centers.  Subsequently, indiv idual 
Investigator s may publish results from the study in compliance with their agreements with the 
Sponsor . 
A pre publication manuscript or abstract is to be provided to the Sponsor  a minimum of 30 days 
prior to the intended submission date of the manuscri pt or abstract to a publisher . Within 30 days 
after receipt by the Sponsor  of the notification, the Sponsor  shall inform the  sites whether it has 
objections to the publication for reasons including, but not limited to, those defined below:  
 If patentable subject  matter is disclosed, the publication shall be delayed for a period 
not to exceed 90 days from the Sponsor ’s receipt of the proposed publication to allow 
time for the filing of patent applications covering patentable subject  matter.  
 If confidential in formation is contained in any proposed publication or public 
disclosure, such confidential information will be removed at the Sponsor ’s request.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 94 14. REFERENCE S 
1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of 
Soft Tissue and Bone, Fourth Edition. Lyon: IARC Press, 2013.  
2. Myers BW, Masi AT. Pigmented villonodular synovitis and tenosynovitis: a clinical 
epidemiologic study of 166 cases and literature review. Medicine. 1980;(59):223 –38. 
3. Monaghan H, Salter DM, Al -Nafussi A. Giant c ell tumour of tendon sheath (localized 
nodular tenosynovitis):  clinicopathological features of 71 cases. J Clin Pathol 
2001;(54):404 –7. 
4. Ushijima M, Hashimoto H, Tsuneyoshi M, Enjoji M. Giant cell tumor of the tendon 
sheath (nodular tenosynovitis). A study  of 207 cases to compare the large joint group 
with the common digit group. Cancer. 1986;57(4):875 –84. 
5. Ushijima M, Hashimoto H, Tsuneyoshi M, Enjoji M. Pigmented villonodular synovitis. A 
clinicopathologic study of 52 cases. Acta Pathol Jpn. 1986;36(3):317 –26. 
6. Rao AS, Vigorita VJ. Pigmented villonodular synovitis (giant -cell tumor of the tendon 
sheath and synovial membrane): A review of eighty -one cases. J Bone Joint Surg Am. 
1984;66:76 –94. 
7. Blay J -Y, El Sayadi H, Thiesse P, and Garret J. Letter to the edito r:  Complete response 
to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor 
(PVNS/TGCT). Ann Oncol. 2008;19:821 –2. 
8. Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the 
treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented 
villonodular synovitis. Cancer. 2012;118(6):1649 –55. 
9. Gelderblom H, Pérol D, Chevreau C, et al. An open -label international multicentric phase 
II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not 
amenable to a conservative surgical treatment. J Clin Oncol. 2013;31(suppl 15S):10516.  
[2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Abstract 
#10516.]  
10. Cassier PA, Italiano A, Gomez -Roca CA, et al. CS F1R inhibition with emactuzumab in 
locally advanced diffuse -type tenosynovial giant cell tumours of the soft tissue: a dose -
escalation and dose -expansion phase 1 study. Lancet Oncol. 2015;16(8):949 -56. 
11. PLX3397 Investigator’s Brochure, v.7. Berkeley, CA:  P lexxikon Inc. Dec 2015.  
12. Tap WD, Wainberg ZA, Anthony SP, et al Structure -Guided Blockade of CSF1R Kinase 
in Tenosynovial Giant -Cell Tumor. N Engl J Med 2015;373:428 -437. 
13. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic 
Reso nance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, 
and the OMERACT RA -MRI scoring system. J Rheumatol. 2003;30(6):1385 –6. 
14. Peterfy C, Guermazi A, Zaim S, et al. Whole -Organ Magnetic Resonance Imaging Score 
(WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage. 2004;12(3):177 –90. 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 95 15. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant -cell 
tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. 
Proc Natl Acad Sci USA. 2006;103(3):690 –5. 
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). 
Eur J Cancer. 2009;45:228 –47. 
17. van der Heijden L, Gibbons CL, Di jkstra PD, et al. The management of diffuse -type giant 
cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath 
(nodular tenosynovitis). J Bone Joint Surg Br. 2012;94(7):882 –8. 
18. van der Heijden L, Gibbons CL, Hassan AB, et al. A  multidisciplinary approach to giant 
cell tumors of tendon sheath and synovium: A critical appraisal of literature and 
treatment proposal. J Surg Oncol. 2013;107(4):433 –45. 
19. O’Sullivan B, Cummings B, Catton C, et al. Outcome following radiation treatment fo r 
high-risk pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys. 1995;32:777 –
86. 
20. Gerhardt JJ, Cocchiarella L, Lea RD. The Practical Guide to Range of Motion 
Assessment. Chicago, IL. Amer Med Assoc Press; 2002.  
21. Flockhart, DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana 
University School of Medicine [2009]. Available from: 
http://medicine.iupui.edu/clinpharm/ddis/main -table/. Accessed October 22, 2014.  
22. Basch, Ethan, Autio, Karen A, Smith, Matthew R, et al, Effects of Cabozan tinib on Pain 
and Narcotic Use in Patients with Castration -resistant Prostate Cancer: Results from a 
Phase 2 Nonrandomized Expansion Cohort, Eur Urol (2014), 
http://dx.doi.org/10.1016/j.eururo.2014.02.013.  
23. The Management of Postoperative Pain Working Grou p. VHA/DoD clinical practice 
guidelines for the management of postoperative pain. version 1.2. Washington, DC:  
Veterans Health Administration, Department of Defense; 2002. p. 44 –5. 
24. Milliken, G.A.; Johnson D.E. The Analysis of Messy Data. In Vol. I: Design ed 
Experiments. Chapman & Hall: New York; 1992.  
25. Little R J A., Rubin D B. Statistical Analysis with Missing Data. 2nd ed. New York: 
Wiley; 2002.  
26. Mallinckrodt C H, Clark W S, David S R. Accounting for dropout bias using mixed -
effects models. J of Biopharm S tatist. 2001; 11: 9 –21. 
27. Siddiqui, O., Hung, H. M., O’Neil, R. MMRM versus LOCF: A comprehensive 
comparison based on simulation study and 25 NDA data sets. J of Biopharm Statist. 
2009;.19: 227 –46. 
28. Siddiqui, O. MMRM versus MI in Dealing with Missing Data —A Comparison Based on 
25 NDA Data Sets, J of Biopharm Statist. 2011; 21(3): 423 -36. 
29. Wilson, EB: Probable Inference, the Law of Succession, and Statistical Inference. J of the 
Amer Statist Assoc. 1927;22: 209.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 96 30. Newcombe, RG: Interval Estimation for the Differen ce Between Independent 
Proportions: Comparison of Eleven Methods. Statis in Med. 1998;17: 873 –90. 
31. Lancaster HO. Significance tests in discrete distributions. J Am Statist Assoc. 
1961;294(56):223 –34. 
32. Lydersen S, Fagerland MW, Laake P. Recommended tests for association in 2 x 2 tables. 
Statist Med. 2009;28:1159 –75. 
33. Westfall PH, Krishen A. Optimally weighted, fixed sequence and gatekeeper multiple 
testing procedures. J Statist Plan Infer. 2001;99(1):25 –40. 
34. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting t he Clinical Importance of 
Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. J 
Pain. 2008; 9(2): 105 -21. 
35. Farrara JT, Young Jr. JP, LaMoreaux L, et al. Clinical importance of changes in chronic 
pain intensity measured on an 11 -point numerical pain rating scale. Pain. 2001; 94(2): 
149–58. 
36. International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guidelines. Clinical 
Safety Data Management: Definiti ons and Standards for Expedited Reporting E2A. 
Current Step 4 Revision. 27 October 1994. Available from: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/
Step4/E2A_Guideline.pdf. Accessed November 4, 2014.  
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 97 15. APPEN DICES  
15.1. List of Common CYP3A4 Inhibitors and Inducers  
Strong Inhibitors   Strong Inducers  
Protease inhibitors   Anticonvulsants, mood stabilizers  
  Ritonavir     Phenytoin  
  Indinavir     Carbamazepine  
  Nelfinavir     Oxcarbazepine  
Macrolide antibiotics   Non-nucleoside reverse transcriptase inhibitors  
  Erythromycin        Efavirenz  
  Telithromycin      Nevirapine  
  Clarithromycin      Etravirine    
Azole antifungals   Phenobarbital (barbiturate)  
  Fluconazole   Rifampicin (bactericidal)  
  Ketoconazole   Modafinil (stimulant)  
  Itraconazole   Hyperforin (constituent of St. John’s Wort)  
Chloramphenicol (antibiotic)    Cyproterone (antiandrogen, progestin)  
Nefazodone (antidepressant)    
Bergamottin (constituent of grapefruit juice)      
Aprepitant (antiemetic)      
Verapamil (calcium channel blocker)      
Source: Flockhart, DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of 
Medicine [2009]. Available from: http://medicine.iupui.edu/clinpharm/ddis/main -table/ . Accessed October 22, 2014.  
15.2. Detailed Study Procedures by Visit — Part 1  
15.2.1.  Screening (Day –42 to Day –1) 
Procedures performed as part of patient care within the 42 -day period before the first dose of 
study treatment may be used for screening purposes if they conform to protoco l requirements and 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 98 standards. All screening test results must be reviewed prior to dosing to assess the study 
candidate’s eligibility for inclusion.  
The following procedures must  be performed within the 42-day period before P1 -C1D1 , unless 
otherwise noted , and the results must  be obtained and evaluated for eligibility prior to  the 
P1-C1D1 visit:  
To be performed before  any other procedures:  
 Informed consent.  
To be performed before  any invasive procedures carried out on the same day:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 12-lead ECG.  
Other procedures to be performed:  
 Medical history  (including PVNS/GCT -TS treatment history and smoking history) ; 
 Demographics, including ethnicity and race;  
 Concomitant medications;  
 BPI Worst P ain NRS item  
o This assessment is performed at the Screening Visit only. The recall period 
will be the preceding week . The subject’s response must be documented in the 
medical notes ; 
 Worst Stiffness NRS item  
o This assessment is performed at the Screening Visi t only. The recall period 
will be the preceding week . The subject’s response must be documented in the 
medical notes ; 
 PROMIS Physical Function Scale  
 Height and weight;  
 Physical examination;  
 AE assessment;  
 Clinical laboratory tests — serum chemistry, hemato logy, liver function, hepatitis 
panel, hormone testing (as applicable), serum pregnancy testing (as applicable).  
Note: Women who are not using hormonal contraception will be tested for levels of 
FSH, LH, progesterone, and estradiol. Hormone testing will no t be required for 
women who have either had an oophorectomy or are post -menopausal. Men will be 
tested for levels of LH, FSH, and testosterone. Men whose testosterone level is below 
baseline at the last study visit should be followed until their level has stabilized or 
returned to baseline.  
Note: Women of childbearing potential must have a serum pregnancy test within 14 
days of randomization (or, where different regulations apply, within 72 hours of 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 99 randomization). (Women who have documentation of at least 12 months of 
spontaneous amenorrhea and have an FSH level > 40 mIU/mL will be considered 
postmenopausal and need not undergo pregnancy testing.)  
 ECHO or MUGA scanning;  
 MRI of the affected joint  within 56 days of P1-C1D1 ; 
 Third -party blinded range -of-motion  assessment of the affected joint;   
 Dispense subject diary for recording daily BPI Worst Pain NRS, Worst Stiffness NRS 
and analgesic use during the 2-week  period prior to P1 -C1D1;  
 Surgical Assessment Questionnaire.  
To be performed any time during or after the Screening visit:  
 Obtain archival tumor tissue.  
15.2.2.  Part 1 – Cycle 1 ( Randomization)  
To be performed after  the subject is determined to meet all eligibility criteria:  
 Subject randomization ( time frame between randomization and first dose of study 
treatment can be up to 3 days prior to P1 -C1D1).  
15.2.3.  Part 1–Cycle 1, Day 1 (P1 -C1D1; Week 1)  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 12-lead ECG;  
 PRO instruments, in the following order:  
o BPI Worst Pain NRS Item;  
o Worst Stiffness NRS item;  
o PROMIS Physical Function Scale;  
o Patient Global Rating of Concept item for carrying out every day physical 
activities;  
o EQ-5D-5L 
To be performed before  the first morning dose of study treatment:  
 Review of outp atient PRO instruments;  
 AE assessment;  
 Concomitant medications;  
 Analgesic use assessment;  
 Most disturbing symptom assessment;  
 HCRU and productivity;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 100  Clinical laboratory tests (only need to be done if they were not done within 72h of 
Day 1) — serum chemistr y, hematology, coagulation, hormone lev els, liver function, 
urinalysis;  
 Blood sampling for PK and PDy analysis;  
 Dispense study treatment bottles.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 101 Subject is dosed in clinic.  
To be performed after  dosing:  
 Record the dose (subject diary, source records, eCRF);  
To be performed 2 hours ±  10 minutes after  dosing:  
 12-lead ECG.  
15.2.4.  Part 1–Cycle 1, Day 8 (P1 -C1D8; Week 2) ± 2 days  
 Clinical laboratory tests — liver function;  
 AE assessment;  
 Concomitant medications.  
15.2.5.  Part 1–Cycle 1, Day 15 (P1 -C1D15; Week 3) ± 2 days  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 12-lead ECG.  
To be performed before  the morning dose:  
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment complianc e assessment;  
 Clinical laboratory tests — liver function, hematology;  
 Blood sampling for PK and PDy analysis;  
Subject is dosed in clinic.  
To be performed after  the morning dose:  
 Record the dose (subject diary, source records, eCRF);  
 Re-dispense study treat ment bottles;  
 Blood sampling for PK analysis at various post -dose time points  (see Section  6.4.16 ). 
To be performed 2 hours ±  10 minutes after  dosing:  
 12-lead ECG.  
15.2.6.  Part 1–Cycle 1, Day 22 (P1 -C1D22; Week 4) ± 2 days  
 Clinical laboratory tests — liver function;  
 AE assessment;  
 Concomitant med ications.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 102 15.2.7.  Part 1–Cycle 2, Day 1 (P1 -C2D1; Week 5) ± 2 days  
To be performed before any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 HCRU and produ ctivity;  
 Treatment compliance assessment.  
Other procedures to be performed:  
 Physical examination;  
 Clinical laboratory tests — serum chemis try, hematology, liver function,  serum 
pregnancy testing (as applicable);  
 Blood sampling for PK and PDy analysis;  
 Dispense study treatment bottles  
15.2.8.  Part 1–Cycle 2, Day 8 (P1-C2D 8; Week 6) ± 2 days  
To be performed before any invasive procedures:  
 Clinical laboratory tests — liver function;  
 AE assessment . 
 Concomitant medications.  
15.2.9.  Part 1–Cycle 2, Day 15 (P1 -C2D15; Week 7) ± 2 days  
 Clinical laboratory tests — liver function;  
 AE assessment;  
 Concomitant medications.  
15.2.10.  Part 1–Cycle 2, Day 22 (P1-C2D 22; Week 8) ± 2 days  
To be performed before any invasive procedures:  
 Clinical laboratory tests — liver function;  
 AE assessment . 
 Concomitant medications.  
15.2.11.  Part 1–Cycle 3, Day 1 (P1 -C3D1; Week 9) ± 7 days  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 PRO instruments, in the following order:  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 103 o BPI Worst Pain NRS i tem; 
o Worst Stiffness NRS item;  
o PROMIS Physical Function Scale  
o Patient Global Rating of Concept item for carrying out every day physical 
activities;  
o EQ-5D-5L. 
Other procedures to be performed:  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant me dications, including analgesics;  
 HCRU and productivity;  
 Treatment compliance assessment;  
 Clinical laboratory tests — serum chemis try, hematology, liver function,  serum 
pregnancy testing (as applicable);  
 Random post -dose blood sampling for PK and PDy analysis;  
 Dispense study treatment bottles.  
 Analgesic use assessment.  
15.2.12.  Part 1–Cycle 3, Day 15 (P1-C3D15; Week 11) ± 7 days  
To be performed before any invasive procedures:  
 Clinical laboratory tests — liver function;  
 AE assessment . 
 Concomitant medications.  
15.2.13.  Part 1–Cycle 4, Day 1 (P1 -C4D1; Week 13) ± 7 days  
To be performed within (±) 7 days of the visit:  
 ECHO or MUGA scanning;  
 MRI of the affected joint  (with local assessment of progression status) . The 
Investigator may request a centrally read blinded MRI to c onfirm progression, eg, if a 
subject’s mid -study clinical profile or local radiological a ssessment indicates 
progression ; 
 Third -party blinded range -of-motion assessment of the affected joint.  
To be performed before  any invasive procedures:  
 Vital signs, inc luding blood pressure, pulse rate, and oral temperature.  
Other procedures to be performed:  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 104  Dispense study treatment bottles ; 
 AE assessment;  
 Concomitant medications, including analgesics;  
 HCRU and productivity;  
 Treatment compliance assessment;  
 Physical exam ination;  
 Clinical laboratory tests — serum chemistry, hematol ogy, liver function, serum 
pregnancy testing (as applicable),  and urinalysis . 
15.2.14.  Part 1–Cycle 5, Day 1 (P1 -C5D1; Week 17) ± 7 days  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 PRO instruments, in the following order:  
o BPI Worst Pain NRS Item;  
o Worst Stiffness NRS item;  
o PROMIS Physical Function Scale;  
o Patient Global Rating of Concept item for carrying out every day physica l 
activities;  
o EQ-5D-5L. 
Other procedures to be performed:  
 Dispense study treatment bottles;  
 Analgesic use assessment;  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 HCRU and productivity;  
 Treatment complian ce assessment;  
 Random post -dose blood sampling for PK and PDy analysis;  
 Clinical laboratory tests — serum chemistry, hematology, liver function , serum 
pregnancy testing (as applicable) .  
15.2.15.  Part 1–Cycle 6, Day 1 (P1 -C5D1; Week 21) ± 7 days  
To be performed before any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 105 Other procedures to be performed:  
 Dispense study treatment bottles ; 
 AE assessment;  
 Concomitant medications , including analgesics;  
 HCRU and productivity;  
 Treatment compliance assessment;  
 Clinical laboratory tests — serum chemistry, hematology, liver function , serum 
pregnancy testing (as applicable) . 
15.2.16.  Part 1 Completion visit/Early Termination  Visit  (Week 25) ± 7 days  
For subjects continuing to Part 2, see Sec tion 15.3.1  instead.  
To be performed within the 7 -day period before  the visit:  
 ECHO or MUGA scanning;  
 MRI of the affected joint  (with local assess ment of progression status) ; 
 Third -party blinded range -of-motion assessment  of affected joint . 
To be performed before any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 12-lead ECG.  
 PRO instruments, in the fol lowing order:  
o BPI Worst Pain NRS Item;  
o Worst Stiffness NRS item;  
o PROMIS Physical Function Scale;  
o Patient Global Rating of Concept item for carrying out every day physical 
activities;  
o EQ-5D-5L; 
o Patient Global Impression of Change item for tumor -related stif fness.  
Other procedures to be performed:  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 HCRU and productivity.  
 Treatment compliance assessment;  
 Analgesic use assessment;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 106  Weight;  
 Physical examination;  
 Clinical laboratory tests — serum chemistry, hematology, coagulation, liver function, 
hormone levels, serum pregnancy test ing (as applicable), urinalysis;  
 Surgical Assessment Questionnaire.  
 For subjects who undergo surgical resection of the tumor within 12 weeks of the last 
dose of study treatment, refer to Section  15.4 for collection of  surgery related data . If 
a subject has surgery within 4 weeks  of the last dose, the subject does not need to 
have the 28 Day Post-Treatment Visit evaluations. However, if a subject has surgery 
after 4 weeks of the last dose, the subject should have the 28 Day Post-Treatment 
Visit evaluations . None of these subjects need to have the End-of-Study Visit.  
As of 30 Sep 2016, subjects who wish to continue onto the open label part of this study (Part 2) 
will be unblinded after completion of the end of Part 1 ass essments (Part 1 Completion 
visit/Early Termination visit)  and those on placebo will be discontinued; subjects on pexidartinib 
in Part 1 may continue into Part 2 to continue to receive pexidartinib . Subjects who discontinue 
Part 1 early, should complete th e end of Part 1 assessments ( Part 1 Completion visit/Early 
Termination ) at or before the time of their last treatment (MRI or range of motion assessments do 
not need to be repeated, if completed in the previous 28 days).  
15.2.17.  Part 1 28 Day Post-Treatment Visit (last dose + 28 days)  ± 7 days  
As of 30 Sep 2016, subjects who wish to continue onto the open label part of this study (Part 2) 
will be unblinded after completion of the end of Part 1 assessments (Part 1 Completion 
visit/Early Termination visit) and those on placebo will be discontinued and will not need to 
complete the Part 1 28 Day Post-Treatment Visit and associated procedures.  
This visit is scheduled 28 ± 7 days after the last dose of study treatment.  
To be performed within (±) 7 days of the visit : 
 MRI of the affected joint (for subjects who withdraw from the study for reasons other 
than progression ; local assessment of progression status will be recorded ); 
 Third -party blinded range -of-motion assessment of the affected joint.  
To be performed before any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 12-lead ECG;  
 PRO instruments, in the following order:  
 BPI Worst Pain NRS item;  
 Worst Stiffness NRS item;  
 PROMIS Physical Function Scale;  
 Patient Global Rating of Concept item for carrying out every day physical 
activities;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 107  EQ-5D-5L; 
 Patient Global Impression of Change item for tumor -related stiffness.  
Other procedures to be performed:  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 HCRU and productivity;  
 Analgesic use assessment;  
 Weight;  
 Physical examination;  
 ECHO or MUGA scanning (only if >  3 months have elapsed since the previous scan);  
 Clinical laboratory tests — serum chemistry, hematology, coagulation, liver function, 
hormone levels, serum pregnancy test ing (if  applicable), urinalysis;  
 Surgical Assessment Questionnaire.  
 For subjects terminating the study because of progression, document if they plan to 
undergo any new PVNS/GCT -TS therapy, including surgery, during the 28 -day 
period (± 7 days) after thei r last do se of study treatment.  
 For subjects who undergo surgical resection of the tumor within 12 weeks of the last 
dose of study treatment, refer to  Section  15.4 for collection of surgery related data . 
15.2.18.  Part 1 End-of-Study /12 Week Post -Treatment  Visit  (12 weeks ± 7 days after the 
last dose)  
As of 30 Sep 2016, subjects who wish to continue onto the open label part of this study (Part 2) 
will be unblinded after  completion of the end of Part 1 assessments (Part 1 Completion 
visit/Early Termination visit) and those on placebo will  be discontinued and will not need to 
complete the Part 1 End-of-study /12 Week Post -Treatment  Visit and associated procedures.  
This visi t is scheduled 12 weeks ± 7 days after the last dose of study treatment or before any new 
PVNS/GCT -TS therapy, including surgery, whichever occurs first. It is scheduled for subjects 
who withdraw from the study for reasons other than progression.   
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 108 To be pe rformed within (±) 7 days of the visit:  
 MRI of the affected joint (with local assessment of progression status)  
Other procedures to be performed:  
 Clinical laboratory tests — serum pregnancy testing (if applicable) ; 
 AE assessment;  
 Concomitant medications;  
 Ask the subject if s/he plans to begin any new PVNS/GCT -TS therapy, including 
surgery.  For subjects who undergo surgical resection of the tumor within 12 weeks of 
the last dose of study treatment, refer to Section  15.4 for collection of surgery related 
data.  
 For other subjects, t erminate the subject from the study.  
15.3. Detailed Study Procedures by Visit — Part 2  
If the subject  is known to have been on pexidartinib treatment in Part 1, then visits and 
associated procedures are only required on Day 1 of each cycle in Part 2.  
15.3.1.  Part 2–Cycle 1, Day 1 (P2 -C1D1; Week 25)  
For subjects continuing to Part 2, the P2 -C1D1 visit will serve a s both the Part 1 Completion 
visit and the first visit of Part 2.  Some procedures for both visits can occur on the same day.  
The following procedures are performed as part of the P1 -Completion visit.  
To be performed within the 7 -day period before  the P2-C1D1 visit:  
 ECHO or MUGA scanning;  
 MRI of the affected joint  (with local assessment of progression status) . The 
Investigator may request a centrally read MRI to confirm progression , eg, if a 
subject’s mid -study clinical profile or local radiological assessme nt indicates 
progression.  
 Third -party blinded range -of-motion assessment of the affected joint.  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 PRO instruments, in the following order : 
o BPI Worst Pain NRS item;  
o Worst Stiffness NRS item;  
o PROMIS Physical Function Scale;  
o EQ-5D-5L.  
To be performed before  dosing  at the P2 -C1D1 visit : 
 Review outpatient PRO instruments;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 109  AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment c ompliance assessment;  
 Analgesic use assessment.  
 Weight;  
 Physical examination;  
 Clinical laboratory tests - serum chemistry, hematology, coagulation, liver function, 
hormone levels, serum pregnancy test ing (as applicable), urinalysis.  
Note: Women who are not using hormonal contraception will be tested for levels of 
FSH, LH, progesterone, and estradiol. Hormone testing will not be required for 
women who have either had an oophorectomy  or are post -menopausal. Men will be 
tested for levels of LH, FSH, and testosterone. Men whose testosterone level is below 
baseline at the last study visit should be followed until their level has stabilized or 
returned to baseline.   
 Surgical Assessment Qu estionnaire.  
The following procedures will be performed as part of the P2 -C1D1visit.  
To be performed before  dosing:  
 Blood sampling for PK and PDy analysis  
Subject is dosed in clinic.  
To be performed after  dosing:  
 Record the dose (subject diary, source reco rds, eCRF);  
 Dispense study treatment bottles.  
To be performed 2  hours ±  10 minutes after  dosing:  
 12-lead ECG.  
15.3.2.  Part 2–Cycle 1, Day 8 (P2 -C1D8; Week 26) ± 2 days  
 Clinical laboratory tests — liver function;  
 AE assessment;  
 Concomitant medicati ons. 
15.3.3.  Part 2–Cycle  1, Day 15 (P2 -C1D15; Week 27) ± 2 days  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 12-lead ECG.  
To be performed before  the morning dose:  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 110  Blood sampling for PK an d PDy analysis;  
 Clinical laboratory tests — hematology, liver function;  
Subject is dosed in clinic.  
To be performed after  the morning dose:  
 Record the dosing (subject diary, source records, eCRF);  
 Blood sampling for PK analysis at various post -dose time points ( see Section  6.4.16  
for details).  
To be performed 2  hours ±  10 minutes after  dosing:  
 12-lead ECG.  
Other procedures to be performed:  
 AE assessment;  
 Concom itant medications, including analgesics;  
 Treatment compliance assessment;  
15.3.4.  Part 2–Cycle 1, Day 22 (P2 -C1D22; Week 28) ± 2 days  
 Clinical laboratory tests:  liver function;  
 AE assessment;  
 Concomitant medications.  
15.3.5.  Part 2–Cycle 2, Day 1 (P2 -C2D1; Week 29) ± 2 days  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature.  
Other procedures to be performed:  
 Dispense study treatment bottles ; 
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment compliance assessment;  
 Random post -dose blood sampling for PK and PDy analysis;  
 Clinical laboratory tests - serum chemistry, hematology, liver function;  serum 
pregnancy testing (if applicable);  
 Physical examination.  
15.3.6.  Part 2–Cycle 2, Day 8 (P2-C2D 8; Week 30) ± 2 days  
 Clinical laboratory tests — liver function;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 111  AE assessment . 
 Concomitant medications.  
15.3.7.  Part 2–Cycle 2, Day 15 (P2 -C2D15; Week 31) ± 2 days  
 Clinical laboratory tests — liver function;  
 AE assessment;  
 Concomitant medications.  
15.3.8.  Part 2–Cycle 2, Day 22 (P2-C2D 22; Week 32) ± 2 days  
To be performed before any invasive procedures:  
 Clinical laboratory tests — liver function;  
 AE assessment . 
 Concomitant medications.  
15.3.9.  Part 2–Cycle 3, Day 1 (P2 -C3D1; Week 33) ± 7 days  
To be performed before  any i nvasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature.  
Other procedures to be performed:  
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment compliance assessment;  
 Clinical laboratory tests — serum chemistry, hematology, liver function;  serum 
pregnancy testing (if applicable);  
 Dispense study treatment bottles.  
15.3.10.  Part 2–Cycle 3, Day 15 (P2-C3D15; Week 35) ± 7 days  
To be performed before any invasive procedures:  
 Clinical laboratory tests — liver function;  
 AE assessment . 
 Concomitant medications.  
15.3.11.  Part 2–Cycle 4, Day 1 (P2 -C4D1; Week 37) ± 7 days  
To be performed within (±) 7 days of the visit:  
 ECHO or MUGA scanning;  
 MRI of the affected joint  (with local assessment of progression status) ; 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 112  Third -party blinded range -of-motion assessment of the affected joint;  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 PRO instruments, in the following order:  
 BPI Worst Pain NRS Item  
 Worst Stiffn ess NRS item  
 PROMIS Physical Function Scale  
 EQ-5D-5L 
Other procedures to be performed:  
 Dispense study treatment bottles.  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment compliance assessment;  
 Physi cal examination;  
 Clinical laboratory tests — serum chemistry, hematology, liver function,  serum 
pregnancy testing (if applicable) , urinalysis;  
 Analgesic use assessment . 
15.3.12.  Part 2–Cycle 5, Day 1 (P2 -C5D1; Week 41) ± 7 days  
To be performed before any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature.  
Other procedures to be performed:  
 Dispense study treatment bottles;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment compliance assessment;  
 Clinical  laboratory tests — serum chemistry, hematology, liver function , serum 
pregnancy testing (if applicable) . 
15.3.13.  Part 2–Cycle 6, Day 1 (P2 -C6D1; Week 45) ± 7 days  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, a nd oral temperature.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 113 Other procedures to be performed:  
 Dispense study treatment bottles;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment compliance assessment;  
 Clinical laboratory tests — serum chemistry, hematology, liver function , serum 
pregnancy testing (if applicable) ; 
15.3.14.  Part 2–Cycle 7, Day 1 (P2 -C7D1; Week 49) ± 7 days  
To be performed within (±) 7 days of the visit:  
 ECHO or MUGA scanning;  
 MRI of the affected joint  (with local assessment of progression status) ; 
 Third -party blinded  range -of-motion assessment of the affected joint.  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 12-lead ECG (performed every 24 weeks from this point forward, ie, P2-C13D1, P2-
C19D1, etc.);  
 PRO instruments, in the following order:  
o BPI Worst Pain NRS Item  
o Worst Stiffness NRS item  
o PROMIS Physical Function Scale  
o EQ-5D-5L 
To be performed before  dosing:  
 Blood sampling for hormone levels (performed every 24 weeks from this point 
forward, ie, P2-C13D1, P2 -C19D1, etc.);  
 Dispense study treatment bottles.  
Subject is dosed in clinic.  
To be performed after  the morning dose:  
 Record the dose ( subject  diary, source records, eCRF);  
Other procedures to be performed:  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant medications, including analgesics;  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 114  Treatment compliance assessment;  
 Physical examination;  
 Clinical laboratory tests — serum chemistry, hematology, liver function , serum 
pregnancy testing (if applicable) ; 
 Analgesic use assessment ; 
 Surgical Assessment Questionnaire.  
 For subjects who undergo surgical re section  of the tumor within 12 weeks of the last 
dose of study treatment, refer to Section  15.4 for collection of surgery related data . If 
a subject has surgery within 4 weeks of the last dose, the subject does not need to 
have the Post -Treatment Visit evaluations.  However, if a subjec t has surgery after 4 
weeks of the last dose, the subject should have the Post -Treatment Visit evaluations . 
None of these subjects need to have the End-of-Study Visit.  
15.3.15.  Part 2–Cycle 10+, Day 1 (P2 -C10+D1; Week 61+) ± 7 days  
The procedures described below a re performed at P2 -C10D1 ± 7 days and every 12  weeks 
thereafter ( eg, P2-C13, P2 -C16).  
To be performed within (±) 7 days of the visit:  
 MRI of the affected joint  (with local assessment of progression status) ; 
 Third -party blinded range -of-motion assessment of  the affected joint.  
To be performed before  any invasive procedures:  
 Vital signs, including blood pressure, pulse rate, and oral temperature;  
 PRO instruments, in the following order:  
o BPI Worst Pain NRS Item  
o Worst Stiffness NRS item  
o PROMIS Physical Function  Scale  
o EQ-5D-5L 
Other procedures to be performed:  
 Dispense study treatment bottles.  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment compliance assessment;  
 Physical examination;  
 Clinical laboratory tests — serum chemistry, hematology, liver function , serum 
pregnancy testing (if applicable) ; 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 115  Analgesic use assessment;  
15.3.16.  Post-Treatment Visit (Part 2)  
The Post -treatment Visit is scheduled 28 ± 7 days after the last dose of study treatment.  
To be performed within (±) 7 days of the visit:  
 MRI of the affected joint  (with local assessment of progression status) ; 
 Third -party blinded range -of-motion assessment of the affected joint.  
To be performed before  any invasive procedures:  
 Vital signs, including blood pres sure, pulse rate, and oral temperature;  
 12-lead ECG;  
 PRO instruments (if not done within the last 30 days), in the following order:  
o BPI Worst Pain NRS Item  
o Worst Stiffness NRS item  
o PROMIS Physical Function Scale  
o EQ-5D-5L 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 116 Other procedures to be performed:  
 Review outpatient PRO instruments;  
 AE assessment;  
 Concomitant medications, including analgesics;  
 Treatment compliance assessment;  
 Analgesic use assessment;  
 Weight;  
 Physical examination;  
 ECHO or MUGA scanning (only if >3 months have elapsed since the previo us scan);  
 Clinical laboratory tests — serum chemistry, hematology, coagulation, liver function, 
hormone levels, serum pregnancy testing (as applicable), urinalysis;  
 Surgical Assessment Questionnaire;  
 For subjects terminating the study because of progression, document if they plan to 
undergo any new PVNS/GCT -TS therapy, including surgery, during the 28 -day 
period (±  7 days) after their last dose of study treatment.   
 For subjects who undergo  surgical resection of the tumor  within 12 weeks of the las t 
dose of study treatment , refer to Section  15.4 for collection of surgery related data .  
15.3.17.  End-of-Study or Early Termination Visit  
The End -of-Study/E arly Termination Visit is scheduled 12 weeks ± 7 days after the last dose of 
study treatment or before any new PVNS/GCT -TS therapy, including surgery, whichever occurs 
first.  
To be performed within (±) 7 days of the visit:  
 MRI of the affected joint  (with local assessment of progression status) ; 
Other procedures to be performed:  
 Clinical laboratory tests - serum pregnancy testing (if applicable);  
 AE assessment;  
 Concomitant medications;  
 Ask the subject if s/he has begun any new PVNS/GCT -TS therapy, including  surgery;  
For subjects who undergo  surgical resection of the tumor  within 12 weeks of the last 
dose of study treatment , refer to Section  15.4 for collection of surgery related data . 
 For other subjects, terminate the subject from the study.  
15.4. Detailed Study Procedures by Visit — Surgical Outcome  
For subjects who undergo surgical resection of the tumor within 12 weeks of the last dose of 
study treatment , they will remain on the study and follow a different study visit schedule to 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 117 obtain data on the surgical procedure and its outcome. There is no need to have  the End-of-Study 
visit. 
If a subject has surgery within 4 weeks of the last dose  of study treatme nt, the subject does not 
need to have the Post -Treatment Visit evaluations per Section  15.2 and Section  15.3, but will 
need to have the safety lab tests (blood chemistry, hematology, liver function tests, coagulation  
tests, urinalysis, and serum pregnancy test) and an ECG performed at least 7 days  after the last 
dose of study treatment, but prior to surgery.  
If a subject has surgery after 4 weeks of the last dose  of study treatment , the subject should have 
the Po st-Treatment Visit evaluations per  Section  15.2 and Section  15.3. 
15.4.1.  Four weeks P rior to Surgery  
For subjects undergoing surgical r esection , the following procedures are performed within the 4-
week  period before  surgery : 
 MRI of the affected joint ( Only perform if not done within 12 weeks prior to the 
surgery)  
 Third -party blinded range -of-motion assessment of the affected joint.  
 PRO in struments, in the following order:  
o BPI Worst Pain NRS item;  
o Worst Stiffness NRS item;  
o PROMIS Physical Function Scale;  
 Collection of SAEs  (Note: hospitalization for the surgery is not considered as SAE)  
 Reasons for surgery  
15.4.2.  During or shortly  after Surgery  
 Surgical procedures and findings  
 Tumor sample submission  
 Collection of SAEs  
15.4.3.  4 Months ( ± 2 weeks) after Surgery  
 MRI of the affected joint  
 Third -party blinded range -of-motion assessment of the affected joint.  
 PRO instruments, in the following order:  
o BPI Worst Pain NRS item;  
o Worst Stiffness NRS item;  
 Collection of SAEs  (Note: hospitalization for the su rgery is not considered as SAE)  
 Disease Recurrence  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 118 15.4.4.  8, 12, 18, and 24 Months ( ± 2 weeks) after Surgery  
 Disease Recurrence  
 No End-of-Study visit is required , however an End of Study eCRF will be completed 
at this time  
15.5. Brief Pain Inventory (BPI) Worst Pain Numeric Rating Scale (NRS) 
Item  
The following question asks about pain at the site of your tumor.  
 
15.6. Worst Stiffness NRS item  
The following question asks about stiffness at the site of your tumor.  
 
 

Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 122 15.8. EQ-5D-5L 
 
 
 
Health Questionnaire  
 
 
English version for the USA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
USA (English) © 2009 EuroQol Group. EQ -5D™ is a trade mark of the EuroQol Group  

Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 123 Under each heading, please check the ONE box that best describes your health TODAY  
 
MOBILITY  
I have no problems walking        
I have slight problems walking      
I have moderate  problems walking       
I have severe problems walking       
I am unable to walk        
 
SELF -CARE  
I have no problems washing or dressing myself    
I have slight problems washing or dressing myself    
I have moderate problems washing or dressing myself   
I have severe problems washing or dressing myself   
I am unable to wash or dress myself      
 
USUAL ACTIVITIES  (eg work, study, housework,  
family or leisure activities)  
I have no problems doing my usual activities    
I have slight problems doing my usual activities    
I have moderate problems doing my usual activities   
I have severe problems doing my usual activities    
I am unable to do my usual activities     
 
PAIN / DISCOMFORT  
I have no pain or discomfort       
I have slight pain or discomfort      
I have moderate pain or discomfort      
I have severe pain or discomfort      
I have extreme pain or discomfort      
 
ANXIETY / DEPRESSION  
I am not anxious or depressed      
I am slightly anxious or depressed      
I am moderately anxious or depressed     
I am severely anxious or depressed      
I am extremely anxious or depressed     
 
 
 
 
 
 
 
 
 
2 
USA (English) © 2009 EuroQol Group. EQ -5D™ is a trade mark of the EuroQol Group  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 125 15.9. Patient Global Impression of Change and Rating of Concept Items  
Patient Global Rating of Concept – Physical Functioning  
Please rate your tumor -related physical functioning. Please focus  on your ability to carry out 
your everyday physical activities, such as walking, climbing  stairs, or carrying groceries.  
How much has your tumor limited your physical functioning today?  
 Not at all   
 A little   
 Somewhat   
 Severely   
 Extremely   
 
Patient Global Impression of Change in Symptoms – Stiffness  
Please rate the change in your stiffness at the site of your tumor today compared to your 
stiffness at the site of your tumor before you received treatment at the start of the study.  
 Much improved  
 Modera tely improved  
 A little improved  
 No change  
 A little worse  
 Moderately worse  
 Much worse  
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 126 15.10.  Surgical Assessment Questionnaire  
Table  15.1: Sample Surgical Assessment Questionnaire  
Question  Response  
Expected probability of a complete resection with 
no microscopic residual tumor:  High  
Medium  
Low 
None  
Expected postoperative morbidity:  None  
Mild  
Moderate  
Severe  
Complexity of surgical procedure:  Low 
Medium  
High  
Operative risk due to other medical conditions:  Low 
Medium  
High  
Pre-Operative Assessment Not Done  
15.11.  Employment status and productivity questions  
Please choose one of the following which best describes your current work situation.  
□   Employed  
□   Self-employed  
□   Unemployed  
□   Student  
□   Retired  
□   Other, please specify: __________  
If employed, self -employed or unemployed, which of the following best describes your current 
work situation?  
□   I am working full time for pay  
□   I am only working part -time for pay because of my tumour  
□   I am only working part -time for pay for reasons not related to my tumour  
□   I am not working for pay because of my tumour  
□   I am not working for pay for reasons not related to my tumour  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 127  
If you are working, in the past 4 weeks, on average, how many days per week did you miss from 
work due to your tumour?  
Include time when you were late getting to work, when you left work early, and time spent for 
doctors’ visits and hospitalizations . 
 
                Days (Please record to the nearest half day. If none, record 0.)  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 128 15.12.  Healthcare  Resource Use Questions  
1. Has the subject been hospitalized  in the past 4 weeks?  
□   Yes 
□   No 
If Yes,  
1a. What was the date of admission?    ___/___/____ ( DD/MM/YYYY)  
 
1b. What was the date of discharge?    ___/___/____ (DD/MM/YYYY)  
 
1c. Was the hospitalization  related to the subject’s tumour?  
□   Yes 
□   No 
 
1d. What was the reason/diagnosis for hospitalization ? 
Specify: __________  
 
1e. What was the nature of the hospitalization ? (Please tick one)  
□   Urgent/ Emergency  
□   Scheduled/Planned  
□   Prolongation of existing hospitalization  
 
1f. Number of days spent in general ward: __________  
 
1g. Number of days spent in intensive care unit (ICU)  
(or equivalent units, e.g. cardiac care or high dependency unit): __________  
 
1h. Did the subject have any additional hospitalizations  in the past 4 weeks?  
□   Yes 
□   No 
If Yes, repeat questions 1a to 1g. If No, proceed to question 2.  
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 129 2. Did the subject have any Accident & Emergency (emergency room) visits that did not result in 
hospitalization  in the past 4 weeks?  
Number of visits: __________ (If none, record 0)  
 
2a. For each A&E (ER) visit record the following:  
Was the visit related t o the subject’s tumour?  
□   Yes 
□   No 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 130 15.13.  Schedule of Events  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 131 Table  15.2: Schedule of Events – Part 1 (Blinded, Placebo -controlled Phase)  
Procedurea Day 
-42 to -
1b P1- 
C1D1  P1- 
C1D8  
± 2d  P1- 
C1D15  
± 2d P1- 
C1D22  
± 2d P1- 
C2D1  
± 2d P1- 
C2D8  
± 2d P1- 
C2D15  
± 2d  P1- 
C2D22  
± 2d P1- 
C3D1  
± 7d P1- 
C3D15  
± 7d P1- 
C4D1  
± 7d P1- 
C5D1  
± 7d P1- 
C6D1  
± 7d P1 
Compl./
Early 
Termc 
± 7d P1- 
28 Day 
Post T x
d 
± 7d P1 End 
St/12 
Week 
post- 
Tx ± 7d  
 Scree n
b Week 
1 Week 
2 Week 
3 Week 
4 Week 
5 Week 
6 Week 
7 Week 
8 Week 
9 Week 
11 Week 
13 Week 
17 Week 
21 Week 25  LD+28d  LD+12 
Week  
/ < new 
Txe 
Informed 
consent  X                 
Demog. & 
medical 
history  X                 
Height, 
weight  X              Xf Xf  
Vital signs, 
incl. BP, 
pulse, temp.  Xg X  X  X    X  X X X X X  
Physical 
examinatio nh X     X      X   X X  
ECGi X X  X           X X  
ECHO or 
MUGA 
scannin gj X           X   X Xk  
Chemistry, 
hematolog y X X  Xl  X    X  X X X X X  
Liver 
function test s
m X Xm Xm Xm Xm Xm Xm Xm Xm Xm Xm Xm Xm Xm Xm Xm  
Urinalysis   X          X   X X  
Hepatitis 
panel  X                 
Coagulation 
testsn  X             X X  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 132 Procedurea Day 
-42 to -
1b P1- 
C1D1  P1- 
C1D8  
± 2d  P1- 
C1D15  
± 2d P1- 
C1D22  
± 2d P1- 
C2D1  
± 2d P1- 
C2D8  
± 2d P1- 
C2D15  
± 2d  P1- 
C2D22  
± 2d P1- 
C3D1  
± 7d P1- 
C3D15  
± 7d P1- 
C4D1  
± 7d P1- 
C5D1  
± 7d P1- 
C6D1  
± 7d P1 
Compl./
Early 
Termc 
± 7d P1- 
28 Day 
Post T x
d 
± 7d P1 End 
St/12 
Week 
post- 
Tx ± 7d  
 Scree n
b Week 
1 Week 
2 Week 
3 Week 
4 Week 
5 Week 
6 Week 
7 Week 
8 Week 
9 Week 
11 Week 
13 Week 
17 Week 
21 Week 25  LD+28d  LD+12 
Week  
/ < new 
Txe 
Hormone 
testin go X X             X X  
BPI Worst 
Pain NRSp, q X X        X   X  X X  
Worst 
Stiffness 
NRS ite mp,q X X        X   X  X X  
Most 
disturbing Sx 
assessment   X                
PROMIS 
Physical 
Function 
Scalep X X        X   X  X X  
Global 
Rating of 
Concept item   X        X   X  X X  
EQ-5D-5L 
instrumentp  X        X   X  X X  
Review 
completed 
outpatient 
PROs   X        X   X  X X  
Pt. Global 
Impress. of 
Change item                X X  
MRI of the 
affected joint
r X           X   X X X 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 133 Procedurea Day 
-42 to -
1b P1- 
C1D1  P1- 
C1D8  
± 2d  P1- 
C1D15  
± 2d P1- 
C1D22  
± 2d P1- 
C2D1  
± 2d P1- 
C2D8  
± 2d P1- 
C2D15  
± 2d  P1- 
C2D22  
± 2d P1- 
C3D1  
± 7d P1- 
C3D15  
± 7d P1- 
C4D1  
± 7d P1- 
C5D1  
± 7d P1- 
C6D1  
± 7d P1 
Compl./
Early 
Termc 
± 7d P1- 
28 Day 
Post T x
d 
± 7d P1 End 
St/12 
Week 
post- 
Tx ± 7d  
 Scree n
b Week 
1 Week 
2 Week 
3 Week 
4 Week 
5 Week 
6 Week 
7 Week 
8 Week 
9 Week 
11 Week 
13 Week 
17 Week 
21 Week 25  LD+28d  LD+12 
Week  
/ < new 
Txe 
Range -of-
motion 
assessmen ts X           X   X X  
Serum 
pregnancy 
testt X     X    X  X X X X X X 
Archival 
tumor tissu eu X                 
PK, PDy 
blood 
samplin gv  X  X  X    X   X     
Analgesic 
use 
assessment  Xw X        X   X  X X  
Subject 
randomizatio
n  X                
Dispense 
study Tx   X  X  X    X  X X X    
In-clinic 
study Tx 
dosin gx  X  X              
Study Tx 
dosin gy  ——  Twice daily dosing through Week 2 4y ——     
Tx 
compliance 
assessment     X  X    X  X X X X   
Concomitant 
medications  X X X X X X X X X X X X X X X X X 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 134 Procedurea Day 
-42 to -
1b P1- 
C1D1  P1- 
C1D8  
± 2d  P1- 
C1D15  
± 2d P1- 
C1D22  
± 2d P1- 
C2D1  
± 2d P1- 
C2D8  
± 2d P1- 
C2D15  
± 2d  P1- 
C2D22  
± 2d P1- 
C3D1  
± 7d P1- 
C3D15  
± 7d P1- 
C4D1  
± 7d P1- 
C5D1  
± 7d P1- 
C6D1  
± 7d P1 
Compl./
Early 
Termc 
± 7d P1- 
28 Day 
Post T x
d 
± 7d P1 End 
St/12 
Week 
post- 
Tx ± 7d  
 Scree n
b Week 
1 Week 
2 Week 
3 Week 
4 Week 
5 Week 
6 Week 
7 Week 
8 Week 
9 Week 
11 Week 
13 Week 
17 Week 
21 Week 25  LD+28d  LD+12 
Week  
/ < new 
Txe 
Adverse 
event sz X X X X X X X X X X X X X X X X X 
Surgical 
Assessment 
Questionnair
e X              X X  
Collection of 
surgical dat a
aa               Xaa Xaa Xaa 
HCRU & 
productivity 
assessment   X    X    X  X X X X X  
PGx blood 
samplingbb                  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 135  AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BP = blood pressure; BPI = Brief Pain I nventory; C = cycle; Compl   = Completion; D/d = Day; Demog. = 
demographics; ECG = electrocardiogram; ECHO = echo cardiography; End St./ 12 Week post Tx . = End -of-Study/ 12 Week Post -Treatment ; EQ-5D-5L =EuroQol five -dimensional descriptive system; 
FSH = follicle -stimulating hormone; GCT -TS = giant cell tumor of the tendon sheath; GGT = g amma -glutamyl transpeptidase ; HCRU = healthcare resource use; incl. = including; LD = last dose; LH 
= luteinizing hormone; MRI = magnetic resonance imaging; MUGA = multi -gated acquisition; NRS = numeric rating scale; P  = Part; PDy = pharmacodynamic; PGx = pharmacogenomic; PK = 
pharmacoki netic; PRO = patient -reported outcome; PROMIS = Patient -reported Outcomes Measurement Information System; Pt  = patient; PVNS = pigmented villonodular synovitis; Screen = 
Screening; Sx = symptom; temp. = temperature; Tx = treatment; Week = week  
 
a Effective 30 Sep 2016, subjects who wish to continue onto the open label part of this study (Part 2) will be unblinded after completion of the end o f Part 1 assessments (Part 1 Completion visit/Early 
Term ination visit) and those on placebo will  be discontinued and will not have the 28 Day Post-treatment and End -of-Study Visit assessments.  
b Procedures performed as part of patient care within the 42-day period before the first dose of study treatment may  be used for screening purposes if they conform to protocol requirements and 
standards. All screening test results must be reviewed prior to dosing to assess the study candidate’s eligibility for in clusion.  
c The Part 1 Completion visit applies to subjects who are not continuing into Part 2. Those continuing into Part 2 will instead  have the assessments indicated at P2 -C1D1 (see Table 15.3). Effective 
30 Sep 2016, subjects who wish to continue onto the open label part of this study (Part 2) will be unblinded after completion of the end o f Part 1 assessments (Part 1 Completion v isit/Early 
Termination visit) and those on placebo will be discontinued; subjects on pexidartinib in Part 1 may continue into Part 2 to continue to receive pexidartinib . Subjects who discontinue Part 1 early, 
shoul d complete the end of Part 1 as sessments (Part 1 Completion visit/Early Termination) at or before the time of their last treatment (MRI or range of motion assessments do not need to be repeated, 
if completed in the previous 28 days).  
d As of 30 Sep 2016, subjects who wish to continue onto the open label part of this study (Part 2) will be unblinded after completion of the end o f Part 1 assessments (Part 1 Completion visit/Early 
Termination visit) and those on placebo will  be discontinued and will not need to complete the Part 1 28 Day Post-Treatment Visit and associated procedures. Subjects who exit the study with 
radiologic disease progression will undergo their last study evaluation 28 ± 7 days after their last dose of study treatment or before any new PVNS therapy, including surgery, whichever occurs first. 
Any planned new PVNS therapy, including the type of surgical procedure, will be recorded. Subjects who withdraw from the stud y with radiolog ic progression do not undergo a Part 1  End-of-
Study/ 12 Week Post -Treatment  MRI.  
e Subjects who end their study participation with no radiologic disease progression will undergo post -treatment procedures 28 ± 7 days after their last dose o f study treatment and a final MRI 12 weeks 
± 7 days after their last dose of study treatment or before any new PVNS therapy, including surgery, whichever occurs first. The latter MRI need not be performed if new PVNS therapy starts within 4 
weeks of the 28 Day Post-treatment Visit. Before or at the Part 1 End-of-Study/ 12 Week Post -Treatment  Visit, plans for any new PVNS therapy will be obtained.  (see Footnote  aa) As of 30  Sep 2016, 
subjects who wish to continue onto the open label part of this study (Part 2) will be unblinded after completion of the end o f Part 1 assessments (Part 1 Completion visit/Early Termination visit) and 
those on placebo will be disc ontinued and will not have the 28 Day Post-treatment and End -of-Study Visit assessments.  
f Weight only.  
g Vital signs should be performed before any invasive procedures are carried out on the same day.  
h In the event of early withdrawal or if the subject completes Part 1 but does not enter Part 2, a physical examination i s performed at the 28 Day Post-treatment Visit.  
i A standard 12 -lead ECG is performed prior to dosing. Subjects should be told not to take their morning dose of study treatment at home on d ays wh en an ECG is performed; instead, they should bring 
their study treatment bottle to the clinic and take their morning dose upon site instruction. At the P1 -C1D1 and P1 -C1D15 visits only, the ECG is performed before and 2 hours after dosing. The 2 
hour post -dose ECG should begin within 10 minutes of the 2 hour post -dose time point.  
j ECHO or MUGA scanning is chosen by Investigator preference. However, the same imaging platform must be used throughou t the study.  
k ECHO or MUGA scanning should only be repeated if more than 3 months have elapsed since the last procedure. Subjects who show a reduced ejection fraction relative to baseline at th e last visit 
should be followed until a stable ejection fraction is measured by two consecutive tests.  
l Hematology only.  
m Alkaline p hosphatase, ALT, AST, total and direct bilirubin , and GGT  should be assessed at screening, weekly during P1-C1 beginning on Day 1, weekly during P1-C2 beginning on Day 1, biweekly 
during P1-C3 beginning on Day 1 , and on Day 1 of every cycle thereafter.  More frequent monitoring is required in the case of i ncreased liver function tests (s ee Section  5.3). 
n Subjects receiving concomitant warfarin should have their anti -coagulation status carefully monitored for any necessary dose adjustments (see  Section  5.3). 
o Women who are not using hormonal contraception will be tested for levels of FSH, LH, progesterone, and estradiol. Hormone tes ting will not be required for women who have either had an 
oophorectomy or are post -menopausal. Men will be tested for levels of LH, FSH, and testosterone. Men whose testosterone level is below baseline at the  last study visit should be followed until their 
level has stabilized or returned to baselin e. 
p Subjects should record responses to the BPI Worst Pain NRS item, Worst Stiffness NRS item, PROMIS Physical Function Scale, an d EQ -5D-5L in the eDiary before any invasive procedures. (NOTE: 
at the Screening Visit only, the recall period will be the preceding week for the BPI Worst Pain NRS item and Worst Stiffness NRS item. The subject’s response must be documented in the medical 
notes.)  
q Subjects should be reminded to complete the BPI Worst Pain NRS item and the Worst Stiffness NRS item, at least 4 of 7 consecu tive days for 2 weeks prior to randomization, and prior to Day 1 of 
P1-C1, P1-C3, and P1-C5 and before the Part 1 Completion  Visit (Week 25). In the event of early withdrawal or if the subject completes Part 1 but does not enter Part 2, this item wil l be completed 
prior to the 28 Day Post-treatment Visit.  
r The Invest igator may request a centrally read blinded MRI to confirm progression, eg, if a subject’s mid -study clinical profile or local radiological assessment indicates progression.  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 136 s A range -of-motion a ssessment in the affected joint or tumor location will be performed by a blinded  independent third party assessor.  
t Women of childbearing potential must have a serum pregnancy test within 14 day s of randomization (or, where different regulations apply, within 72 hours of randomization). (Women who have 
documentation of at least 12 months of spontaneous amenorrhea and have an FSH level > 40 mIU/mL will be considered postmenopa usal and need not und ergo pregnancy testing.)  
u Archival surgical tissue from PVNS/GCT -TS tumors should be obtained at screening (or whenever available) for biomarker assessment.  
v Details on blood sampling are found in Section  6.4.16  (PK) and Section  6.4.15  (PDy).  
w A diary of analgesic use must be kept for the 2 -week period before the first dose of study treatment.  
x The morning dose of study treatment should be administered in the clinic on the days indicated; P1 -C1D1 should be within 3 days after randomization.  
y Dose administration by  the subject at home. See Section  3.1 for dose  reduction as of P1 -C1D15. Subjects should take their last dose of study treatmen t the evening before their scheduled Part 1 
Completion Visit (Week 25).  
z After the subject provides signed informed consent; AEs are monitored throughout the study via safety assessments, observation, and subject reporting (see Section  6.4.17 ). 
aa If surgical resection of th e tumor is performed within 12 weeks after the last dose of study treatment, details of the surgery and its outcome should be  obtained (see Table  15.4). After completion of the 
end of Part 1 assessments (Part 1 Completion visit/Early Termination visit), subjects who wish to continue onto the open labe l part of this study (Part 2) will be unblinded and those on placebo will be 
discontinued and will not nee d to have surgical data follow -up. 
bb The pharmacogenomics blood sample is optional. If taken,  it should only be taken once as soon as reasonably possible after the subject has signed the consent form . 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 137 Table 15.3: Schedule of Events – Part 2 (Open -label Phase)  
 P2- 
C1D1a P2- 
C1D8  
± 2d  P2- 
C1D1
5 
± 2d P2- 
C1D 22 
± 2d  P2- 
C2D1  
± 2d P2- 
C2D8  
± 2d P2- 
C2D1
5 
± 2d  P2- 
C2D22  
± 2d P2- 
C3D1  
± 7d P2- 
C3D1
5 
± 7d P2- 
C4D1  
± 7d P2- 
C5D1  
± 7d P2- 
C6D1  
± 7d P2- 
C7D1  
± 7d P2- 
C10+D1b 
± 7d P2-Post 
Txc 
± 7d End St./ 
Ear. 
Term. ± 
7d 
Procedured Week  
25 Week  
26 Week  
27 Week  
28 Week  
29 Week 
30 Week  
31 Week 
32 Week  
33 Week 
35 Week  
37 Week  
41 Week  
45 Week  
49 Week  
61+ LD  
+ 28d  LD + 12 
Week/ < 
new T xe 
Weight  X               X  
Vital signs, 
incl. BP, 
pulse, temp.  X  X  X    X  X Xf Xf Xf Xf Xf  
Physical 
examinatio n X    X      X   X X Xf  
ECG Xg  Xg           X  X  
ECHO or 
MUGA 
scanning  X          X   X  Xh  
Chemistry, 
hematolog y X  Xi  X    X  Xf Xf Xf Xf Xf Xf  
Liver 
function 
testsj X X X X X X X X X X X X X X X X  
Urinalysis  X          X     X  
Coagulation 
testsk X               X  
Hormone 
testin gl  X             X  X  
BPI Worst 
Pain NRS 
item X          Xf,m   Xf,m Xf,m Xf,m  
Worst 
Stiffness 
NRS item  X          Xf,m   Xf,m Xf,m Xf,m  
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 138  P2- 
C1D1a P2- 
C1D8  
± 2d  P2- 
C1D1
5 
± 2d P2- 
C1D 22 
± 2d  P2- 
C2D1  
± 2d P2- 
C2D8  
± 2d P2- 
C2D1
5 
± 2d  P2- 
C2D22  
± 2d P2- 
C3D1  
± 7d P2- 
C3D1
5 
± 7d P2- 
C4D1  
± 7d P2- 
C5D1  
± 7d P2- 
C6D1  
± 7d P2- 
C7D1  
± 7d P2- 
C10+D1b 
± 7d P2-Post 
Txc 
± 7d End St./ 
Ear. 
Term. ± 
7d 
Procedured Week  
25 Week  
26 Week  
27 Week  
28 Week  
29 Week 
30 Week  
31 Week 
32 Week  
33 Week 
35 Week  
37 Week  
41 Week  
45 Week  
49 Week  
61+ LD  
+ 28d  LD + 12 
Week/ < 
new T xe 
PROMIS 
Physical 
Function 
Scale  X          Xf   Xf Xf Xf  
EQ-5D-5L 
instrument  X          Xf   Xf Xf Xf  
Review 
completed 
outpatient 
PROs  X          X   X X X  
MRI of the 
affected joint
n X          Xf   Xf Xf Xf Xo 
Range -of-
motion 
assessmen tp X          Xf   Xf Xf Xf  
Serum 
pregnancy 
test X    X    X  X X X X X X X 
PK, PDy 
blood 
samplin gq X  X  X             
Analgesic 
use 
assessment  X          X   X X X  
Dispense 
pexidartinib  X    X    X  X X X X X   
In-clinic 
pexidartinib 
dosin gr X  X           X    
Pexidartinib 
dosin gs X 
——  Twice daily dosin gs ——    
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 139  P2- 
C1D1a P2- 
C1D8  
± 2d  P2- 
C1D1
5 
± 2d P2- 
C1D 22 
± 2d  P2- 
C2D1  
± 2d P2- 
C2D8  
± 2d P2- 
C2D1
5 
± 2d  P2- 
C2D22  
± 2d P2- 
C3D1  
± 7d P2- 
C3D1
5 
± 7d P2- 
C4D1  
± 7d P2- 
C5D1  
± 7d P2- 
C6D1  
± 7d P2- 
C7D1  
± 7d P2- 
C10+D1b 
± 7d P2-Post 
Txc 
± 7d End St./ 
Ear. 
Term. ± 
7d 
Procedured Week  
25 Week  
26 Week  
27 Week  
28 Week  
29 Week 
30 Week  
31 Week 
32 Week  
33 Week 
35 Week  
37 Week  
41 Week  
45 Week  
49 Week  
61+ LD  
+ 28d  LD + 12 
Week/ < 
new T xe 
Tx 
compliance 
assessment  X  X  X    X  X X X X X X  
Concomitant 
medications  X X X X X X X X X X X X X X X X X 
Adverse 
event st X X X X X X X X X X X X X X X X X 
Surgical 
Assessment 
Questionnair
e X             X  X  
Collection of 
surgical dat a
u              Xu  Xu  Xu 
PGx blood 
samplingv                  
 AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BP = blood pressure; BPI = Brief Pain I nventory; C = cycle; D/d = Day; ECG  = electrocardiogram; ECHO = 
echocardiography; End St./Ear. Term. = End -of-Study/Early Terminati on; EQ -5D-5L =EuroQol five -dimensional descriptive system; FSH = follicle -stimulating hormone; GGT = gamma -glutamyl 
transpeptidase ; incl. = including; LD = last dose; LH = luteinizing hormone; MRI = magnetic resonance imaging; MUGA = multi -gated acquisitio n; NRS = numeric rating scale; P = Part; PDy = 
pharmacodynamic; PGx = pharmacogenomic;  PK = pharmacokinetic; PRO = patient -reported outcome; PROMIS = Patient -reported Outcomes Measurement Information System; PVNS = pigmented 
villonodular synovitis; temp. =  temperature; Tx = treatment; Week = week  
a The Part 1 Completion (Week 25) Visit will serve as the first visit of Part 2 and will be designated as P2 -C1D1. All procedures listed for this visit a re for reference only and will already have been 
conducted at the Part 1 Completion (Week 25) Visit except for the following, which should be performed at this visit:  (i) ad ministering the morning dose of pexidartinib; (ii) dispensing the dosing 
diary; (i ii) 2-hour post -dose ECG; and (iv) dispensing the analgesic use diary.  
b Starting with P2 -C10 (Week 61), subjects will return to the clinic every 12 weeks (ie, P2 -C13, P2 -C16, etc.) to undergo th e procedures indicated.  
c If the subject withdraws before completing Part 2 or completes Part 2 but declines to continue treatment for study of longer efficacy and safety follow -up or in the sepa rate continuation study, the post -
treatment procedures should be completed 28 ± 7 days after the last dose of study treatment and before initiating any new PVN S therapy, including surgery. Subjects who complete Part 2 without 
experiencing progression or in tolerability, or subjects who undergo surgical resection of their tumor after study treatment will be eligible to continue fo r longer efficacy and safety follow -up or to enter 
a separate protocol to continue receiving pexidartinib or for surgical data coll ection. . Subjects who enter the separate protocol will not undergo Post -treatment and End -of-Study Visits.  
d Effective 30 Sep 2016, subjects who wish to continue onto the open label part of this study (Part 2) will be unblinded after completion of the end of Part 1 assessments (Part 1 Completion visit/Early 
Termination visit)  and those on placebo will be discontinued; subjects on pexid artinib in Part 1 may continue into Part 2 to continue to receive pexidartinib . If the patient is known to have been on 
pexidartinib treatment in Part 1, then visits and associated procedu res are only required on Day 1 of each cycle  in Part 2.  
e The End -of-Study/Early Termination MRI need not be performed if new PVNS therapy begins within 4 weeks of the Post -treatment Visit. Before or at the End -of-Study/Early Termination Visit, plans 
for any new PVNS therapy will be obtained. Details of any surgical treatment will be obtained per Footnote u. 
f A physical examination by study staff, MRI, blinded range -of-motion assessment of the joint location by a third -party examiner not otherwise affiliated with the trial, and administration of the PRO 
instruments are performed at all of the indicated visi ts including the P2 -C4D1 visit, every 12 weeks thereafter (ie, P2 -C7D1, P2-C10D1, etc.), and at the Post -treatment Visit. Vital sign assessment, 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 140 clinical laboratory studies (chemistry, hematology), and PK /PDy  blood sampling will be performed at all of the indicated visits, including the P2 -C4D1 visit, every 12 weeks thereafter (ie, P2 -C7D1, 
P2-C10D1, etc.), P2 -C5D1, and P2 -C6D1. [NOTE:  On study visit days, the PRO instruments, including the EQ -5D-5L, should be administered before performing any invasive pr ocedures.]  
g A standard 12 -lead ECG is performed 2 hours after dosing at the P2 -C1D1 visit and before and 2 hours after dosing at the P2 -C1D15 visit. The 2 -hour post -dose ECG measurements should begin 
within 10 minutes of the 2 hour post -dose time point. Thereafter, the ECG and blood draw for hormone testing is performed before dosing at the C13D1 visit, every 24 weeks thereafter (ie, C19D1, 
C25D1, etc.), and at the Post -treatment Visit.  
h ECHO or MUGA scanning should only be repeated if more than 3 months have elapsed since the last procedure. Subjects who show a reduced ejection fraction relative to baseline at the last visit 
should be followed until a stable ejection fraction is measured by two consecutive tests.  
i Hematology only.  
j Alkaline phosphatase, ALT, AST, t otal and direct bilirubin, and GGT should be assessed weekly during P2-C1 beginning on Day 1, weekly during P2-C2 beginning on Day 1, biweekly during P2-C3 
beginning on Day 1, and on Day 1 of every cycle thereafter.  More frequent monitoring is required in the case of i ncreased liver function tests (s ee Section  5.3).  
k Subjects receiving concomitant warfarin should have their anti -coagulation status carefully monitored for any necessary dose adjustments (see Section  5.3) . 
l Women who are not using hormonal contraception will be tested for levels of FSH, LH, progesterone, and estradiol. Hormone tes ting will not be required fo r women  who have either had an 
oophorectomy  or are post -menopausal. Men will be tested for levels of LH, FSH, and testosterone. Men whose testosterone level is below baseline at the  last study visit should be followed until their 
level has stabilized or returned to baseline.  
m Subjects should be reminded to complete the BPI Worst Pain NRS item and Worst Stiffness NRS item for at least 4 of 7 consecutive days   prior to Day 1 of P2 -C4, P2-C7, P2-C10, and before the 
Post-treatment Visit.  
n The investigator may request a centrally read MRI to confirm progression as detailed in the Imaging Charter.  
o For subjects who discontinue the study before completing Part 2 or complete Part 2 but decline to continue treatment for study of longer efficacy and safety follow -up or to enter the separate 
continuation study for reasons other than progression, the end -of-study or early termination MRI should be completed 12 weeks ± 7 days after the last dose of study treatment or before startin g any 
new PVNS therapy, including surgery, whichever occurs first. Subjects who withdraw from the study with progression do not u ndergo an End -of-Study/Early Termination MRI.  
p A range -of-motion assessment in the affected joint or tumor location will be performed by a  blinded independent third party assessor.  
q Details on blood sampling are found in Section  6.4.16  (PK) and Section  6.4.15  (PDy).  
r The morning dose of pexidartinib should be administered in the clinic a t all of the indicated time points.  
s Dose administration by the subject at home.  
t AEs are monitored throughout the study via safety assessments, observation, and subject reporting (see Section  6.4.17 ). 
u If surgical resection of the tumor is performed within 12 weeks after the last dose of study treatment, details of the surger y and its outcome should be obtained (see Table  15.4). 
v The pharmacogenomic blood sample is optional. If taken,  it should only be taken once as soon as reasonably possible after the subject has signed the consent form . 
 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 141 Table  15.4: Schedule of Events – For Subjects Who Undergo Surgical Resection  
 Follow Up Visit 1   Follow Up Visit 2  Follow Up 
Contact 1  Follow Up Contact 
2 Follow Up Contac t 
3 Follow Up Contact 
4 
Procedurea Within 4 Weeks 
prior to  Surgery  During or Shortly 
after Surgery  4 months (+/ - 2 
weeks) after 
Surgery  8 months (+/ - 2 
weeks) after 
Surgery  12 months (+/ - 2 
weeks) after 
Surgery  18 months (+/ - 2 
weeks) after 
Surgery  24 months (+/ - 2 
weeks) after 
Surgery  
BPI Worst Pain NRS  Xb  X     
Worst Stiffness NRS item  Xb  X     
PROMIS Physical Function 
Scale  Xb  X     
MRI of the affected joint  Xc  X     
Range -of-motion assessment  Xb  X     
Reasons of Surgery  Xb       
Blood Chemistry, Hematology  Xd       
Liver function tests Xd       
Coagulation tests  Xd       
Urinalysis  Xd       
Serum pregnancy test  Xd       
ECG  Xd       
Surgical Procedure and 
Findingse  X      
Surgical Complications    X     
Tumor Sample Submission   X      
Collection of serious adverse 
events  X   X     
Disease Recurrencef   X X X X X 
End of Study CRF Completion        X 
PGx blood samplingg        
 BPI = Brief Pain Inventory; CRF = Case report form; ECG  = electrocardiogram; MRI = magnetic resonance imaging; NRS = numeric rating scale; PGx = pharmacogenomic;  PROMIS = Patient -
reported Outcomes Measurem ent Information System; TGCT = tenosynovial giant cell tumor  
a If a subject has surgery within 4 weeks of the last dose of study treatment, the subject does not need to have the Post -Treatment Visit evaluations ( in Table  15.2 and Table 15.3), but will need to have 
the safety lab tests (blood chemistry, hematology, liver function tests, coagulation tests, urinalysis, and serum pregnancy t est) and an ECG performed at least 7 days after the last dose of study 
treatment, but prior to surgery. Ho wever, if a subject has surgery after 4 weeks of the last dose of study treatment, the subject should have the Post -Treatment Visit evaluations ( in Table  15.2 and 
Table 153). None of these subjects need to have the End -of-Study Visit ( in Table  15.2 and Table 15.3). 
Protocol Amendmen t PLX108 -10 
Vers ion 10.0 , 22 Jan 2020  
Proprietary and Confidential  
Page 142 b Only perform if not done within 4 weeks prior to the surgery.  
c Only perform if not done within 12 weeks prior to the surgery.  
d Only for subjects who have surgery within 4 weeks of the last dose of study treatment.  
e Including planned surgical procedure and actual surgical procedure performed, surgical margin, copies of surgical report and pathology report, if available .  
f Disease recurrence is defined as the need for any new therapeutic intervention of TGCT. Such follow -up can be performed via phone contact with the subject.  
g The pharmacogen omic blood sample is optional.  If taken,  it should only be taken once as soon as reasonably possible after the subject has signed the consent form . 